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Preface 
 
This thesis describes research that was undertaken as part of an Engineering Doctorate which 
was carried out in collaboration with Onyx Scientific Limited and sponsored by the 
Engineering and Physical Sciences Research Council. 
Being an industrially focused Engineering Doctorate, the work undertaken reflects the 
requirements and research challenges identified by Onyx Scientific Limited.  
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Abstract 
 
The research project, conducted in collaboration with Onyx Scientific Limited and Newcastle 
University, is focused on the anti-convulsant drug topiramate that is best known as a treatment 
for epilepsy.  The established data on the efficacy and limitations of topiramate highlighted it 
as a promising drug candidate for reprofiling, repurposing or modification.  The interest in 
topiramate stems primarily from its multi-factorial mode of biological action that results in a 
complex combination of pharmacological effects.  This is manifested by the drug having a 
complex side effects profile with the most common being related to the central nervous system, 
weight loss and gastrointestinal disorders.   
The drug influences the activity of a number of in vivo sites including certain types of voltage 
activated sodium and calcium ion channels, AMPA glutamate receptors and particular 
isozymes of the enzyme carbonic anhydrase (CA).  Of particular interest to this work is the 
specific inhibition of mitochondrial CAs, CAVA and CAVB by topiramate.  The inhibition of 
these mitochondrial CAs is thought to contribute to the weight loss effects observed in patients 
being treated with topiramate.  The project aims to develop novel selective CA inhibitors 
(CAIs) that have inhibitory properties towards only particular and relevant CAs.  It is hoped 
that this will enable the pharmacological activity of topiramate to be optimised and certain of 
its aspects positively exploited whilst limiting toxicity and off-target biological effects.      
The objective of the project is to identify potential new APIs by assessing the biological 
activity of known derivatives of topiramate on the CA targets of interest and by creating 
novel molecules that introduce structural modifications to topiramate that may increase the 
specificity for certain CAs and vary the drug’s pharmacological effects.  The approach of the 
project is to undertake a classical drug design cycle using modern drug discovery techniques.  
In silico models were used to identify compounds, both known and novel, which show 
promising interactions with one or more of the target active sites and which therefore may 
demonstrate a selective biological response.  The in silico hits generated from modelling will 
be the primary synthetic targets and are the focus of this research.   
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CHAPTER 1. INTRODUCTION 
1.1. Topiramate 
 
1.1.1. Introduction 
Topiramate 1, 2,3:4,5-di-O-isopropylidene--D-fructopyranose sulfamate, is derived from the 
naturally occurring monosaccharide D-fructose bearing a sulfamate (-OSO2NH2) group. 
 
1 
Figure 1: Chemical structure of topiramate (2,3:4,5-di-O-isopropylidene--D-fructopyranose 
sulfamate) 
Topiramate is a drug best known for the treatment of epilepsy. 1  It was originally synthesised 
as part of a research project to discover structural analogues of fructose-1,6-diphosphate.2, 3   
The subsequent discovery of topiramate’s anticonvulsant properties was first reported by Bruce 
E. Maryanoff et al in 1987.1 Topiramate was evaluated for potential anticonvulsant effects due 
to the structural resemblance of its sulfamate group to the sulfonamide moiety in acetazolamide 
2 and other arene sulphonamides, such as benzenesulfonamide 3, that were known to be potent 
anticonvulsants.1 Topiramate was found to be highly active in the traditional maximal 
electroshock seizure (MES) test in mice and rats1 and a range of other seizure models.4  The 
drug has since undergone extensive clinical trials and was found to be clinically effective as 
both a monotherapy and as an adjunctive to other drugs in the treatment of various forms of 
epilepsy.5 Topiramate is approved as an anticonvulsant medication in over 95 countries.6  In 
addition, it is approved for migraine prophylaxis in both the UK 5 and US.7  In 2012, the US 
Food and Drug Administration approved the use of Qsymia, a combination of phentermine, an 
amphetamine derivative, and topiramate, for chronic weight management in obese and 
overweight patients.8, 9   
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Figure 2: Chemical structures of acetazolamide 2 and benzenesulfonamide 3 
Topiramate is FDA approved 7 and other studies have subsequently been carried out to consider 
the longer term effects of using the drug.10  In all cases, the most common side effects occurring 
in over 30% of patients were related to the central nervous system (e.g. headache, dizziness, 
fatigue and somnolence) and gastrointestinal disorders (e.g. nausea).11  Another recognised side 
effect is a decrease in body weight with recorded weight loss being greatest among patients 
with the highest body weight at baseline. 11  
 
1.1.2. Pharmacokinetics 
Topiramate is taken orally and its pharmacokinetics are characterised by rapid and linear 
absorption, a half-life of 19-25 hours and low oral clearance, which is predominantly through 
renal excretion.12  It distributes to all tissues including the brain.11  Topiramate is not 
extensively metabolised in humans (ca. 20%) and is eliminated predominantly unchanged in 
the urine.13  Six minor metabolites 4-9 have been isolated and characterised and result from 
metabolic pathways involving hydroxylation and hydrolysis of the two isopropylidene groups.3  
The metabolites are present in plasma and urine in very small quantities; 9 and 4 were identified 
as the most prominent urinary metabolites, with a recovery accounting for 4% of the 
administered topiramate dose.  The remaining metabolites account for less than 1% of the 
original dose.6  The metabolites are cleared from the body quickly without accumulation.13  
None of the metabolites are thought to play a role in anticonvulsant activity.14      
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Figure 3: The structure of the six known metabolites of topiramate 
 
1.1.3. Pharmacology 
The pharmacology of topiramate has been extensively researched in order to elucidate and 
study its mode of action in the control of seizures.  The precise mechanism by which topiramate 
exerts its antiseizure and migraine prophylaxis effects are unknown.5  However, evidence 
suggests that the drug possesses a unique combination of pharmacological properties resulting 
in multiple mechanisms of action.1, 14  A number of electrophysical and biochemical studies on 
cultured neurons have identified three properties that may contribute to the antiepileptic 
efficacy of topiramate.15 16 17    
• the inhibition of voltage sensitive sodium channels 
Action potentials, or nerve impulses, are electrical signals produced by the flow of ions across 
the plasma membrane of a neuron.  They are mediated by transient changes in the permeability 
of the cell to sodium and potassium ions.  The neuronal membrane contains specialised proteins 
which form pores in the membrane that are selectively permeable to particular ions.  The 
activation of these voltage sensitive channels results in the diffusion of ions into and out of the 
neuron.  In a resting neuron, there is a higher concentration of sodium ions outside the neuron 
with a higher concentration of potassium ions within.  This gives rise to the membrane 
potential.  Action potentials occur due to depolarisation of the neuronal membrane that 
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propagates along the nerve.  Local depolarisation leads to the flow of positively charged ions 
across the neuronal membrane.  Sodium channels in the neuronal membrane are opened in 
response to a small depolarisation of the membrane potential.  If sodium channels are opened, 
positively charged sodium ions diffuse into the neuron, making the inside of the neuron 
momentarily positively charged and the membrane becomes depolarised.  The sodium channels 
spontaneously close and potassium channels begin to open, leading to a reversal in the 
membrane potential.  The potassium channels then also inactivate and the membrane 
equilibrates to its resting potential.  Topiramate has been found to reduce the frequency at 
which action potentials are generated when neurons are subjected to sustained depolarisation. 
The amplitude of the inward ion currents via voltage gated sodium channels was found to be 
reduced by the drug.15, 18   In particular, topiramate was found to be capable of significantly 
inhibiting both the fast and persistent components of sodium currents and sustained neuronal 
depolarisation that feature in seizure initiation and activity.19     
• the antagonism of the activity of kainate/ AMPA subtype of glutamate receptor 
Neuroexcitatory function mediated by glutamate, a neurotransmitter, through AMPA (α-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate) and kainate receptors is critically 
involved in normal synaptic function in the brain and central nervous system.  It is also critical 
in the generation of the activity underlying epileptic seizures.20   Calcium is an important 
intracellular regulator of neuronal excitability and calcium currents may play an important role 
in seizure generation.21   Topiramate has been found to selectivity antagonise calcium ion 
permeable AMPA receptors and/ or kainate receptors.20 16  This finding can be rationalised by 
examination of the active docking interactions of topiramate within AMPA (Figure 4).  It can 
be envisioned how reducing excess activation of these AMPA and kainate receptors during 
epileptic seizure activity could result in a powerful antiepileptic mechanism.16   
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 B 
Figure 4: Cartoon diagram of AMPA (A) showing topiramate docked into active site; the white 
ellipse (B) denotes the binding sites of other known AMPA antagonists (e.g. perampanel).  (The 
structure was drawn in pyMOL using the crystal structure PDB:3KG2) 
 
• the enhancement of the activity of GABA (-aminobutyric acid) at some types of GABA 
receptors 
γ-Aminobutyric acid, or GABA, is produced by the decarboxylation of glutamic acid and is a 
potent inhibitory neurotransmitter. It plays a role in regulating neuronal excitability throughout 
the central nervous system, mediating inhibitory synaptic transmission. GABAA receptors are 
part of a ligand-gated ion channel complex that influence the flow of ions into and out of cells 
and affects the transmembrane potential.  Topiramate has been found to have a modulatory 
effect on these GABAA receptors increasing the frequency of channel activation and the flux 
of chloride ions into neurons.17, 22  
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• the inhibition of carbonic anhydrase 
 
Topiramate is also known to inhibit all isozymes of the enzyme carbonic anhydrase (CA).23  
Studies have shown that topiramate, selectively, but not specifically inhibits the isozymes 
CAII, CAIV, CAVA and CAVB more effectively than other CAs.14, 24, 25  Topiramate has been 
shown to have particularly effective inhibitory activity against CAII (Ki=10nM), CAVA 
(Ki=63nM) and CAVB (Ki=30nM).
25, 26   Evidence suggests that the drug’s inhibition of certain 
isozymes of CA contributes to its properties as an anticonvulsant but that it is not the dominant 
factor in this particular therapeutic area.14  The inhibition of CAII, CAVA and CAVB in 
humans by topiramate has a potency that is sufficient to have an appreciable effect on the 
activity of these CA isozymes at therapeutically relevant doses.24  Particular side effects 
experienced by patients using topiramate can be attributed to its potent inhibition of CAs, such 
as weight loss, transient myopia and renal nephrolithiasis.11, 23, 24, 27   Topiramate’s mode of 
action as a carbonic anhydrase inhibitor (CAI) is detailed in section 1.3.5. 
 
1.2. Carbonic Anhydrase (CA) 
 
1.2.1. Introduction 
CAs are enzymes that are ubiquitous throughout virtually all living organisms.  Five genetically 
distinct classes of CAs are known, α, β, γ, δ and ζ. The α-class of CAs are found in vertebrates 
and are the most well characterised and researched.  α–CAs are the only type present in humans 
and other mammals.  β-CAs are present in higher plants and some prokaryotes, γ-CAs are 
observed only in Archaebacteria, and δ and ζ have only been found in marine diatoms.  These 
classes of CAs differ from each other in their primary amino acid sequences and 3D tertiary 
structure (α, β, γ).28  All are metalloenzymes; α-, β-, and δ-CAs contain a Zn2+ ion within the 
active site.  γ-CAs are thought to contain a Fe2+ ion within the active site, but they are also 
active with bound Zn2+ or Co2+ ions, whereas Cd2+ or Zn2+ ions are present in ζ-CAs.  Many 
representatives of all these enzyme classes, except the δ-CAs, have been crystallised and 
characterised in detail.27    
All classes of CAs regulate the concentrations of CO2, bicarbonate ions and protons by 
catalysing the reversible hydration of carbon dioxide to yield a bicarbonate anion and a proton: 
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The reaction is biologically important and, as such, CAs are expressed variably in different 
species, tissues and cells.  As well as the critical role CAs play in the transport of CO2 and 
HCO3
-, they also influence a diverse range of physiological and pathological processes.  In 
vertebrates, the role of CAs in pH regulation, CO2 homeostasis, electrolyte secretion, 
biosynthetic processes, such as gluconeogenesis, lipogenesis, and ureagenesis, bone resorption 
and calcification have been thoroughly studied.29, 30  In algae, plants, and some bacteria they 
play an important role in photosynthesis and other biosynthetic reactions.  In diatoms δ- and ζ-
CAs play a crucial role in carbon dioxide fixation.27 
 
1.2.2. α-Carbonic Anhydrases 
At present, there are 15 known forms of α-CAs found in humans differing in their molecular 
features, their distribution in organs and tissues, their kinetic properties and their response to 
different types of inhibitors (Table 1).28   Of these, 13 are catalytically active and three (CAVIII, 
CAX and CAXI) are known as CA-related proteins (CARPs) and do not show catalytic activity 
due to the lack of histidine residues required for the coordination of a zinc ion within the active 
site.31   
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Isozyme 
 
Organ/ tissue distribution 
 
 
Subcellular location 
CAI erythrocytes, gastrointestinal tract, 
eye 
cytosol 
CAII erythrocytes, gastrointestinal tract, 
eye, lung, bone, testis, brain, 
osteoglasts, kidney 
cytosol 
CAIII skeletal muscle, adipocytes cytosol 
CAIV kidney, lung, pancreas, brain 
capillaries, colon, heart muscle, 
eye 
membrane-bound 
CAVA Liver mitochondrial 
CAVB heart and skeletal muscle, 
pancreas, kidney, spinal cord, 
gastrointestinal tract 
mitochondrial 
CAVI salivary and mammary glands secreted in saliva and milk 
CAVII central nervous system cytosol 
CAVIII central nervous system cytosol 
CAIX tumours, gastrointestinal mucosa transmembrane 
CAX central nervous system cytosol 
CAXI central nervous system cytosol 
CAXII kidney, intestine, reproductive 
epithelia, eye, tumours 
transmembrane 
CAXIII kidney, brain, lung, gut, 
reproductive tract 
cytosol 
CAXIV kidney, brain, liver, eye transmembrane 
   
Table 1: Organ/ tissue distribution, subcellular location of the 15 α-CA isozymes found in 
humans 28 
To date X-ray crystallographic structures of all isoforms of human CA except CAVB are 
available (an example is presented in Figure 5).28  These structures indicate high sequence 
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homology throughout the isozymes with a high level of conservation of key residues within the 
active site.  The enzymes present a similar structure that is characterised by a central twisted 
β-sheet surrounded by helical connections and additional β-strands.   Despite the high sequence 
and structural homology of the active sites of the α-CA isozymes, there are some differences 
in the quaternary structure.    Most of the isozymes are monomeric apart from three isozymes, 
CAIX, CAXII and CAVI that are dimeric although this is not thought to influence catalytic 
activity in any way.28 
 
 
Figure 5: The structure of human CAII shown in cartoon representation showing the zinc ion 
as a grey sphere and the three coordinating histidine ligands (the structure was drawn in 
pyMOL using the crystal structure PDB:1CA2) 
The active site of the enzyme is located within a conical cleft approximately 15Å deep from 
the surface of the enzyme to the centre of the molecule.  The catalytic zinc ion is located at the 
base of this cavity in a distorted tetrahedral coordination liganded to three conserved histidine 
residues (His 94, His 96, His 119) and an oxygen atom of a water molecule that ionises to a 
hydroxide ion at physiological pH (Figure 7).30  In all of the α-CA isozymes, the active site 
cavity has two distinct regions; a hydrophobic region delimited by a group of hydrophobic 
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amino acids and an adjacent area comprising of hydrophilic residues (Figure 6).  This particular 
active site environment is important to the catalytic activity of the enzyme.  The hydrophobic 
binding site is important in the facilitation of CO2 into the active site and the hydrophilic 
residues form a network of hydrogen bonds that maintain an active catalytic structure (Figure 
7).28  In particular, a threonine residue (Thr 199) forms a hydrogen bond with the zinc bound 
hydroxide ion and a glutamic acid residue (Glu 106) orientates the hydroxide ion in the optimal 
position for nucleophilic attack on the CO2 substrate held in the hydrophobic pocket (see 
Figures 7 and 8).  The electrostatic environment, and thus the reactivity of the zinc bound 
hydroxide ion, is further modulated by “second shell” or indirect ligand residues which are 
defined as those that hydrogen bond with direct metal ligands, for example, the three histidine 
residues.30  “Deep water” (Figure 7) refers to an ordered water molecule positioned near the 
hydrophobic pocket which plays a role in the enzyme’s catalytic activity.  Figure 7 shows three 
such residues interacting with the zinc coordinated histidines, a glutamine (Gln 92), glutamic 
acid (Glu 117) and an asparagine (Asn 244).   
 
 
 
 
Figure 6: Surface representation of human CAII showing active site cleft.  Hydrophobic 
residues are shown in red and hydrophilic in blue (the structure was drawn in pyMOL using 
the crystal structure PDB:1CA2) 
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Figure 7: The active site of human CAII (which has been chosen as a representative CA) 
showing the scheme of hydrogen bond networks, represented by green dashed lines 
  
 
1.2.3. Catalytic Mechanism 
CAs are one of the most efficient biological catalysts known with several isozymes having 
catalytic efficiency approaching the limit of diffusion control.30  The kinetics and catalytic 
mechanism of CA has been extensively studied using human CAII as a model.   However, it is 
thought that all α-CAs exhibit the same general mechanistic scheme where the reversible 
hydration of carbon dioxide proceeds via a tandem chemical reaction (Figure 8).32     
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Figure 8: General mechanism for the catalysis of CO2 hydration by CAs 
 
The active form of the enzyme has a hydroxide ion bound to the zinc ion’s fourth coordinating  
position. This nucleophilic zinc bound hydroxide attacks the enzymatically bound CO2 
molecule and converts it to a bicabonate ion that coordinates to the zinc.  The bicarbonate ion 
is then displaced by a water molecule and is liberated into solution.  The transfer of a proton 
from the zinc bound water molecule from the active site to the bulk solvent is needed to 
regenerate the active enzymatic environment.  This is the rate limiting step of the entire 
catalytic process.29  In certain CA isozymes (I, II, IV, VI, VII, IX and XII – XIV) the proton 
transfer reaction is assisted by a histidine residue (His 64) whereas in others, buffers present in 
the medium play a role.27  In those isozymes where His 64 is present, the ionisation reaction is 
achieved via a series of proton hops across a hydrogen bonded solvent network or proton wire 
(Figure 9) in which the His 64 and the zinc bound water are linked by two water molecules.33    
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Figure 9: Mechanism of ionisation of zinc bound water in human CAII via a proton shuffle 
assisted by His 64 to regenerate a nucleophilic zinc bound hydroxide ion 
  
1.2.4. Carbonic Anhydrase Inhibitors 
CAs play a role in a number of important physiological processes and thus CA isozymes are 
important targets for the development of new pharmacological applications.  Extensive 
research into the drug design of both CA inhibitors (CAIs) and CA activators has been 
undertaken during the last 30 years.26, 27   CA activators may have pharmacological applications 
in pathologies in which learning and memory are impaired, such as Alzheimer’s disease or 
ageing.34  The inhibition of CAs have potential therapeutic value in treating a range of disorders 
including oedema, glaucoma, obesity, cancer and epilepsy (Table 2), as well as in the emerging 
areas of antifungal or antibacterial agents.27, 35, 36   
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Isozyme 
 
Disease in which isozyme is involved 
 
CAI Retinal/ cerebral oedema 
CAII Glaucoma, oedema, epilepsy, altitude sickness 
CAIII Oxidative stress 
CAIV Glaucoma, retinitis pigmentosa, stoke 
CAVA Obesity 
CAVB Obesity 
CAVI Cariogenesis 
CAVII Epilepsy 
CAVIII Neurodegeneration/ cancer 
CAIX Cancer 
CAXII Cancer/ glaucoma 
CAXIII Sterility 
CAXIV Epilepsy, retinopathy 
  
Table 2:  Human CA isozymes as drug targets in various diseases.  (No data is available in the 
literature on the involvement of CAX and CAXI in diseases) 28 
 
As specific isozymes of CAs are responsible for different biological responses, the challenge 
is to design isozyme-specific CAIs to selectively target particular pathologies and minimise off 
target biological activities that manifest as unwanted side effects or toxicity.  This poses certain 
difficulties; there are 13 catalytically active human CA isozymes spread diffusely throughout 
the tissues and organs of the body, the isozymes have a high level of structural similarity within 
their active sites and each isozyme functions via the same catalytic mechanism.  This explains 
why none of the CAIs currently used clinically show selectivity for a specific isozyme but 
indiscriminately inhibit several CA isozymes, behaviour that is shared by topiramate.29   
CAIs generally bind to the active site of the enzyme and prevent or hinder the sequence of 
reactions detailed in Figure 8 from occurring.  CAIs can be divided into two main classes, those 
that contain a zinc binding group and those that bind to the active site of CA but have no direct 
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interaction with the zinc ion.  Sulfonamides (R-SO2NH2) and their isosteres, sulfamates (R-
OSO2NH2) and sulfamides (R-NHSO2NH2), constitute the main class of CAIs and fall into the 
first category.29  Several compounds such as acetazolamide 2, methazolamide 10, 
ethoxzolamide 11, sulthiame 12, dichlorophenamide 13, dorzolamide 14, brinzolamide 15, 
sulpiride 16 and zonisamide 17 have been in clinical use for many years, as diuretics, 
antiglaucoma agents, as well as antiepileptics.29   Sulfamates including topiramate 1 and 
irosustat 18 although developed independently of their potential CA inhibitory properties, are 
also potent CAIs. Irosustat 18 is a first-in-class steroid sulfatase inhibitor to be used clinically 
in patients with advanced hormone-dependent cancers.28   
 
 
 
Figure 10: Structures of sulfonamide and sulfamate CAIs currently in clinical use 
 
Both sulfonamides and sulfamates bind to the zinc ion in the enzyme active site in their 
deprotonated form as anions.  Figure 11 shows the key binding interactions between a generic 
sulfonamide inhibitor and the active site of human CAII.  Crystallographic studies are available 
for many sulfonamide adducts with several CA isozymes and this has enabled the elucidation 
of the key factors responsible for the binding of the sulfonamide moiety to the CA active site.28  
In all of the studied adducts the binding of the sulfonamide derivatives is primarily by the 
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coordination of the deprotonated nitrogen atom of the sulfonamide to the catalytic zinc ion 
leading to the substitution of the zinc bound water molecule.  Additionally, two hydrogen bonds 
between the sulfonamide and the important Thr199 residue form and, depending on the nature 
of the sulfonamide’s molecular scaffold (depicted as R in Figure 11), interactions with the 
hydrophilic and/or hydrophobic region of the active site can be also present.  Sulfamates show 
a similar pattern of interactions with the active site of human CAII.28  
 
 
 
Figure 11: Schematic illustration of the key interactions between a generic sulfonamide 
inhibitor and the human CAII active site with hydrogen bonds represented by green dashed 
lines 28   
 
Other families of CAIs possess different mechanisms of action in which they do not directly 
interact with the zinc ion.   Phenols (e.g. phenol 19) anchor to the zinc bound water molecule/ 
hydroxide ion within the active site through two hydrogen bonds with the phenolate group.28  
Polyamines (e.g. spermine 20) were found to have a similar mechanism of inhibition as phenol 
with one of the terminal ammonium moieties anchored to the zinc-coordinated water 
molecule/hydroxide ion by means of a hydrogen bond.37  Coumarins (e.g. 21) and 
thiocoumarins (e.g. 22) have a mechanism of action independent of the catalytical zinc ion.  
They act as “prodrug” inhibitors, binding in their hydrolysed form.  Crystallographic studies 
of adducts of coumarins and several of their derivatives with various CA isozymes showed that 
these compounds bind to the enzyme at the entrance of the CA active site cavity in a region 
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where only CA activators had been observed earlier.29  The result is the partial occlusion of the 
entrance to the active site. 
 
 
Figure 12: Structures of various CAIs which have a different mode of inhibition than 
sulfonamides and related compounds  
 
1.2.5. Topiramate as a CAI 
The enzyme inhibition interactions between topiramate and the active site of human CAII can 
be confidently represented, as shown in Figure 13, as a known crystal structure of the complex 
exists.38   The 3D enzyme-inhibitor structure reveals the molecular interactions that readily 
account for the good CAII inhibition observed for topiramate.39  The sulfamate group of 
topiramate acts as a zinc binding group and participates in a network of hydrogen bond 
interactions with residues within the active site. The ionised nitrogen atom of the sulfamate 
coordinates to the zinc and displaces a hydroxide ion.  In addition, this nitrogen atom donates 
a hydrogen bond to the hydroxyl group of residue Thr 199.  One of the sulfamate oxygen atoms 
accepts a hydrogen bond from the backbone NH group of Thr 199.38  The sugar scaffold plays 
an important role in securing the molecule into the appropriate position within the enzyme 
active site.  The oxygen of the pyranose ring makes a hydrogen bond with Thr 200 whilst the 
methyl groups of the two acetal groups of the sugar are positioned appropriately to interact 
with the hydrophobic pocket of the active site and form Van der Waals interactions with the 
active site cleft.  Additionally, the oxygen atoms of the two acetal groups form polar 
interactions with active site residues Gln 92 and Asn 62.28  
18 
 
 
Figure 13: Schematic diagram of the active site of the human CAII/ topiramate adduct crystal 
structure (with topiramate shown in red and hydrogen bonds represented by green dashed lines) 
(PDB: 3HKU) 28  
 
Of particular interest to this project is the inhibitory effect of topiramate 1 on the two 
mitochondrial CA isozymes, CAVA and CAVB.  A side-effect observed in epileptic patients 
treated with topiramate was that they experienced weight loss.11, 40  A new obesity therapy 
consisting of a combination of topirimate and phentermine, branded as Qsymia, was approved 
by the US Food and Drug Administration in 2012 and has been found to have robust efficacy 
for weight loss.8, 9  Although, the pharmacological explanation for the weight loss observed 
with topiramate is still under investigation, it is thought to be a result of its inhibition of CAVA 
and CAVB.26  Dysfunctional mitochondrial activity can be a fundamental cause of obesity and 
it is thought that topiramate mediates mitochondrial metabolism pathways via its inhibition of 
CA isozymes.27 Figure 14 shows the binding interactions between topiramate and human 
CAVA.  Although there is no known crystal structure of the topirimate/CAVA adduct, the 
schematic diagram has been proposed following in silico structural and sequence homology 
studies of the known crystal structures of murine CAVA with that of human CAII.41   Figure 
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14 shows that the tetrahedral geometry of the zinc binding site and the key hydrogen bonds 
between the sulfamate group of topiramate and the active site are all retained in the 
topiramate/CAVA complex.  The extended network of hydrogen bonds and Van der Waals 
interactions between the sugar scaffold and the active site cleft are also retained, although the 
pattern is different, and exert a stabilising effect as observed in CAII.41 
     
 
 
Figure 14: Schematic diagram of the active site of the human CAVA/ topiramate adduct crystal 
structure (with topiramate shown in red and hydrogen bonds represented by green dashed lines) 
based upon homology studies 41 
 
CAVA and CAVB are involved in several biosynthetic processes including ureagenesis, 
gluconeogenesis and lipogenesis.  The hydration reaction catalysed by CAVA and CAVB 
within mitochondria, assisted by CAII in the cytosol, ensures the provision of sufficient 
bicarbonate ions for several key processes involving pyruvate carboxylase, acetyl coenzyme A 
(acetyl CoA) and carbamoyl synthetases.26  CAVA and CAVB are thought to be critical to the 
synthesis of fatty acids and the action of CAIs on these particular isozymes leads to the potent 
inhibition of lipogenesis.39  This has been rationalised by considering the role of CA isozymes 
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within fatty acid synthesis, as shown schematically in Figure 15.  Fatty acid synthesis takes 
place in the cytosol whereas acetyl CoA, the building block of fatty acids, is formed in 
mitochondria from pyruvate.  Acetyl CoA must therefore be transferred from mitochondria to 
the cytosol.  However, mitochondria are not readily permeable to acetyl CoA and this barrier 
is bypassed by citrate which carries acetyl groups across the mitochondrial membrane.  Citrate 
is formed from pyruvate within the mitochondrial matrix by a pathway involving the enzyme 
pyruvate carboxylase.  Citrate is translocated from mitochondria to the cytoplasm and a further 
biosynthetic pathway leads to de novo lipogenesis.  Bicarbonate ions are required in two key 
steps; within the mitochondria the carboxylation of pyruvate to oxaloacetate, the precursor to 
citrate, is carried out in the presence of bicarbonate.  The mitochondrial isozymes CAVA and 
CAVB will thus influence this reaction.  Bicarbonate ions also play a key role in the 
carboxylation of acetyl CoA to malonyl coenzyme A (malonyl CoA) within the cytosol and it 
is suggested that this is mediated by CAII, the cytosolic isozyme.27   
 
 
 
Figure 15: Fatty-acid biosynthesis and the role of CA isozymes 26 
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1.2.6. Development of novel CAIs based on topiramate 
Topiramate is known to inhibit both CAII and the mitochondrial CA isozymes, CAVA and 
CAVB.28  As such it represents a valid pharmacophore from which to consider the design of 
isozyme specific CAIs.  Further to the discovery and characterisation of the mitochondrial 
isozymes human CAVA and CAVB, they are now considered as “druggable” targets and that 
novel sulfonamide and sulfamate CAIs directed specifically against these isozymes may have 
applications for the development of antiobesity drugs.26, 39   It is hypothesised that designing a 
novel agent with a specific inhibition profile for CAVA and CAVB will enable the weight loss 
effects associated with inhibition of these isozymes to be positively exploited whilst 
minimising off-target biological effects.  The project has adopted a rational drug design process 
with the active sites of CAII, CAVA and CAVB being the initial biological targets against 
which potential drug candidates, both known and novel compounds, will be assessed (Figure 
16).  In silico modelling has been used to identify and predict which of the metabolites and 
postulated analogues of topiramate will act as specific CAIs.  The in silico hits generated from 
modelling will be the primary synthetic targets and a first round has been completed.  These 
compounds will be used for biological testing to act as either a positive, or negative, test of the 
computational models and to guide further in silico development work. 
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Figure 16: The approach to isozyme specific drug design and modulation of the inhibition 
profile of topiramate   
 
1.3. In silico Evaluation Study 
The computational modelling study has been carried out by Prosarix Limited, a Cambridge 
based biotechnology firm that specialises in modern drug design methods.  The information 
presented in the following section is adapted from a confidential report prepared for the 
research partnership by Prosarix Limited. 
The objectives of the initial in silico work were to: 
• analyse the likely activities of topiramate metabolites (4 – 9) on CAII, CAVA and 
CAVB in order to identify which may retain CA inhibitory properties; 
• model iminosugar analogues of topiramate on CAII, CAVA and CAVB; 
• predict the likely activities of such compounds on these targets. 
A number of molecular studies were conducted.  The Molecular Operating Environment 
(MOE) software suite developed by Chemical Computing Environment (CCG Inc.) was used 
to visualise and understand the details of the active sites of the relevant CAs and receptor ligand 
Identification of topiramate 
as a pharmacophore 
Modify topiramate  
structure 
in silico evaluation  
of modified molecules 
Synthetic targets  
identified 
Biological testing of  
targets 
Potential CAI 
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interactions.  The crystal structure of human CAII complexed with topiramate was analysed 
with MOE in order to understand the important interactions present in the inhibitor complex.  
Accurately mapping the network of hydrogen bonds and hydrophobic interactions between 
topiramate and the active site cleft of CAII can then be used to inform subsequent models which 
introduce the active sites of other CA isozymes and topiramate-like compounds.   
As no crystal structures of human CAVA and CAVB exist, models of the active sites of these 
CA isozymes were constructed based upon a murine CAVA template.  Murine CAVA has high 
sequence homology to human CAVA sharing 76% sequence identity.41  Homology modelling 
tools within MOE were used to prepare an initial sequence alignment of murine CAVA with 
human CAVA and human CAVB followed by detailed model construction.  Various 
refinements were made to the models to account for solvent electrostatics, molecular mechanics 
and energy minimisation calculations.  The optimised models of human CAVA and CAVB 
were structurally aligned with the human CAII structure to enable analysis of the active site 
differences and predict the likely major binding site differences.  Topiramate was docked into 
the active site models of CAVA and CAVB and the pose and interactions of the molecule with 
active site residues were analysed.  Prosarix employed their proprietary software, Protoscreen 
and Protodiscovery, to explore binding site flexibility to assess all possible binding site 
conformations of both active site residues and the ligand.   
The results for the CAVA/ topiramate receptor–ligand interactions agreed with those depicted 
in Figure 14 with several important features exhibited.  Mutations of a number of residues 
within an α-helix loop region adjacent to the zinc ion affects its orientation. 41  Of particular 
influence is the change from Ala 64 in CAII to a bulkier leucine residue in CAVA which 
projects into the binding site.  As a consequence, the active site cleft is narrower in human 
CAVA than in human CAII.  This reduction in the active site volume does not accommodate 
topiramate in the CAII binding mode and enforces an altered residue conformation. In addition, 
Phe 131 in CAII is a tyrosine residue in CAVA which projects a hydroxyl group into the 
binding site resulting in a clash with one of the geminal methyl groups of topiramate when it 
is aligned in its CAII conformation and thus an alternative conformation of topiramate is 
required within the CAVA active site.        
The results of the CAVB docking studies suggest that topiramate adopts a similar binding pose 
with CAVB as is shown with CAII.  The reason for this is twofold; the Ala 64 residue in CAII 
is replaced by a serine group in CAVB which results in a similar active site volume, also Phe 
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131 is conserved in CAVB.  This means that the enforced changes in the binding mode of 
topiramate observed in CAVA when Phe 131 is replaced by a tyrosine residue does not occur 
in CAVB.   A further binding site difference in CAVB is residue 92 which is glutamine in 
CAII, asparagine in CAVA but is a leucine residue in CAVB.  In CAVB, this residue is in a 
position that could potentially allow for interactions to one of the oxygen atoms of the acetal 
groups.  
Armed with an understanding of the likely binding modes of topiramate in both human CAVA 
and CAVB models and the knowledge of a binding mode between topiramate and CAII, the 
next stage of the modelling process was to consider molecular variants of topiramate.  
Topiramate metabolites 4, 5, 8 and 9 were docked into the models of the active sites of CAII, 
CAVA and CAVB.  The metabolites 4 and 5 are predicted to exhibit good affinity with CAVB 
but not with CAVA and CAII.  This difference is due to the residue at position 65 in each 
isozyme.  In CAII it is Ala 65, in CAVA it is Leu 65 and Ser 65 in CAVB.  The presence of 
the serine in CAVB active site is predicted to interact specifically with the hydroxyl groups of 
one of the acetals whereas these hydroxyl groups present energetically unfavourable 
interactions with Ala 65 in CAII and Leu 65 in CAVA.   This suggestion of selectivity towards 
only one isoform of CA warrants further investigation.   
In addition, further in silico models in which two compounds related to the anti-epileptic drug 
zonisamide 17 were docked into the CA receptor models were developed.  2-sulfamoylacetyl 
phenol 23 is a reductive metabolite of zonisamide and N-acetyl zonisamide 24 results from the 
acetylation of zonisamide.42  It was of interest to explore the likely binding modes and affinities 
of both molecules to assess whether there was any scope of metabolites and analogues of 
zonisamide as inhibitors of CAVA and/or CAVB.  The modelling predicted that both 23 and 
24 did not present interesting leads on which to extend the scope of the project. However, 24 
was considered to have utility as a reference for biological  evaluation as it would provide an 
interesting comparative data set to topiramate and related compounds.     
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Figure 17: Compounds related to zonisamide; 2-sulfamoylacetyl phenol 23 and N-acetyl 
zonisamide 24 
 
Table 3 summarises the predicted affinities of metabolites of topiramate and zonisamide with 
various isozymes of carbonic anhydrase.  Within the table, predicted positive affinity is 
represented by “+”, weaker predicted affinity by “-” and likely weak affinity by “- -“.  
Interestingly, topiramate metabolites 4 and 5 are predicted to exhibit weaker affinities with 
respect to CAII and considerably weaker to CAVA, but higher affinities to CAVB.  This 
suggestion of selectivity for one isozyme above others identified 4 and 5 as interesting targets 
for synthesis in order that biological testing could be carried out to assess their pharmacological 
properties and support the modelling process.  The metabolites are known compounds having 
been isolated, characterised and synthesised 3 but their pharmaceutical potential has not been 
fully explored. 
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Compound CAII CAVA CAVB 
 
- -- + 
 
- -- + 
 
-- - - 
 
- -- - 
 
- - - 
 
-- -- -- 
Table 3: Predicted affinities of various compounds to isozymes of carbonic anhydrase  
(Key to affinity predictions: + = positive/++ = highly positive/- = negative/-- = highly 
negative) 
 
 
27 
 
The novel compounds under consideration are iminosugar analogues of topiramate, the basic 
structure of which is shown in Figure 18.  All in silico models developed to date initially 
considered the analogue 25.  However, further substitution of the endocyclic nitrogen may be 
beneficial to the affinity of the molecule for the active site, may enhance isozyme specificity 
or may be necessary to afford the molecule with the necessary stability for in vivo application. 
Compounds 26 – 29 may be subject to further modelling work.  However, the synthetic 
complexity in terms of construction of such scaffolds is worthy of mention and is a known 
issue within this field of chemistry.    
 
Figure 18: Iminosugar analogues of topiramate 
 
The iminosugar analogue of topiramate 25 is predicted to bind with CAII in an almost identical 
binding pose to topiramate as depicted in Figure 13.  The key difference is that the hydrogen 
bond between the oxygen atom of the pyranose ring of topiramate and the hydroxyl group of 
Thr 200 is replaced by a hydrogen bond donated by the secondary amine nitrogen in the new 
ligand to the hydroxyl group of Thr 200.  In the protonated form, the new amine can also donate 
its other hydrogen to form a hydrogen bond with a complexed water present within the CAII 
active site (Figure 19).  
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Figure 19:  Schematic diagram of the predicted active site of human CAII and an iminosugar 
analogue of topiramate (with the ligand shown in red and hydrogen bonds represented by green 
dashed lines)  
 
Overall, the iminosugar is predicted to bind with reduced affinity to CAII versus topiramate.   
This is related to increased energetics of docking due to structural differences in the iminosugar 
compared to its topiramate equivalent that will slightly penalise the binding of the ligand.   It 
is proposed that the iminosugar will exhibit increased strain energy compared to that of 
topiramate.  It is expected that the iminosugar analogue will have increased desolvation energy 
by virtue of the solvation required for a secondary amine versus an ether oxygen, even though 
the nitrogen atom is partially exposed to solvent and only directly contacts one amino acid.  Of 
course, a prime objective of the research is to try and develop topiramate analogues that exhibit 
specificity for only particular CA isozymes and not CAII in particular.  Thus a compound that 
has less affinity for CAII may be of benefit in that it may avoid CAII inhibition activity.  The 
predicted reduced affinity of the iminosugar analogue may be compensated by other 
advantageous features of the ligand such as in its pharmacokinetics or increased solubility.  
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Introducing alternative functionalisation to the nitrogen atom of the iminosugar as in 26 - 29 
affords opportunity to improve affinity and selectivity and this will be further assessed.       
The binding modes of the iminosugar analogue 25 with CAVA is similar to topiramate.  Of 
interest is that the proposed hydrogen bond interactions of the protonated amine with both the 
Thr 200 residue and a water molecule held within the active site is predicted to be conserved 
between CAII and CAVA.  Similar to CAII, the compound exhibits slightly more strain energy 
than its topiramate counterpart and also slightly higher desolvation energy.  Despite 
confirmation strain energy and desolvation energy increases, 25, is predicted to achieve a 
positive binding affinity for CAVA and CAVB.  It is also of note that modelling suggests there 
is increased scope to introduce additional functionality/structural motifs onto the sugar scaffold 
which could in turn lead to advantageous isozyme differentiation.  The specifics of this were 
intended as part of the second iteration of compounds once positive conformation of affinity, 
through in vivo testing, was obtained. 
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CHAPTER 2. Synthesis and Biological Evaluation of Metabolites and 
Isoteres of Topiramate and N-acetyl Zonisamide 
The in silico modelling work as detailed in Section 1.3 suggested that several metabolites of 
topiramate 1 may have potential as CAIs with the ability to demonstrate a greater specificity 
than topiramate for the CA isozymes CAVA and CAVB.  Compounds 4, 5 and 8 were identified 
as initial synthetic targets with the objective of obtaining CA inhibitory data on these 
compounds that would be used to evaluate the predictions generated by the in silico modelling 
and to further develop the computational models to identify other possible CAIs. 
A second group of compounds, 30 to 34 (Figure 20), were also of interest and were identified 
as additional synthetic targets.  In respect of this range of compounds, the sulfamate group that 
is present in topiramate 1 is replaced with various five membered heterocycles that have a loose 
isosteric relationship to the sulfamate group.  It was hypothesised that the heteroatoms present 
within the five membered rings would provide comparable opportunities for hydrogen bond 
interactions with residues within the active sites of CA isozymes to those observed for the 
sulfamate group.  This may lead to alternative binding modes to that of the lead compound 
topiramate 1 which may generate favourable biological results in terms of CA affinity and 
specificity.  In addition, measurement of the biological activity of these compounds would 
provide additional and useful indicators for the ongoing development of selective CAIs.   
 
 
Figure 20: Heterocyclic analogues of topiramate  
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A second tranche of related novel compounds, 35 to 38 (Figure 21), in which the linker between 
the heterocycle and the pyranose ring is extended by a methylene group were also of synthetic 
interest. The heterocycles offer hydrogen bonding opportunities and the additional methylene 
group at the anomeric position of the pyranose ring affords greater conformational flexibility.  
Whilst this greater flexibility may incur an energy penalty in terms of affording a fixed binding 
conformation, this was likely to be offset by the potential to allow increased interactions with 
key amino acid residues within the active site as well as with zinc. 
 
 
Figure 21: Additional heterocyclic analogues of topiramate 
The synthesis of N-acetyl zonisamide 24 (Figure 22) was also supported.  Although the in silico 
modelling work predicted that 24 was likely to have limited affinity for the CA isozymes of 
interest, obtaining biological data for this compound would provide a useful reference to 
support the ongoing programme of in silico modelling.  In addition, any data collected was 
useful to assess the ongoing potential of derivatives and analogues of zonisamide as selective 
CAIs. 
 
Figure 22: Structure of N-acetyl zonisamide 
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2.1. Synthesis of Topiramate Metabolites 
Scheme 1 details the proposed preparative route to the hydroxylated diastereomeric metabolites 
4 and 5 of topiramate (Scheme 1).  The desired third metabolite, 8, is obtained as an 
intermediate in the overall synthetic scheme.  Scheme 1 was adapted from a literature precedent 
with several changes introduced to improve product purity and yield at particular stages.3  
Initially, the starting material, 2,3:4,5-di-O-isopropylidene-D-fructopyranose 39, was readily 
prepared from the condensation reaction of the monosaccharide D-fructose with acetone and 
concentrated sulphuric acid.  However, for later syntheses, a cheap commercial source of 39 
was identified and purchased in bulk.  
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Scheme 1: Preparation of 4,5-O-(1-hydroxymethylethylidene)-2,3-O-isopropylidene--D-
fructopyranose sulfamate (R/S) 
 
The first stage of the synthetic route was to introduce the biologically important sulfamate 
group to 2,3:4,5-di-O-isopropylidene-D-fructopyranose 39 to obtain topiramate 1.  The 
reported approaches to installing a sulfamoyl group on alcohols are very limited.43   The most 
widely cited procedure for sulfamoylation is to treat the appropriate alcohol, in this case the 
primary alcohol group attached to the anomeric carbon of 39, as a solution in an anhydrous 
aprotic solvent under nitrogen with a suitable base, generally sodium hydride, at low 
temperature, followed by the addition of sulfamoyl chloride 43.  The resulting reaction mixture 
is then allowed to warm to room temperature under nitrogen.44  Sulfamoyl chloride has been 
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widely used as the reagent to effect this transformation in steroids and other primary alcohols 
and was considered appropriate for use here. 45 46   
 
As an inexpensive commercial supply of sulfamoyl chloride was not readily available, it was 
necessary to prepare the reagent in a quantity sufficient to support the chemistry that was 
planned.  The methodology for preparing sulfamoyl chloride from the reaction of 
chlorosulfonyl isocyanate 41 and formic acid 42, Scheme 2, was employed.47  Several 
adaptations were introduced to the literature procedure to improve the results obtained and 
maximise product yield when the reaction was carried out on a larger scale.  It was hoped that 
it would be necessary to only undertake one or two large scale preparations of sulfamoyl 
chloride to support ongoing chemistry development.  Initially, the reaction shown in Scheme 2 
was carried out without solvent.  On a small scale, ca 1g, this was found to work satisfactorily.  
However, increasing the scale resulted in a viscous and immobile reaction mixture despite the 
use of overhead agitation.  The addition of anhydrous toluene whilst the formic acid was added 
to the chlorosufonyl isocyanate was found to aid reaction mobility and homogeneity and thus 
improve reaction progression.  Sulfamoyl chloride is often stored and used as a solution in 
toluene but decomposes rapidly and is generally used in situ.44 47  This was not readily 
amenable to the production of a large quantity of sulfamoyl chloride that could be used over a 
period of time.  It was found that a more effective solution on a larger scale was to isolate the 
sulfamoyl chloride as a solid by removal of the toluene by concentration in vacuo at low 
temperature.  No further purification of the sulfamoyl chloride was undertaken and the material 
was used in its crude form in the subsequent chemistry steps.  Careful storage of the resulting 
solid under nitrogen and at temperatures below 0°C was necessary to prevent decomposition 
due to ingress of air and moisture.  The reaction was successfully completed on a 100g scale 
producing sulfamoyl chloride considered to be of satisfactory activity and purity.  The prepared 
sulfamoyl chloride was shown to have a good “shelf-life” when stored appropriately with no 
reduction in activity observed in reactions carried out over six months after its initial 
production.       
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Scheme 2: Preparation of sulfamoyl chloride 43 
 
 
 
Scheme 3: Preparation of topiramate 1 from 2,3:4,5-di-O-isopropylidene-D-fructopyranose 39 
 
In order to obtain reliable reference data of the initial step of Scheme 1 and confirm reaction 
outcomes, a model reaction was carried out using a small amount of commercially sourced 
sulfamoyl chloride. An initial small scale reaction was attempted with 2,3:4,5-di-O-
isopropylidene-D-fructopyranose 39 and the commercially sourced sulfamoyl chloride in order 
to produce reference NMR, mass spectrometry and TLC analysis of 1.  DMF was used as the 
reaction solvent in accordance with literature procedure1 although triethylamine was used as 
base in replacement of sodium hydride.  The analytical data of the product obtained from this 
first reaction conformed to published data.1  The reaction was repeated under identical 
conditions using sulfamoyl chloride that had been synthesised in accordance with Scheme 2.  
It was noted that a slightly greater stoichiometric amount of sulfamoyl chloride was required 
in the second reaction to push the reaction to completion than was necessary in the first when 
the commercial supply of sulfamoyl chloride was used.  This suggested that the sulfamoyl 
chloride produced from formic acid and chlorosulfonyl isocyanate was less active, more prone 
to decomposition under the reaction conditions employed leading to a larger impurity profile.  
The core analytical data obtained for the resulting product of the reaction was concordant with 
that of 1 prepared using the commercial supply of sulfamoyl chloride.  Active yields of ca 40% 
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were achieved in both experiments which were broadly in line with literature reported yields.3  
However, an impurity was observed in the 1H NMR of the isolated crude product from the 
second reaction, using prepared sulfamoyl chloride, in an approximately 10% molar quantity.  
The impurity remained post purification of the crude material by chromatography.  The 
chemical shifts of the impurity suggested that it related to a DMF adduct from the competing 
reaction between DMF and sulfamoyl chloride, although the identity of the impurity was not 
readily apparent by mass spectrometry.  Similar results have been reported in the literature 
where DMF was used as the reaction solvent and excess equivalents of strong base were used.44  
As the formation of this impurity was only apparent in the second reaction where sulfamoyl 
chloride synthesised from chlorosulfonyl isocyante and formic acid was used it may be 
attributable to it having lower overall purity than that of the commercial supply which meant 
that it was necessary to use a greater excess of sulfamoyl chloride to achieve reaction 
completion.  To assess whether the impurity would affect the subsequent stages of chemistry 
of Scheme 1, trial reactions were carried out using a small amount of 1 prepared in the second 
reaction which contained the 10% impurity.  Disappointingly, 1H NMR data showed that the 
impurity was carried through subsequent reaction stages despite several purification steps in 
the downstream chemistry.   
 
The use of purchased sulfamoyl chloride was not an available solution to preventing the 
impurity with the costs being too prohibitive on a larger scale.  Purification of sulfamoyl 
chloride prepared in-house was not a viable option either as the material was too reactive.  
Methods of optimising the reaction to prepare sulfamoyl chloride were also considered as a 
means of increasing the purity of the reagent.  This proved challenging with very little literature 
guidance and generally small scope for improvement offered by the reaction.  The challenge 
was, therefore, to attempt to optimise the conditions of the sulfamoylation reaction of 2,3:4,5-
di-O-isopropylidene-D-fructopyranose 39 in order to prevent the formation of the impurity 
while still obtaining a reasonable yield of active material.  The first option was to alter the 
conditions of the reaction of fructopyranose 39 with sulfamoyl chloride from those followed.  
The most obvious change to be considered was the replacement of DMF as reaction solvent as 
it was postulated that the impurity was solvent derived.  Alternative solvents used as the 
medium for the sulfamoylation reaction reported in the literature were DMA, NMP, DCM, 
DME and THF. 44, 45  A trial reaction to prepare 1 with a sample of sulfamoyl chloride from 
the same batch prepared in accordance with Scheme 2 was carried out in THF and was 
successful.  A similar yield was obtained to that when the reaction was carried out in DMF and 
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analysis of the product by NMR and mass spectrometry confirmed the desired product had 
formed.  No impurities were evident as in the earlier reaction carried out in DMF representing 
a very positive result. The reaction was subsequently scaled up successfully applying the same 
conditions.  
 
Consideration was also given to the potential of developing alternative sulfamoylation 
reagents.  There has been recent pharmaceutical research interest in a range of antibiotic and 
anti-tumour agents containing the sulfamate group.43  This has led to a focus on the 
development of novel sulfamoylating reagents that improve upon the stability, safety, reactivity 
and “process-friendliness” of sulfamoyl chloride. 43,48  A recently reported sulfamoylation 
reagent is the Burgess-type analogue 44 which was demonstrated to readily install a sulfamoyl 
group on a range of primary and secondary alcohols under relatively mild conditions. 49 43   
 
 
Figure 23: Burgess-type sulfamoylation reagent, N-(tert-butoxycarbonyl)-N-[(triethylenedi-
ammonium)sulfonyl]azanide 
 
However, the synthesis of this Burgess-type reagent was not trivial and it was considered of 
interest to pursue other avenues.  It was postulated that the replacement of the chlorine atom 
with a suitable leaving group e.g R–O-SO2-NH2 would result in an effective sulfamoylation 
reagent that would confer improved stability to that of sulfamoyl chloride.  The preparation 
and use of phenyl sulfamate 46 as an alternative sulfamoylation reagent was investigated in the 
first instance.  Scheme 4 outlines the preparative method employed to prepare phenyl sulfamate 
46.  Chlorosulfonyl isocyanate 41 was reacted with phenol in toluene to give the intermediate 
isocyanate 45.  The addition of 45 to water resulted in formation of phenyl sulfamate 46 which 
was obtained as a white solid.  NMR and LCMS data confirmed the desired product had been 
prepared in good yield and purity. 
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Scheme 4: Preparation of phenyl sulfamate 
 
 
Scheme 5: Preparation of topiramate 1 from 2,3:4,5-di-O-isopropylidene-D-fructopyranose 39 
with phenyl sulfamate  
 
The reaction of phenyl sulfamate 46 with 2,3:4,5-di-O-isopropylidene-D-fructopyranose 39 
(Scheme 5) resulted in the formation of the desired product 1 without any significant impurities 
present.  The conditions used for the reaction are shown in Scheme 5.  Toluene was chosen as 
the reaction solvent and triethylamine as base.  No reaction between 39 and phenyl sulfamate 
was observed at room temperature.  Increasing the reaction temperature to ca 100°C did induce 
some reaction progression with evidence of the presence of phenol as a by-product by TLC.  
Reaction progression was slow despite the addition of a large excess of phenyl sulfamate to the 
reaction in an attempt to consume starting material.  A poor overall yield of 1, ca 8%, was 
achieved which was disappointing and the recovery of ca 46% of the input fructopyranose 39 
confirmed a poor reaction profile under the conditions employed.     
 
The reaction outcomes were positive insofar as analysis of the product obtained from the 
reaction of fructopyranose 39 and phenyl sulfamate correlated with that obtained from the 
analogous reaction with sulfamoyl chloride confirming that phenyl sulfamate could be used as 
an alternative sulfamoylation reagent.  However, poor reaction progression and suspected 
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decomposition of phenyl sulfamate at sustained high temperatures resulted in a very low yield.  
This demonstrated that further development work would be required to sufficiently optimise 
the reaction conditions in order for phenyl sulfamate to be able to offer a viable alternative to 
the use of sulfamoyl chloride.  Had time permitted, the scope for developing this reaction and 
of alternative sulfamoylation reagents would have afforded an interesting avenue for the 
project.  The next obvious steps would be a change of solvent and use of a stronger base e.g. 
sodium hydride.   As the ultimate goal of the project was synthesis of the metabolites to obtain 
in vitro data, priority was not given to this interesting side investigation.  This is considered as 
an interesting area for additional development.       
 
 
Scheme 6: Selective deprotection of topiramate 1 
 
With the sulfamate group successfully installed, the next step in the preparation of topiramate 
metabolites 4 and 5 was the selective deacetalisation of the dioxolane ring at the 4,5- position 
around the pyranose ring under acidic conditions to give the diol 2,3-O-isopropylidine-β-D-
fructopyranose sulfamate 8 (Scheme 6).  It was important to maintain a controlled reaction in 
order to avoid the hydrolysis of the second acetal group at the 2,3- position.  Monitoring of the 
reaction by TLC and HPLC enabled adequate tracking of reaction progression. It was 
established that heating the reaction for three and a half hours at ca 50°C allowed for sufficient 
starting material to be selectively deprotected to give the desired product.  The product was 
isolated as a white solid following chromatography in a reasonable yield of 29% in line with 
that reported in the literature.50  1H NMR of the purified product confirmed the presence of 
only two remaining methyl groups and data conformed to that in the literature.1  The product 
of the reaction 8 is a metabolite of topiramate 1 and its submission for biological testing was 
supported.   
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Scheme 7: Preparation of 4,5-O-(1-benzyloxymethylethylidene)-2,3-O-isopropylidene-β-D-
fructopyranose sulfamate 40 
 
The next stage of the synthesis was the formation of 4,5-O-(1-benzyloxymethylethylidene)-
2,3-O-isopropylidene-β-D-fructopyranose sulfamate 40 from the reaction of 2,3-O-
isopropylidine-β-D-fructopyranose sulfamate 8 with benzyloxyacetone in the presence of 
triethyl orthoformate and concentrated sulphuric acid (Scheme 7).  A mixture of R and S acetals 
in a 6:1 ratio was reported in the literature.3  Analysis of the reaction by HPLC and LCMS 
clearly showed the formation of two products in a similar ratio to that reported confirming 
successful preparation of the two diastereomers.  The separation of the diastereomers by 
chromatography was challenging and deemed unnecessary at this point.  Therefore the isomeric 
mixture was taken through to the subsequent reaction.  An overall yield of for the two isomers 
of 56% was obtained.   
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Scheme 8: Preparation of 4,5-O-[(1R)-1-hydroxymethylethylidene]-2,3-O-isopropylidene-β-
D-fructopyranose sulfamate 5 and 4,5-O-[(1S)-1-hydroxymethylethylidene]-2,3-O-
isopropylidene-β-D-fructopyranose sulfamate 4 
 
 
The final stage of the synthesis (Scheme 8) was the debenzylation of 40 by hydrogenolysis and 
the separation of the two resulting diastereomers.  The reaction proceeded satisfactorily and 
although the separation of the two products by column chromatography was not trivial, two 
compounds were successfully obtained in 39% and 6% yields which was comparable to those 
reported in the literature.3  It was anticipated from the literature that the ratio of the R:S 
diastereomers would be roughly 6:1.  The hydrogenolysis resulted in the isolation of two white 
solids that were readily distinguishable by their NMR and mass spectrometry data; 762mg of 
one diastereoisomer and 109mg of the other diastereoisomer were obtained.  This result largely 
reflected the expected ratio of R:S diastereomers and thus the product obtained in the highest 
proportion was tentatively assigned as the R-isomer 5 and the minor product obtained was 
proposed to be the S-isomer 4.    However, comparison of the 1H NMR data for 4 and 5 to that 
reported in the literature 3 highlighted some differences in the relative chemical shifts of certain 
protons that warranted further investigation before the stereochemistry of the two products 
could be confidently assigned.  The data collected for each compound is summarised in Table 
4. 
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Major Product 
Proposed R-isomer (5) 
Minor Product 
Proposed S-isomer (4) 
 
Melting point 
 
 
104 - 106C 
(Literature: 106 - 108C)3 
 
122 - 124C 
(Literature: 136 - 140C)3 
 
1H NMR Assay 
 
 
97% purity 
 
97% purity 
 
Mass spectra 
 
m/z 378 (MNa+) 
         373 (MNH4
+) 
     356 (MH+) 
m/z  378 (MNa+) 
          373 (MNH4
+) 
     356 (MH+) 
 
Table 4: Summary of analytical data for the major and minor products from the debenzylation 
reaction of 4,5-O-(1-benzyloxymethylethylidene)-2,3-O-isopropylidene-β-D-fructopyranose 
sulfamate 40 
 
The melting point recorded for the major product is sufficiently close to the value quoted in the 
literature to suggest it is the R isomer.  The melting point for the minor product, however, is 
markedly lower than the literature value and therefore does not readily assist in confirming the 
identification of this compound.  The impact of impurities or entrapped solvent were postulated 
as depressing the melting point.  The same key peaks were visible in the mass spectrum of each 
compound, both mass spectra indicated the correct mass for the desired product, 355.36gmol-
1.  The 13C NMR spectra of the products show the correct number of carbon atoms (12) with 
appropriate chemical shifts.  Unfortunately, 13C NMR data was not included within the 
published literature so a direct comparison of this data was not possible.  The 1H NMR data for 
both the major and minor products is shown in Figure 24 and  
Figure 25 respectively and the NMR data is summarised below. Proton numbering is in 
accordance with the molecule below. 
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1H NMR data of the major product from the debenzylation reaction of 40:1H NMR (DMSO-
d6, 270MHz):  1.25, 1.34, 1.46 (3 s, 9H, CH3),  3.34 (s, 2H, CH2OH),  3.62 (d, 1H, J = 
13.2Hz, H6),  3.76 (d, 1H, J = 13.2Hz, H6)  3.99 (s, 2H, H1),  4.27(d, 1H, J = 2.7Hz, H3),  
4.30 (d, 1H, J = 8.6Hz, H5),  4.64 (dd, 1H, J = 2.7, 8.6Hz, H4),  4.9 (bs, 1H, OH),  7.62 (bs, 
2H, NH2) 
 
1H NMR data of the minor product from the debenzylation reaction of 40:1H NMR (DMSO-
d6, 270MHz):  1.26, 1.33, 1.46 (3 s, 9H, CH3),  3.29 (dd, 2H, CH2OH),  3.62 (d, 1H, J = 
13.2Hz, H6),  3.74 (d, 1H, J = 13.2Hz, H6),  3.95 – 4.04 (dd, 2H, H1),  4.24 (d, 1H, J = 
2.7Hz, H3),  4.32 (d, 1H, J = 7.8Hz, H5),  4.66 – 4.69 (dd, 1H, J = 2.7, 7.8Hz, H4),  4.96 (t, 
1H, OH),  7.64 (bs, 2, NH2) 
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Figure 24: 1H NMR spectrum of the major product from the debenzylation reaction of 40
45 
 
 
Figure 25: 1H NMR spectrum of the major product from the debenzylation reaction of 40 
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A D2O shake of each sample revealed the position of the primary CH2-OH group.  A 2D COSY 
NMR experiment confirmed proton assignments.  The assignment of the stereochemistry of 
each isomer was not straightforward by the direct comparison of the 1H NMR data with that 
contained in the literature as there were some subtle differences that did not render the 
compounds readily identifiable.3  The key differences in the 1H NMR data were the relative 
chemical shifts of the protons at positions three (H3) and five (H5) on the pyranose ring.  Further 
NMR experiments were undertaken to attempt to elucidate the stereochemistry of each 
compound and thus make a positive identity.   A 2D NOESY NMR experiment was carried out 
for each compound.  The resulting spectrum of a 2D NOESY experiment contains both 
diagonal and cross peak signals.  The diagonal spectrum consists of the 1D spectrum and the 
cross peak signals arise from protons that are close in space. It thus can provide valuable 
information about the spatial proximity between protons even if they are not bonded together. 
It can therefore be a powerful tool in the assessment of molecular geometry and assignment of 
stereochemistry.     Although the 2D NOESY spectra obtained for the two diastereoisomers 
had low resolution and were relatively difficult to interpret, the spectrum for the major product 
of the reaction did show a weak correlation between the protons of one of the three methyl 
groups, presumed to be the single methyl group on the 4,5-acetal group, and the proton at 
position four on the pyranose ring (H4).  This correlation was not evident in the 2D NOESY 
spectrum of the minor product.  Consideration of the 3D models of each of 5 and 4, Figure 26 
and Figure 27 respectively, a through space interaction between the methyl protons and H4 
would be an expected result for 5 with R stereochemistry.  The interaction would not be 
expected in 4 which has S stereochemistry.     
     
 
47 
 
 
 
Figure 26:  3D representation of 4,5-O-[(1R)-1-hydroxymethylethylidene]-2,3-O-
isopropylidene-β-D-fructopyranose sulfamate 5  
 
 
 
 
Figure 27: 3D representation of 4,5-O-[(1S)-1-hydroxymethylethylidene]-2,3-O- 
isopropylidene-β-D-fructopyranose sulfamate 4 
 
H4 
Possible NOE 
interaction 
 
H5 H6 
H4 
H5 H6 
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Additional NMR experiments were carried out at the Newcastle University NMR Department 
to provide further data to confirm the structures and stereochemistry of the two compounds 
prepared.  An important outcome of this was the ability to distinguish between the three methyl 
groups of each isomer so as to make meaningful interpretations of the observed 2D NOESY 
data.    2D HSQC and 2D HMBC experiments were carried out for both the major and minor 
product.   For HSQC, the resulting 2D spectrum correlates directly bonded carbon and proton 
nuclei that can be used to map known proton assignments onto their directly attached carbons.  
An HMBC spectrum is used to identify long-range couplings, generally across two to three 
bonds, between protons.  Consideration of each spectrum in conjunction with the 1H, 13C and 
2D COSY NMR data confirmed the correct proton and carbon assignments had been made and 
enabled the elucidation of particular methyl groups.   
 
Equipped with a clear interpretation of the NMR data collected thus far, several 1D NOE 
experiments were carried out for each compound.  The value of these experiments relies upon 
the correct assignment of each proton to be able to establish the appropriate experiments to 
undertake.  This method would support the results of the 2D NOESY experiments and provide 
further salient information about the spatial relationship between the single methyl group on 
the 4,5-acetal and the protons around the pyranose ring.    A 1D NOE experiment differs from 
its 2D counterpart in that it relies on selective excitation of one peak by irradiation at a specific 
frequency and observing the NOE at another position within a molecule.  The method is 
particularly useful if the determination of a correlation between a precise pair of protons is 
required.  In the resulting NOE spectrum, a positive interaction with another proton is 
represented by an inverse peak, the position of which correlates with the chemical shift of that 
particular proton.  The selectively excited peak is shown as a positive peak at the position 
corresponding to the relevant chemical shift of the excited proton.       
 
For the major isomeric product of the reaction, tentatively proposed as the R isomer 5, 
irradiation at the frequency of H4 showed a strong positive interaction with the singular methyl 
group on the 4,5-acetal as shown by Figure 28.  Figure 29 also shows positive correlation with 
H3 and H5 protons.  Both of these results would be anticipated for the R isomer as confirmed 
by inspection of Figure 26.  
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Figure 28: 1D NOE spectrum of major isomer – irradiated at the frequency of H4 
The 1D NOE experiment where the major isomer was irradiated at the frequency of the singular 
methyl group of the 4,5-acetal gave a positive interaction with protons H4, H5 and the 
methylene group of the hydroxyl group of the 4,5-acetal (Figure 29).  This was a promising 
result if the 3D representation of the molecule (Figure 26) is considered as through space 
interactions would certainly be expected between each of the H4 and H5 proton and the protons 
of the methylene group within the R isomer. 
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Figure 29: 1D NOE spectrum of major isomer – irradiated at the frequency of the single methyl 
group 
  
In addition to the previous two experiments, further 1D NOE experiments were conducted in 
order to test the correct assignment of the three methyl groups.  A sample of the major isomer 
was irradiated at a frequency that was considered to correspond with the chemical shift of one 
of the methyl groups of the acetal group at the 2,3-position of the pyranose ring.  This resulted 
in a clear interaction with the geminal methyl group and thus confirmed the correct assignment 
and frequency of the third singular methyl group of the 4,5-acetal. 
Similar 1D NOE experiments were conducted for the minor isomer, tentatively proposed as the 
S isomer 4.  The following results were observed: 
- irradiation at the frequency of the singular methyl group of the 4,5-acetal gave no 
interaction with any protons of the pyranose ring as shown in Figure 30.  This would appear 
to be a reasonable result if the 3D representation of the molecule (Figure 27) is considered 
with the position of the singular methyl group being more remote from the protons around 
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the pyranose ring.  These results support the proposed stereochemical assignment of S to 
the minor isomer. 
 
Figure 30: 1D NOE spectrum of minor isomer – irradiated at the frequency of the single methyl 
group 
 
The extensive analysis undertaken for each of the two final products obtained by following 
Scheme 1 has enabled the structures of each compound to be defined with some confidence.  
All data collected confirms the major isomer as the desired metabolite 4,5-O-[(1R)-1-
hydroxymethylethylidene]-2,3-O-isopropylidene-β-D-fructopyranose sulfamate 5 and the 
minor isomer as 4,5-O-[(1S)-1-hydroxymethylethylidene]-2,3-O-isopropylidene-β-D-
fructopyranose sulfamate 4.  It is difficult to account for the differences between the 1H NMR 
data of the compounds prepared here and that included within the literature but it may be related 
to slight conformational differences induced by temperature or concentration or differences in 
the purity profiles of the materials.  Analytical data collected for each intermediate compound 
of Scheme 1 conformed to the published 1H NMR data which meant that any potential problems 
with the intermediate compounds could be ruled out.   
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Sufficient quantities of 4, 5 and 8 were successfully prepared in suitable purity to submit for 
biological evaluation to determine CA inhibition against a range of CA isozymes.  
 
2.2. Synthesis of five-membered heterocyclic analogues of topiramate 
A range of analogues of topiramate, 30 to 34 (Figure 20) have been synthesised in which the 
sulfamate group has been replaced by various hetereocycles.  Although known compounds,51 
they represent an interesting class of compounds from which novel derivatives may be obtained 
relatively easily.  There is currently no known literature on the biological activity of these 
compounds and as such they may represent an opportunity for the development of novel APIs 
if any demonstrate CA activity and specificity.   
Scheme 9 shows the total synthetic pathway from 2,3:4,5-di-O-isopropylidene-D-
fructopyranose 39 to the oxadiazoles 31 and 32.  The efficient methodology was adapted from 
a literature procedure with the key chemical step being the formation of the tetrazole 30 by 1,3-
dipolar cycloaddition.51 52  The “diacetone fructose” 47, was obtained by the oxidation of the 
primary alcohol of 2,3:4,5-di-O-isopropylidene-D-fructopyranose 39.  Pyridinium 
chlorochromate, o-iodobenzoic acid (IBX), Pfitzner-Moffatt reagent and manganese dioxide 
have been reported as oxidising agents used to prepare 47. 51, 53, 54 1  However, none of these 
reagents was ideal for reasons of toxicity and safety and so an alternative means of oxidation 
was sought.  Three trial oxidation reactions of fructopyranose 39 were performed; the use of 
Dess-Martin periodinane, a Swern oxidation and a Corey-Kim oxidation and the reaction 
outcomes compared (Table 5).  Each of the oxidation reactions resulted in the preparation of 
“diacetone fructose” 47 obtained as a colourless syrup following purification by column 
chromatography.  The NMR spectra of the products of the reactions were concordant although 
the level of impurities present varied.  In each case, the IR spectrum of the product of each 
reaction showed a clear absorption that was characteristic of an aldehyde C=O bond stretch 
which had not been present in the starting material 39.  The Corey-Kim conditions using n-
chlorosuccinimide and dimethyl sulfide produced superior results in terms of reaction profile, 
product yield and product purity and these conditions were selected for scale up.  The Corey-
Kim oxidation of fructopyranose 39 was successfully carried out on a 10g scale.   
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Oxidation methodology Product Yield 
Dess Martin Periodinane 
Dess Martin Periodinane 
(1.1eq)/ DCM/ 0°C to RT 
71% 
Swern oxidation 
(COCl)2 (1.1eq)/DMSO 
(2.4eq)/DCM/-5°C/Et3N/H2O 
74% 
Corey-Kim oxidation 
NCS (1.5eq)/ Me2S (3 
eq)/DCM/-25°C/Et3N 
86% 
 
Table 5: Comparison of product yields from each oxidation reactions to prepare “diacetone 
fructose” 47  
 
Figure 31 shows the proton NMR spectrum of the product derived from the Corey-Kim 
oxidation reaction.  The four methyl substituents of the acetal groups surrounding the pyranose 
ring are clearly visible at ca. 1.3 to 1.55ppm as is the proton of the aldehyde at ca 9.5ppm.  
However, the spectrum shows contamination of the aldehyde with varying amounts of hydrate 
that exist in solution.  Additional signals are present in the regions of the spectrum indicative 
of the methyl groups and ring protons as well as a hydroxyl signal at ca 2.2ppm.   The presence 
of this hydrated species did not adversely affect the course of the subsequent reaction.   
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Figure 31: 1H NMR spectrum of “diacetone fructose” 47
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Scheme 9: Preparation of heterocyclic analogues of topiramate; tetrazole 30, methyl 
oxadiazole 31 and phenyl oxadiazole 32 
 
The oxime 48 was prepared by reacting “diacetone fructose” 47 with hydroxylamine 
hydrochloride in the presence of base at room temperature.  The literature procedure suggested 
the use of sodium bicarbonate as base but using this methodology gave slow reaction 
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progression and a complicated reaction profile resulted which made purification challenging.51    
Triethylamine and DIPEA were both trialled as alternative bases.  The reaction containing 
DIPEA proved more successful in terms of product yield (ca 78%) and ease of product 
purification.  These reaction conditions were adopted.  The dehydration of the oxime 48 to give 
the nitrile 49 was achieved using an acylating mixture of acetic anhydride in pyridine as defined 
in the literature.51  The reaction could not be reproduced using these conditions and resulted in 
an incomplete reaction and a mixture of products.  There are several literature examples where 
thionyl chloride in basic media is used to dehydrate oximes into their corresponding nitriles.  
Therefore, a trial reaction was carried out in which oxime 48 was reacted with thionyl chloride 
in pyridine as base and solvent.  The reaction outcomes were unsatisfactory despite having 
been successfully demonstrated on a range of carbohydrate moieties within the literature.55  
Replacing pyridine with THF as reaction solvent resulted in a clean reaction profile.  No 
additional base was required when two equivalents of thionyl chloride was used.  NMR and 
LCMS analysis confirmed the desired nitrile 49 had been obtained in a 90% yield.  The 1,3-
dipolar cycloaddition of sodium azide and 49 was carried out in DMF in the presence of 
ammonium chloride and resulted in the formation of tetrazole 30.  The reaction proceeded 
smoothly in line with the procedure reported in the literature although an extended reaction 
duration of 16 hours was necessary to achieve reaction completion.  Oxadiazoles can be 
prepared by the reaction of tetrazoles with carboxylic acid derivatives.52  The proposed 
mechanism of the reaction is interesting and is shown in Scheme 10.56  The more nucleophilic 
nitrogen atom of the tetrazole is acylated first to give the intermediate, 50, the subsequent  
removal of a nitrogen molecule furnishes the oxadiazole and is a driving force of the reaction.  
Thus when the tetrazole 30 was reacted with acetic anhydride, oxadiazole 31 was obtained.  
Likewise the reaction of tetrazole 30 with benzoyl chloride resulted in the formation of phenyl 
oxadiazole 32.       
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Scheme 10: Proposed mechanism for the reaction of tetrazole 30 with acetic anhydride to form 
the oxadiazole 31 
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Scheme 11: Preparation of heterocyclic analogues of topiramate, thiadiazole 33 and thiadiazole 
34 
 
The synthesis of hetereocyclic rings containing sulfur and nitrogen were also of interest due to 
their wide application in the pharmacological field and to probe for interactions within the CA 
active sites.  Two thiadiazoles 33 and 34 were successfully prepared from “diacetone fructose” 
47 in accordance with Scheme 11.  The intermediate thiosemicarbazone 51 was prepared by 
the reaction of “diacetone fructose” 47 with thiosemicarbazide.  The reaction was carried out 
in ethanol and reaction completion was recorded after four hours heating at reflux.  The product 
was obtained in a 93% yield following column chromatography.  The cyclic thiadiazole 33 was 
then obtained by treating thiosemicarbazone 51 with a 2M ethanolic solution of ferric chloride 
in pyridine.  The reaction was incredibly swift with complete consumption of the starting 
material noted after less than one hour at 50°C.  Selective deprotection of the acetal at the 4,5-
position of cyclic thiodiazole 33 around the pyranose ring to furnish the novel compound 34 
was then considered.   Compound 33 was of interest to the project as it would provide a further 
probe into CA selectivity to support the building of structure activity relationship data.  The 
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reaction conditions selected reflected those successfully employed in the selective acetal 
deprotection of topiramate 1 to give 8, but as the stability of the thiadiazole to strong acid was 
unknown, the reaction was initially carried out using 1M HCl.  The reaction needed to be 
carefully monitored to prevent hydrolysis of the second acetal group at the 2,3-position of the 
pyranose ring and also to assess whether there was any degradation of 33 during the reaction.  
Minimal reaction progression was observed with 1M HCl despite gentle heating of the reaction.  
It was determined by progressively increasing the strength of the hydrochloric acid that 5M 
HCl at 40°C would lead to the formation of the desired thiadiazole product 34.  As in the 
reaction to form 8, once LCMS analysis indicated that ca 25% of the desired product was 
present in the crude reaction mixture the reaction was stopped and neutralised.  Following work 
up, thiadiazole 34 was successfully isolated as a white solid by column chromatography in a 
20% yield.  Unreacted starting material was recovered and the reaction repeated on this material 
to increase the amount of 34 available.         
Sufficient quantities of tetrazole 30, oxadiazoles 31 and 32 and thiodiazoles 33 and 34 were 
prepared in suitable purity to submit for biological evaluation to determine CA inhibition 
against a range of CA isozymes.  The results are presented in Section 2.4.  
 
2.3. Synthesis of N-Acetyl Zonisamide 
Zonisamide 24 is an anti-epileptic drug that, in common with topiramate, is known to induce 
weight loss in epilepsy patients. 41  This pharmacological effect is considered to be due to the 
CA inhibitory action of zonisamide.41  As a sample of zonisamide was to be submitted for 
biological testing as a reference standard against which the metabolites and analogues of 
topiramate were to be tested, it was considered of interest to extend the biological testing to the 
acetylated derivative of zonisamide 24.  The production of any biological results for 24 would 
not only provide a useful comparator to zonisamide and the topiramate family of compounds 
but would help in the development of insights for future design of more selective CA isozyme 
inhibitors with potential use as anti-obesity drugs possessing a novel mechanism of action.  
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Scheme 12: Preparation of N-acetyl zonisamide 24 
 
A small commercial supply of zonisamide was purchased from which to prepare a small 
amount of N-acetyl zonisamide 24.  Scheme 12 shows the methodology employed to prepare 
24.  The N-acetylation of zonisamide using both acetyl chloride and acetic anhydride were 
initially trialled.  Both reactions required the addition of a 10% molar equivalent of DMAP and 
reflux temperatures to progress.  Complete consumption of starting material was observed after 
24 hours for the reaction with acetic anhydride.  Reaction progression was slower for the acetyl 
chloride reaction by LCMS monitoring although data suggested that the desired product 24 had 
successfully formed in both cases.  The acetic anhydride reaction was considered to be more 
favourable and this methodology was selected for scale up.  The crude material from the 
reaction following work up was purified on silica with 24 obtained as a white solid in an 82% 
yield. 
A sufficient quantity of 24 was prepared and with a suitable purity to submit for biological 
evaluation to determine CA inhibition against a range of CA isozymes.  The results are 
presented in Section 2.4.  
          
2.4. Biological activity of topiramate metabolites and analogues 
An initial nine compounds were submitted to the group of Professor C. Supuran at the 
University of Florence for evaluation of carbonic anhydrase inhibitory activity.  The 
compounds were tested against human isoforms of CAII, CAVA, CAVB and CAIX, by a 
stopped-flow CO2 hydrase assay.  Details of the methodology used are provided in Section 2.6.  
Acetazolamide 2 and topiramate 1 were used as standards.  The results in terms of the inhibition 
constants (KI) measured for each compound tested are presented in Table 4.  The inhibitor 
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constant is an indication of how potent an inhibitor is and is reflective of the binding affinity 
of an enzyme and inhibitor.  The smaller the KI, the greater the binding affinity and the smaller 
the amount of inhibitor required to suppress the activity of the enzyme.  Comparison of the KI 
values of different isoforms of a particular enzyme can provide useful information about 
specificity of inhibitors for one isozyme over another.  KI is an important initial measure for 
designating the likelihood that a particular compound will have potential as a clinically relevant 
drug. 
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Compound 
KI (nM) 
CAII CAVA CAVB CAIX 
 
79.9 30.1 85.1 6.3 
 
567 426 920 257 
 
705 91.5 171 261 
 
 
>10,000 349 878 2,970 
 
 
>10,000 178 2,070 4,620 
 
 
>10,000 81.3 2,345 >10,000 
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Compound 
KI (nM) 
CAII CAVA CAVB CAIX 
 
>10,000 
 
 
149 
 
 
 
1,790 >10,000 
 
>10,000 
 
 
91 
 
 
 
6,430 >10,000 
 
>10,000 91.4 162 789 
 
11.9 63.1 54.5 25.3 
 
9.8 62.8 30.1 58.4 
 
Table 4: Inhibition data of selected compounds against isozymes CAII, CAVA, CAVB and 
CAIX at 20°C   
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The inhibition data of the four CA isozymes tested here provides some very interesting 
findings.  The following observations can be made.   
i) Generally, the two mitochondrial enzymes, CAVA and CAVB, were found to be 
most susceptible to inhibition by the selection of compounds tested.  This was a 
positive result in that the enzymes sensitive to inhibition are the ones of particular 
interest as they may be useful for the identification and development of new 
pharmacological applications.  4 was shown to be a potent inhibitor of CAVA with 
an inhibition constant of 30nM which is lower than the figure recorded for both 
topiramate 1 and acetazolamide 2.  A second group of compounds, 8, 24, 31 and 32 
were shown to be effective inhibitors of CAVA with KI values in the range of ca 
80 to 90nM.  A third group of compounds showed moderate CAVA inhibitory 
activity with KI values of 149 to 426nM.  Topiramate 1 and acetazolamide 2 were 
the most effective inhibitors of CAVB followed by 4.  24 and 8 were moderate 
inhibitors of CAVB with KI values of 162nM and 171nM respectively.  The 
remaining compounds were much weaker CAVB inhibitors.   
ii) Compound 4 was observed to be a highly potent inhibitor of CAIX with a KI value 
of 6.3nM.  CAIX is a transmembrane enzyme that is predominantly expressed in 
the cancer cells of tumours making it a particularly interesting target for the 
development of anti-tumour agents. 57  Acetazolamide 2 and topiramate 1 were also 
shown to be effective CAIX inhibitors with KI values of 25.3nM and 58.4nM.  5 
and 8 showed moderate inhibition of CAIX.  None of the other compounds tested 
demonstrated potency as CAIX inhibitors.   
iii) The findings confirmed topiramate 1 and acetazolamide 2 as potent inhibitors of 
CAII.  4 was shown to be an effective CAII inhibitor with a KI value of 79.9nM.  5 
and 8 were found to be weak inhibitors of CAII.  The six other compounds tested 
were ineffective in the inhibition of CAII. 
It is important to consider the inhibitory profile of a potential CAI across a range of CA 
isozymes as this will indicate the general selectivity for particular CAs.  A key issue in the 
development of new CAIs is how to selectively target a specific CA and limit the overall 
promiscuity for CA isozymes often demonstrated by CAIs.   This selectivity will hopefully 
illicit a much more targeted biological response and thus improve the efficacy of any new 
drug.  Determining the selectivity ratio of a CAI for one CA isozyme over another is a 
useful indication of selectivity between isozymes.58  The selectivity ratio of two different 
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isozymes is the ratio of the corresponding inhibition constants.  Table 5 shows the 
selectivity ratios between isozymes CAII and CAVA, CAII and CAVB and CAII and CAIX 
of the tested compounds.  A selectivity ratio of less than one indicates that a compound 
better inhibits CAII over the other isozyme whereas a selectivity ratio of greater than one 
suggests a greater affinity for the other CA isozyme, in this case CAVA, CAVB or CAIX, 
over the cytosolic enzyme CAII.  (It should be noted that when comparing such values, 
absolute KI values must always be recalled when defining positive utility). 
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Compound Selectivity ratio 
KI(CAII)/KI 
(CAVA) 
Selectivity ratio 
KI(CAII)/KI 
(CAVB) 
Selectivity ratio 
KI(CAII)/KI 
(CAIX) 
 
2.65 0.94 12.68 
 
1.33 0.62 2.21 
 
7.70 4.12 2.70 
 
28.65 11.39 3.37 
 
 
56.18 4.83 2.16 
 
 
123.00 4.26 1.00 
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Compound Selectivity ratio 
KI(CAII)/KI 
(CAVA) 
Selectivity ratio 
KI(CAII)/KI 
(CAVB) 
Selectivity ratio 
KI(CAII)/KI 
(CAIX) 
 
109.89 1.56 1.00 
 
67.11 5.59 1.00 
 
109.41 61.73 12.67 
 
0.19 0.22 0.47 
 
0.16 0.33 0.17 
 
Table 5: Selectivity ratios between different CA isozymes for compounds tested  
Generally, the selectivity ratios of the heterocyclic compounds tested confirm that they are 
more effective at inhibiting CAVA and CAVB than CAII.  Conversely, both of the drugs in 
clinical use, topiramate 1 and acetazolamide 2 are more effective at inhibiting CAII than the 
other CA isozymes tested here as indicated by selectivity ratios that are less than one.  An 
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interesting feature that emerges is that several of the compounds tested 31, 32, 24, 8, 30, 33 
and 34 show very positive selectivity for CAVA over CAII as evidenced by the high selectivity 
ratios.  Further consideration of the data for each of these compounds shows that they have 
similar inhibition profiles.  Each compound has a markedly lower KI value for the inhibition 
of CAVA than those measured for the other CA isozymes.  This suggests that there is potential 
scope for a CAI to be developed that will selectively inhibit CAVA whilst having much lower 
affinity for other CA isozymes.  31, 32, 24 and 8 are of interest as they have been shown to be 
particularly effective CAVA inhibitors. Compound 4 has high selectivity ratios for both CAVA 
and CAIX indicating it is a more potent inhibitor of both of these isozymes than of CAII.  The 
data also suggested that not only does 4 have very high affinity for CAIX but demonstrates 
selectively for this isozyme over the other isozymes tested.  This also presents a very exciting 
prospect. 
As the range of compounds tested is relatively limited, it is difficult to arrive at any firm 
conclusions at this point about structure activity relationships.  However, the following 
comments can be made. 
i) CA inhibitory activity is still evident when the sulfamate group is replaced with 
various five-membered nitrogen containing heterocycles.  This suggests a different 
binding mechanism for the heterocyclic compounds as the lone pair of the primary 
amine of the sulfamate group is replaced with an anion in the various hetereocycles.  
The lack of a methylene group between the heterocycle and the sugar scaffold as is 
in place for the derivatives of topiramate will decrease flexibility and further 
indicates differences in binding modes.      
ii) Altering the hydrophilic nature of the substituents at the four and five positions 
around the fructose ring affects the inhibitory profile.  This is demonstrated by 
comparison of the inhibition constants for topiramate 1, 4 and 5 and of the related 
compounds 34 and 33.  It is postulated that the additional hydroxyl group in for 
example, compound 4, must offer another hydrogen bond donor/acceptor site to 
interact with a near amino acid residue.   
The findings from the biological testing will be used to inform further in silico modelling and 
will be used as a test of the predictions generated from the modelling work completed thus far.  
The results have indicated that the chemical synthesis and subsequent biological testing of 
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several related compounds 52 to 58 (Figure 31) would be beneficial in facilitating the building 
of improved structure activity relationship data. 
 
 
Figure 32: Additional heterocyclic analogues of topiramate for which synthesis is supported 
 
Overall, the results of the biological testing were extremely positive in that an interim goal of 
the project was achieved.  Two “old” drugs, topiramate and zonisamide, have been redefined 
by structural modification to provide compounds that have demonstrated high selectivity for 
particular CA isozymes that generates potential in two therapeutic areas.  Moving forward with 
the compounds 4 and 24, it is anticipated that both will have limited toxicity based upon known 
human exposure to the parent drugs and associated metabolites.  Equivalent data for the 
heterocyclic analogues of topiramate is not as readily available.  A key question for the ongoing 
development of the project is whether CAVA and CAIX alone are valid and druggable targets 
for the intended use of any new drugs.  There is precedent for the development of specific 
inhibitors of CAIX for anti-cancer purposes.26  CAVA is perhaps less well defined, but there 
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has been recent research interest into this area in the consideration of anti-obesity drugs. 58  The 
work completed here to date will ultimately inform, and hopefully progress, understanding of 
selective CAIs.       
 
2.5. Synthesis of additional five-membered heterocyclic analogues of topiramate 
The novel compounds, 35 to 38 represent the next round of synthetic targets of this project.  
The compounds are related to the heterocycles described in Section 2.2 but contain an 
additional methylene group between the heterocycle and the pyranose ring.  The compounds 
are of particular interest as they retain a heterocycle at the C1 position of the D-fructose 
scaffold.  The additional methylene group may afford greater flexibility within the compunds 
that may result in increased binding opportunities that are more akin to the sulfamate group 
within topiramate.  It has been demonstrated by biological evaluation of various heterocyclic 
analogues of topiramate that the replacement of the sulfamate group with a heterocycle does 
not negate CA inhibitory activity but, in certain cases, results in different CA inhibition profiles 
between the various ioszymes.  The extension of the linker from the pyranose ring has been 
shown to be of pharmacological importance in topiramate.59  A study into the structure activity 
relationship of topiramate with several biological targets showed that biological activity can be 
modulated by altering the distance between the sulfamate group and the pyranose ring.59  It is 
therefore of interest whether similar pharmacological effects will be observed if the linker is 
extended in length when the sulfamate group is replaced by a heterocycle.   
A comprehensive literature review identified that there are no precedents for the synthesis and 
characterisation of compounds 35 to 38.  A synthetic methodology for the preparation of 59 
from D-galactose provided a useful starting point from which to devise a preparative route to 
the key tetrazole 35.60  Adapting the chemistry successfully employed in the preparation of 
oxadiazoles 31 and 32 from tetrazole 30 was also considered a reasonable initial approach.   
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Figure 33: Chemical structure of 5-[6-deoxy-(1,2:3,4-di-O-isopropyliene-α-D-
galactopyranose-6-yl)]tetrazole  
Scheme 13 provides an outline of the proposed preparative route from 2,3:4,5-di-O-
isopropylidene-D-fructopyranose 39.  Tetrazole 35 and oxadiazole 36 have been successfully 
prepared in quantities sufficient to support biological testing utilising the postulated 
methodology following development of the route. 
 
 
 
 
 
 
 
 
 
72 
 
 
Scheme 13: Synthetic route to heterocyclic analogues of topiramate 
 
The selection of a suitable group with which to activate the anomeric alcohol group of 
fructopyranose 39 was the key consideration for stage 1 of Scheme 13.  The formation of a 
sulfonate ester was successfully achieved using both p-toulene sulfonyl chloride (tosylate 
chloride) and methanesulfonyl chloride (mesylate chloride) (Scheme 14).  The formation of 
both the toylsate 62 and mesylate 63 derivatives of 39 was reasonably facile.  The reaction with 
mesylate chloride proceeded at room temperature with the addition of triethylamine as base 
(Scheme 15).  Likewise, the reaction with tosylate chloride was carried out under equivalent 
conditions (Scheme 14).  Both products were obtained as white crystalline solids in good yield 
and purity.      
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Scheme 14: Tosylation of 2,3:4,5-di-O-isopropylidene-D-fructopyranose 39 
 
 
Scheme 15: Mesylation of 2,3:4,5-di-O-isopropylidene-D-fructopyranose 39 
 
The nucleophilic displacement of the mesylate and/or tosylate group by cyanide to form a 
nitrile was the next step (Scheme 16).  The reaction was attempted on both the mesylate 62 and 
tosylate 63 substrates in order to assess whether superior results were obtained from one or the 
other.  
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Scheme 16: Attempted introduction of a nitrile group 
 
The reactions were initially carried out using potassium cyanide with DMF as solvent as these 
conditions had proved successful in the literature for the analogous D-galactose example.60  
However, despite maintaining elevated reaction temperatures in excess of 125°C for prolonged 
periods, no reaction progression was stimulated with only starting material visible when 
monitoring by TLC and HPLC.  The difference in reactivity between this substrate and D-
galactose was attributed to the presence of additional hindrance in the D-fructose substrate 
versus D-galactose and non-equivalence in the possible angles of attack of the nucleophile.      
A series of small scales reactions were then carried out in parallel (Table 6) in which various 
conditions were altered to establish if there was a reaction parameter that was vital for the 
substitution reaction to proceed satisfactorily.   
 
 
 
 
 
 
75 
 
 
Reaction 
 
Substrate 
Molar 
Ratio 
of KCN 
Molar 
Ratio 
of 
NaCN 
Solvent Temperature Catalyst After 72 
hours 
1 62 1:2 - DMSO 120°C - No 
reaction 
2 62 1:5 - DMSO 120°C - No 
reaction 
3 62 1:2 - DMF 120°C 18-crown-
6 ether 
No 
reaction 
4 62 1:5 - DMF 120°C 18-crown-
6 ether 
No 
reaction 
5 62 1:5 - NMP 120°C - No 
reaction 
6 62 - 1:2 DMSO 120°C - No 
reaction 
7 62 - 1:5 DMSO 120°C - No 
reaction 
8 62 - 1:2 DMF 120°C 15-crown-
5-ether 
No 
reaction 
9 62 - 1:5 DMF 120°C 15-crown-
5-ether 
No 
reaction 
10 62 - 1:5 NMP 120°C - No 
reaction 
11 63 1:2 - DMSO 120°C - No 
reaction 
12 63 1:5 - DMSO 120°C - No 
reaction 
13 63 1:2 - DMF 120°C 18-crown-
6 ether 
No 
reaction 
14 63 1:5 - DMF 120°C 18-crown-
6 ether 
No 
reaction 
15 63 1:5 - NMP 120°C - No 
reaction 
16 63 - 1:2 DMSO 120°C - No 
reaction 
17 63 - 1:5 DMSO 120°C - No 
reaction 
18 63 - 1:2 DMF 120°C 15-crown-
5-ether 
No 
reaction 
19 63 - 1:5 DMF 120°C 15-crown-
5-ether 
No 
reaction 
20 63 - 1:5 NMP 120°C - No 
reaction 
 
Table 6: Trial nucleophilic displacement reactions undertaken on mesylate 63 and tosylate 62 
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The trial reactions attempted are listed in Table 6 and were carried out on both the mesylate 63 
and tosylate 62 substrates.  Both DMSO and NMP have been used as solvents in similar 
reactions and have sufficiently high boiling points to enable vigorous heating.55  An alternative 
source of cyanide anion was also considered with sodium cyanide providing an alternative 
option. Increasing the stoichiometric amount of the cyanide reagent to five equivalents was 
also considered a reasonable method to improve reaction progression.  A widely used 
methodology to accelerate substitution reactions of this nature is the addition of crown ethers 
to reactions due to their affinity for metallic cations.  The cation forms a ligand within the 
crown ether cavity generating “naked” anions which are highly nucleophilic.  18-crown-6 ether 
has a particular affinity for potassium cations and 15-crown-5 ether has an affinity for sodium 
cations.  Therefore 18-crown-6 ether was used in conjunction with potassium cyanide and 15-
crown-5 ether with sodium cyanide. Disappointingly, there was no reaction progression 
observed in any of the trial reactions.   
It was postulated that neither the tosylate or mesylate group was sufficiently reactive to 
efficiently facilitate the desired substitution reaction with this hindered substrate.  Thus the 
triflate group was considered as an alternative.  The conjugate acid of the triflate group, 
trifluoromethansulonic acid, is highly acidic and is a therefore a very good leaving group. It 
was hoped that this increased reactivity would enable the difficulties with the displacement 
reaction to be overcome.  This approach was favoured versus attempting further changes to 
reaction parameters, e,g, solvent.    
The reaction of 2,3:4,5-di-O-isopropylidene-D-fructopyranose 39 with trifluoromethane 
sulfonic anhydride in the presence of trimethylamine in DCM (Scheme 17) resulted in the 
successful formation of the triflate 60.  The reaction was swift at 0°C producing the desired 
product in good purity (>95%).  A 70% yield was achieved.  Analysis of the product of the 
reaction by 19F NMR confirmed the presence of three fluorine nuclei.       
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Scheme 17: Triflation of 2,3:4,5-di-O-isopropylidene-D-fructopyranose 39 
 
The subsequent nucleophilic displacement reaction of triflate 60 was initially carried out using 
sodium cyanide in DMSO as solvent (Scheme 18).  Heating the reaction to 80°C resulted in 
complete consumption of the starting material 60 in 12 hours.  The desired nitrile 61 was 
obtained in a 54% yield following purification by column chromatography.  The successful 
outcome of the reaction does suggest that the more reactive triflate group was necessary to 
facilitate the nucleophilic displacement of the nitrile group of 60 when results are compared to 
the lack of observed reaction with the analogous mesylate and tosylate substrates, despite the 
use of catalysts and harsher conditions.  
                      
 
Scheme 18: Displacement of the triflate group of 60 to produce nitrile 61 
 
The formation of tetrazole 35 was the next key step in the overall scheme.  The proposed 
methodology was to replicate the conditions that were used to successfully prepare the related 
compound, tetrazole 30, from nitrile 49 as depicted in Scheme 19.  It was postulated that a 1,3-
dipolar cycloaddition of sodium azide and 61 would proceed in a similar manner to that of 
sodium azide and nitrile 49 due to the structural similarity of the two nitrile substrates.  Thus, 
the chosen reaction conditions for the preparation of nitrile 35 mirrored those that had been 
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successfully employed previously.  DMF was selected as the aprotic reaction solvent using 
sodium azide as the inorganic azide source in combination with ammonium chloride to form 
the required additive.             
 
 
 
 
Scheme 19: Formation of tetrazole 30 
 
 
Scheme 20: Formation of tetrazole 35 
 
Disappointingly, the cycloaddition reaction showed no appreciable progression after 16 hours 
at 100°C as was observed in the reaction to form tetrazole 30.  However, as a review of the 
literature has demonstrated, often process methods require long reaction times and high 
reaction temperatures to afford the desired azide-nitrile addition process.61  The literature 
methodology reported for the preparation of tetrazole 59 from the corresponding nitrile of D-
galactose suggested that the 1,3-dipolar cycloaddition reaction in this case could only be 
stimulated by heating the reaction to 105°C for five days coupled with the addition of a very 
large excess, 14 equivalents, of sodium azide and ammonium chloride to the reaction.60  
Adopting these conditions for the cycloaddition of nitrile 61 and sodium azide produced a 
successful outcome and after five days of heating the reaction to 105°C, after which time, TLC 
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analysis indicated complete consumption of the starting material.  Tetrazole 35 was isolated as 
a white crystalline solid in a reasonable yield of 54% following purification by column 
chromatography.  It is likely that the harsh conditions required for the reaction to go to 
completion results in degradation of both starting material and product, particularly as the 
reaction duration increases, which will contribute to the relatively low yield.  Comparison of 
the proton NMR spectra for tetrazole 30 and tetrazole 35, Figures 33 and 34 respectively, 
clearly shows the presence of the two additional diasteriomeric protons of the extra methylene 
group in tetrazole 35. 
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Figure 34: 1H NMR spectrum of tetrazole 30 
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Figure 35: 1H NMR spectrum of tetrazole 35 
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The successful preparation of tetrazole 35 provided access to two further heterocyclic 
derivatives of topiramate, methyl oxadiazole 36 and phenyl oxadiazole 37.  Using the same 
principles that were successfully used to prepare methyl oxadiazole 31 and phenyl oxadiazole 
32 from tetrazole 30 appeared a reasonable starting point.  Tetrazole 35 was dissolved in acetic 
anhydride and heated to reflux, ca 140°C.  TLC analysis confirmed reaction completion within 
3 hours.  Following reaction work-up, the crude product of the reaction was successfully 
purified by column chromatography to give a yellow solid in a 48% yield.  Analysis of the 
material by 1H, 13C NMR and LCMS confirmed that the desired methyl oxadiazole 36 had been 
successfully obtained in accordance with Scheme 21.  
 
 
Scheme 21: Formation of methyl oxadiazole 36 
 
Scheme 22: Formation of phenyl oxadiazole 37 
 
The synthesis of phenyl oxadiazole 37 was attempted by reacting tetrazole 35 with benzoyl 
chloride in the presence of pyridine.  The reaction proceeded well, with the formation of two 
highly UV active compounds clearly visible by TLC.  LCMS analysis of the crude reaction 
mixture confirmed the formation of the desired product with a peak at a retention time of 2.3 
minutes that displayed the correct mass of 389 (MH+) in the corresponding mass spectrum.  
Isolation of phenyl oxadiazole 37 by column chromatography proved very challenging.  
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Initially, it was suspected that the product of the reaction was unstable to silica.  However, 2D 
TLC assessment of the crude product did not suggest that this was the case.  Alternative solvent 
systems were trialled to assess if better separation of the product and by-products could be 
achieved.  A three component solvent system of ethyl acetate, heptane and acetone coupled 
with increased equivalents of silica used in the column enabled adequate separation.  1H NMR 
of the product showed that residual benzoic acid remained.  The solid was dissolved in ethyl 
acetate and washed twice with saturated sodium bicarbonate which was successful in removing 
the benzoic acid.  A yield of 94% was achieved.  A modified work-up would facilitate an easier 
purification on silica.  
The biological testing of the novel tetrazole 35 and the two novel oxadiazoles 36 and 37 is 
supported and the compounds will be submitted to assess their CA inhibitory profiles in the 
first instance once additional funding is secured.     
2.6. Conclusions and future work 
The in silico evaluation study identified three metabolites of topiramate whose synthesis was 
considered as an important initial focus of the project.  It was anticipated that the compounds 
would be used as probes to compliment the in silico models and provide positive, or just as 
valuable negative, indicators that could be further developed to design selective CAIs.  The 
successful preparation and characterisation of the three known metabolites led to their 
submission for biological testing for evaluation of carbonic anhydrase inhibitory activity.  Each 
of the compounds were tested against human isoforms of CAII, CAVA, CAVB and CAIX.  
The hydroxylated metabolite of topiramate 4 was shown to be a potent inhibitor of CAIX and 
CAVA and demonstrated positive selectivity for these two isozymes.  The metabolite of 
zonisamide, N-acetyl zonisamide 24 showed excellent selectivity for CAVA whilst having very 
little inhibitory effect on CAII.  This inhibitory profile is of particular interest as it is hoped 
that it will result in a specific and desired biological response.  Both 4 and 24 have been selected 
for further in vivo evaluation with particular emphasis on their mitochondrial and anti-tumour 
activity.  Both compounds have been subjected to stability assessments in DMSO and 
phosphate buffered saline to support the next stage of the screening process and 
pharmacokinetic evaluations.  These compounds will already have been evaluated for 
toxicology when clinical studies were performed on the parent compounds.  For example, 
human exposure has been completed and although this will require further evaluation, this is 
very positive. 
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 A second family of compounds related to topiramate but in which the sulfamate group is 
replaced by a five-membered heterocycle were considered as interesting alternative 
compounds.  Although known compounds chemically, there is no published data (at least in 
the literature review undertaken here), on their biological activity either as carbonic anhydrase 
inhibitors or in other therapeutic areas.  This may lead to interesting opportunities for the 
development of novel APIs if the compounds demonstrate biological activity.  A tetrazole 30, 
two oxadiazole compounds 31 and 32 and two thiodiazoles 33 and 34 were successfully 
prepared and characterised.  All were submitted for biological testing against the panel of 
human carbonic anhydrases used for testing the topiramate metabolites.   
The biological testing for CA inhibition of these heterocyclic compounds revealed that the 
replacement of the sulfamate group of topiramate with various heterocycles does not impede 
the inhibition of CA isozymes but was shown to elicit a different CA inhibitory profile in 
certain instances.  An interesting pattern that was observed was that compounds 31, 32, 33 and 
34 showed very positive selectivity for CAVA over CAII and all other CA isozymes.  This 
desired selectivity for only certain CA isozymes, namely CAVA and to some extent, CAVB, 
presents the potential for the development of selective CAIs that will only negatively influence 
the activity of mitochondrial variants of CA.  Three heterocyclic compounds have been selected 
for further biological evaluation.  Further work is required to establish the likely binding modes 
of this series of compounds within the CA isozymes of interest.    Another feature that may 
have potential for exploitation is the removal or addition of functionalisation around the 
pyranose ring.  The excellent inhibitory response identified for compound 4 in which the acetal 
group at the four and five position around the pyranose ring is hydroxylated suggests that this 
feature of the molecule may be significant to improving its affinity with the active sites of CA 
isozymes.  Also comparing the inhibitory profiles of the two thiodiazoles 33 and 34 shows that 
deprotection of the acetal group at position four and five does improve the inhibitory effect.  
For example, thiodiazole 33 with two unprotected hydroxyl groups the 4,5 position had a KI 
value for CAVA of 149 whereas for 34 with the acetal group present, the KI value for CAVA 
was 178.  Thus developing an understanding of the effect of combining a heterocycle with 
modifications to the functionality around the pyranose ring would be worthwhile.  To date, 
with the exception of the two thiodiazole compounds discussed previously, all other 
heterocyclic compounds that were tested were in the fully acetal protected forms.  The chemical 
synthesis and biological testing of the compounds 52 to 58 (Figure 31) could pose the next 
challenge of the project.          
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The positive CA inhibitory profiles of several of the heterocyclic topiramate analogues led to 
the consideration of alternative variations that could incorporate a heterocycle.  Earlier 
structure-activity studies conducted on different topiramate variants had shown that altering 
the length of the linker between the sulfamate group and the pyranose ring did have a marked 
effect on the biological activity of the molecule.59  Compounds 35, 36, 37 and 38 were therefore 
identified as the next tranche of synthetic targets.  The compounds are novel and thus of 
particular interest.  Tetrazole 35 and the two oxadiazoles 36 and 37 have been successfully 
prepared and characterised and their biological testing is supported.    
Ultimately, the project goals have been achieved and with the heterocyclic compounds, 
exceeded.  Three compounds are moving forwards into in vivo and pharmacokinetic evaluation. 
For efficacy evaluation the validation of biological targets is required, in this instance, CAVA 
for anti-obesity and CAIX for anti-cancer. 
In terms of chemistry, significant development is still required and will be supported once 
validation is achieved.  However, in the first instance, methodology is in place for gram scale 
production with the potential to expand and produce further analogue series.  This in turn will 
lead to second generation and supporting candidates for the current lead.  
 
2.7. Experimental details 
  
2.7.1. General methods 
All commercial reagents and solvents were used as supplied without prior purification. Thin 
layer chromatography was performed on aluminium sheets coated with silica gel 60 with 
fluorescent indicator. TLC plates were visualised using a 10% w/v phosphomolybdic acid in 
ethanol or by UV.  Flash chromatography was performed on Silicagel 40-63 micron silica. 
Melting points were recorded on a Kofler hot block and are uncorrected.  Infrared spectra were 
recorded on a PerkinElmer Spectrum Two spectrometer using a diamond universal ATR 
(attenuated total reflection) sample stage under compression. Characteristic peaks are quoted 
in units of cm-1. Low resolution mass spectra (LRMS) were recorded on Agilent1100 series 
liquid chromatograph. The technique used was electrospray ionisation. Nuclear magnetic 
resonance spectra were recorded on a JEOL ECX 270/400MHz spectrometer and the data was 
acquired using Delta NMR Processing and Control Software version 4.3.  Samples were 
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dissolved in a suitable deuterated solvent as stated. All chemical shifts () are quoted in ppm 
and coupling constants (J) in Hz.  
 
2.7.2. General methods used to assess CA activity 
A generalised methodology for the measurement of CA inhibition by the potential inhibitory 
compounds was provided by Professor Supuran and is provided here for completeness.  An 
Applied Photophysics stopped-flow instrument was used for assaying the CA-catalysed CO2 
hydration activity.62 Phenol red (at a concentration of 0.2mM) was used as indicator, working 
at the absorbance maximum of 557nm, with 20mM Hepes buffer (pH 7.5) and 20mM NaClO4 
for maintaining constant ionic strength, following the initial rates of the CA-catalysed CO2 
hydration reaction for a period of 10-100 seconds at 20°C.  The CO2 concentrations ranged 
from 1.7 to 17mM for the determination of the kinetic parameters and inhibition constants.  For 
each inhibitor, at least six traces of the initial 5-10% of the reaction have been used to determine 
the initial velocity.  The uncatalysed rates were measured in the same manner and subtracted 
from the total observed rates.  Stock solutions of inhibitor (0.01nM) were prepared in distilled-
deionised water and dilutions down to 0.01nM were made thereafter with the assay buffer.  
Inhibitor and enzyme solutions were pre-incubated together for 15 minutes at room temperature 
prior to assay, in order to allow for the formation of the enzyme-inhibitor complex.  The 
inhibition constants were obtained by non-linear least squares methods using PRISM 3 and the 
Cheng-Prusoff equation and represent the mean from at least three different determinations.  
All CA isoforms were recombinant ones and their concentrations in the assay system were 
9.2nM (CAII), 15.8nM (CAVA), 14.7nM (CAVB) and 8.6nM (CAIX) determined 
spectrophotometrically at 280nm. 58      
2.7.3. Synthesis of topiramate metabolites 
 
Preparation of sulfamoyl chloride 43  
 
Chlorosulfonyl isocyanate (100ml/ 1.149mol) was charged to a 500ml flask fitted with an 
overhead stirrer under N2 and cooled to 0°C.  Formic acid (43.35ml/ 1.149mol) was added 
dropwise over 45 minutes maintaining the temperature at 0-5°C during the addition.  
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Anhydrous toluene (100ml) was added during the addition of the formic acid in 20ml portions 
to ensure mobility and homogeneity of the reaction.  A dense off-white precipitate formed.  
Additional anhydrous toluene (150ml) was added and the reaction was warmed and stirred at 
ambient temperature overnight.  The beige suspension was vacuum transferred into a flask and 
the solvent removed in vacuo below 25°C.  A yellow solid (123.40g/ 92%) was obtained.  The 
solid was stored under N2 at <0°C.  No further purification was undertaken due to the reactivity 
of the material and it was used directly its efficacy being assessed by use tests. 
 
 
Preparation of 2,3:4,5-di-O-isopropylidene--D-fructopyranose sulfamate 1 
 
2,3:4,5-di-O-isopropylidene--D-fructopyranose 39 (30g/115.26mmol) was dissolved in 
anhydrous THF (500ml) under N2 and cooled to 0°C.   Et3N (64.23ml/461.04mmol) was added 
and the reaction stirred for ca.30 minutes.  Sulfamoyl chloride 43 (26.6g/ 230.25mmol) was 
added portionwise to the reaction, maintaining the reaction temperature at ca. 0°C.  A white 
suspension was obtained.  Reaction progression was monitored by TLC and 1H NMR.  Further 
additions of Et3N (22.12ml/ 230.52mmol) and sulfamoyl chloride (26.61/ 230.52mmol) were 
made during the next three hours.  TLC and 1H NMR indicated consumption of the starting 
material.  The reaction temperature was allowed to stabilise to room temperature.  A dense 
white paste-like solid formed in the flask impeding stirring.  An overhead stirrer was fitted to 
improve stirring.  The suspension was decanted into water (200ml).  Water (300ml) was added 
to the white solid remaining in the reaction flask.  The white solid dissolved and the solution 
was added to the reaction mixture.  The aqueous solution was extracted with ethyl acetate 
(350ml).  The organic layer was washed with water (3x200ml) and brine (150ml), dried over 
magnesium sulfate and vacuum filtered.  The solvent was removed in vacuo to give a pale 
yellow sticky solid.  The crude yellow solid was purified by column chromatography on silica 
eluted with 60% heptane/ 40% acetone.  The relevant fractions were combined and the solvent 
removed in vacuo.  A colourless crystalline solid (11.84g/ 30%) was obtained.  LCMS showed 
a m/z of 361.9 (MNa+).  The melting point range of the solid was recorded as 120-122°C 
(literature value: 125-126°C).12  1H NMR (CDCl3, 270MHz):  1.33, 1.41, 1.47, 1.54 (4 s, 12H, 
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CH3),  3.77 (d, 1H, J = 13.0Hz, H6),  3.91 (d, 1H, J = 13.0Hz, H6),  4.19 – 4.33 (dd, 2H, J 
= 11.6Hz, 3.8Hz, H1/H1’),  4.26 – 4.28 (m, 2H, H3/H5),  4.58 – 4.62 (dd, 1H, J = 2.7, 10.3Hz, 
H4),  5.04 (bs, 2H, NH2).  
 
 
 
Preparation of 2,3-O-isopropylidene--D-fructopyranose sulfamate 8  
 
2,3:4,5-di-O-isopropylidene--D-fructopyranose sulfamate 1 (11.48g/ 33.8mmol) was 
dissolved in THF (220ml).  3N HCl (116ml) was added and the reaction was stirred and heated 
to 40°C for 3.5 hours.  Reaction progress was monitored by TLC and 1H NMR.  The reaction 
was cooled to 5°C and anhydrous sodium carbonate (30.10g) was added to raise the pH to 7/8.  
The reaction was filtered and ethyl acetate (300ml) was added to the filtrate.  The organic layer 
was separated and the aqueous was further extracted with ethyl acetate (2x100ml).  The 
organics were combined, dried over magnesium sulfate and vacuum filtered.  The reaction was 
concentrated in vacuo to give a yellow oil which crystallised immediately on standing.  The 
solid was dissolved in acetone (100ml) and adsorbed onto silica (20g) by removing the solvent 
in vacuo.  The crude material was purified by column chromatography on silica eluted with 40-
70% acetone/heptane.  Relevant fractions were combined and the solvent removed in vacuo to 
yield the product as a white solid (2.91g/ 29%).    The melting point range of the solid was 
recorded as 140-142°C (literature value: 130-132°C).3   LCMS showed a m/z of 322 (MNa+). 
1H NMR (CD3OD, 270MHz):  1.37, 1.49 (2 s, 6H, CH3),  3.65 – 3.78 (m, 2H, H6/ H6’),  
4.06 – 4.20 (dd, 2H, J = 11.6Hz, 3.8Hz, H1/H1’),  3.93 – 3.98 (m, 1H, H5),  4.13 – 4.17 (m, 
1H, H4),  4.18 (d, 1H, J = 3.5Hz, H3),  4.25 (bs, 2H, NH2).      
 
 
Preparation of 4,5-O-(1-benzyloxymethylethylidene)-2,3-O-isopropylidene--D-
fructopyranose sulfamate 40  
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Benzyloxyacetone (5.05ml/29.07mmol), ethanol (5ml), triethylorthoformate 
(3.71ml/22.29mmol) and concentrated H2SO4 (0.14ml) were charged to a flask under N2.  An 
orange solution was obtained.  The reaction was stirred at room temperature for 3 hours.   2,3-
O-isopropylidene--D-fructopyranose sulfamate 8 (2.91g/9.69mmol) was dissolved in THF 
(18ml) and added to the reaction. The reaction was stirred at room temperature for 4 hours.  
HPLC and TLC confirmed that the desired products were forming.  The reaction was stirred at 
room temperature for a total of 21 hours.  Anhydrous sodium carbonate (11.10g) was added to 
the reaction to raise the pH to 7.  Following filtering, the reaction was concentrated in vacuo to 
give a yellow oil.  The crude material was purified by column chromatography on silica eluting 
with 2:1 heptane/ethyl acetate.  Relevant fractions were combined and the solvent removed in 
vacuo.  Unreacted benzyloxyacetone (2.37g) was recovered with the products obtained as a 
pale yellow sticky syrup (2.83g).  The sample was dissolved in ethanol (50ml) and the reaction 
concentrated in vacuo to give a yellow syrup (2.70g/56%).  LCMS showed two peaks at very 
close retention times in the chromatogram each showing m/z of 467.9 (MNa+) and 446 (MH+).  
1H NMR (CDCl3, 270MHz) (data for major diastereoisomer):  1.34, 1.40, 1.53 (3 s, 9H, CH3), 
 3.51 – 3.60 (dd, 2H, J = 3.2, 13.8Hz, OCH2),  3.78 (d, 1H, J = 13.0Hz, H6),  3.90 – 3.94 
(dd, 1H, J = 13.0, 2.2Hz, H6)  4.20 – 4.30 (m, 4H, H1/H1’/ H3/H5),  4.56 – 4.75 (m, 3H, 
CH2Ph/H4),  4.90 (bs, 2H, NH2),  7.26 – 7.36 (m, 5H, aromatic).  
 
 
Preparation of 4,5-O-(1-hydroxymethylethylidene)-2,3-O-isopropylidene--D-fructopyranose 
sulfamate (R and S diastereomers) 4/5 
 
4,5-O-(1-benzyloxymethylethylidene)-2,3-O-isopropylidene--D-fructopyranose sulfamate 
40 (2.43g/5.46mmol) was dissolved in ethanol (40ml).  10% Pd/C catalyst (50% wet/1.95g) 
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was added and the reaction was stirred at room temperature under nitrogen for 15 minutes.  
Hydrogen was sparged through the reaction for 3 hours and the reaction kept under a hydrogen 
atmosphere overnight.  TLC showed consumption of the starting material.  The reaction was 
placed under nitrogen and then filtered through a pad of Celite.  The Celite pad was washed 
with ethanol (250ml) and the filtrate concentrated in vacuo to give a white foam.   The white 
foam was dissolved in DCM (50ml) and dried over sodium sulfate.  Following vacuum 
filtration, the solvent was removed in vacuo and a white crystalline solid was obtained.  The 
crude material was purified by column chromatography on silica eluted with 2:1 ethyl acetate/ 
heptane.  The relevant fractions were combined and the solvent removed in vacuo.   Mixed 
fractions were repeatedly repurified by column chromatography to provide complete 
separation. Both diastereomers were obtained as white solids and were dried in vacuo at 40C 
overnight resulting in a mass of 762mg of 5 (39% yield) and a mass of 109mg of 4 (6% yield).  
MS data for each solid was positive and both showed peaks at m/z 378 (MNa+) and 356 (MH+).  
Full NMR data presented at Section 2.1.    
 
 
Preparation of phenyl sulfamate 46 
 
Chlorosulfonyl isocyanate (9.25ml/106.25mmol) was stirred in toluene (60ml).  Phenol 
(10g/106.25mmol) in toluene (60ml) was added at room temperature.  The reaction was heated 
to 100C and stirred for 22 hours after which TLC confirmed consumption of phenol.  The 
reaction was cooled to room temperature and the solvent removed in vacuo using a PTFE pump.  
A yellow oil (9ml) was obtained which was added dropwise to water (150ml) with stirring.  A 
white precipitate formed immediately.  The reaction was stirred at room temperature overnight.  
The reaction mixture was filtered in vacuo and the white solid collected.  The solid was washed 
with water (50ml) and dissolved in ethyl acetate (300ml).  The pale yellow solution was washed 
with brine (100ml), dried over magnesium sulfate and filtered.  The solvent was removed in 
vacuo to give an off-white solid.  The solid was dried in vacuo at 40C overnight resulting in 
10.4g of white solid.  LCMS showed a peak with m/z 196 (MNa+).  1H NMR (DMSO, 
270MHz):  7.22 (br, 2H, NH2),  6.92 – 7.02  (m, 5H, aromatic).   
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Preparation of 2,3:4,5-di-O-isopropylidene--D-fructopyranose sulfamate  
 
2,3:4,5-di-O-isopropylidene--D-fructopyranose 39 (1.5g/5.77mmol) was dissolved in toluene 
(30ml) under nitrogen.  Et3N (12ml/86.4mmol) and phenyl sulfamate 46 (5g/28.8mmol) were 
added to the reaction.  The reaction was heated to 80C and stirred for 5 hours.  TLC showed 
the production of phenol, product and starting material but no remaining phenyl sulfamate.   
The reaction was cooled to room temperature and Et3N (2.4ml/17.31mmol) and phenyl 
sulfamate (1g/5.77mmol) were added to the reaction and stirred overnight at 80C.  The TLC 
remained unchanged, so the reaction was cooled to room temperature and Et3N 
(2.4ml/17.31mmol) and phenyl sulfamate (1g/5.77mmol) were added.  The temperature of the 
reaction was raised to 100C and stirred for 1 hour.  A sample of the reaction was removed and 
a 1H NMR obtained which confirmed that the desired product had formed but it was difficult 
to quantify the extent of the reaction.  The reaction was cooled back to room temperature.  A 
brown paste formed in the bottom of the flask and as this turned more solid like on addition of 
ethyl acetate (100ml), the reaction was filtered.  Analysis of the brown solid confirmed it 
contained no product.  The filtrate was washed with NaHCO3 (aq)(3x100ml), water (150ml) 
and brine (100ml), dried over magnesium sulfate and filtered.  The solvent was removed in 
vacuo to give a yellow oil (3.71g).  The oil was purified by column chromatography on silica, 
eluted with 2:1 heptane/ethyl acetate.  Relevant fractions were combined and the solvent 
removed in vacuo to give unreacted starting material (0.696g) and a colourless sticky syrup as 
product (0.165g/8.5%).  Data was as for 1 above. 
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2.7.4. Synthesis of five-membered heterocyclic analogues of topiramate 
Preparation of 2,3:4,5-Di-O-isopropylidene-β-D-arabino-hexos-2-ulo-2,6-pyranose 
“diacetone fructose aldehyde” 47 
 
N-chlorosuccinimide (7.69g/ 57.6mmol) was dissolved in DCM (315ml) in a 500ml three-
necked flask and was cooled to 0°C under N2.  Dimethyl sulphide (8.64ml/ 115.2mmol) was 
added and the reaction cooled to -25°C with an acetone/ CO2 bath.  2,3:4,5-di-O-
isopropylidene--D-fructopyranose 39 (10.0g/ 38.4mmol) was added dropwise as a solution in 
DCM (35ml) maintaining the reaction temperature at ca. -25°C.  The reaction was stirred at -
25°C for 2 hours.  Triethylamine (5.88ml/ 42.2mmol) was added.  The reaction was stirred for 
a further 10 minutes and then poured over water (100ml) and the organic layer separated.  The 
aqueous was further extracted with DCM (2x150ml).  The organic layers were combined and 
dried over sodium sulfate, filtered and concentrated in vacuo to give a colourless opaque syrup.  
The crude material was purified by column chromatography on silica eluted with 70% diethyl 
ether/heptane.  The product fractions were combined and the solvent evaporated to give a 
colourless syrup (8.93g/90%).  MS: 281 (MNa+).  1H NMR (CDCl3, 270MHz):  1.32, 1.38, 
1.41, 1.54 (4s, 12H, CH3),  3.90 (d, 1H, J=13.0Hz, H6),  3.92 (dd, 1H, J=1.8Hz, 13.0Hz, 
H6’),  4.26 (d, 1H, J=8.1Hz, H5),  4.47 (d, 1H, J=2.7Hz, H3),  4.60 (dd, 1H, J=2.7Hz,8.1Hz, 
H4),  9.51 (s, 1H, aldehyde).   
 
 
Preparation of 2,3:4,5-Di-O-isopropylidene-β-D-arabino-hexos-2-ulo-2,6-pyranose oxime 48 
 
“Diacetone fructose aldehyde” 47 (5.0g/ 19.4mmol) was dissolved in ethanol (100ml) in a 
250ml three-necked flask.  Hydroxylamine hydrochloride (1.75g/ 25.2mmol) and DIPEA 
(6.64ml/ 38.7mmol) were added.  The reaction was stirred at room temperature overnight.  TLC 
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indicated consumption of starting material.  The reaction was transferred into an evaporating 
flask and was concentrated in vacuo to give a colourless syrup (9.23g). The crude material was 
purified by column chromatography on silica eluted with 10-20% acetone/ heptane.  The 
product fractions were combined and the solvent evaporated to give a white amorphous solid 
(4.1g/ 77%).  The melting point range of the solid was recorded as 138-140°C (literature value: 
137-138°C).51  MS: 296 (MNa+).  1H NMR (CDCl3, 270MHz):  1.34, 1.37, 1.45, 1.54 (4s, 
12H, CH3),  3.78 (dd, 1H, J=1.0Hz, 13.0Hz, H6),  3.92 (dd, 1H, J=1.8Hz, 13.0Hz, H6’),  
4.25 (dd, 1H, J=1.8Hz, 8.1Hz, H5),  4.60 – 4.66 (m, 2H, H3,4),  7.80 (s, 1H, OH).  13C NMR 
(CDCl3, 67.5MHz): 24.30, 24.67, 25.90, 26.03, 61.15, 70.13, 70.50, 71.64, 100.39, 109.02, 
109.30, 149.62.  
 
Preparation of 2,3:4,5-Di-O-isopropylidene-β-D-arabino-hexos-2-ulo-2,6-pyranose 
thiosemicarbazone 51 
 
“Diacetone fructose aldehyde” 47 (2.0g/7.74mmol) was dissolved in ethanol (50ml).  
Thiosemicarbazide (0.87g/11.61mmol) was added.  The reaction was heated to reflux.  
Reaction progression was monitored by TLC and LCMS.  On full consumption of starting 
material (2 hours), the reaction was cooled to ambient temperature and transferred to an 
evaporating flask and concentrated in vacuo to give a white solid.  The crude material was 
purified by column chromatography on silica eluted with 40% acetone/heptane.  Product 
fractions were combined and the solvent evaporated.  Product was obtained as a white 
amorphous solid (2.53g/98%).  The melting point range of the solid was recorded as 100-102°C 
(literature value: 98-100°C).51 MS showed a peak with m/z 354 (MNa+).  1H NMR (CDCl3, 
270MHz):  1.33, 1.37, 1.41, 1.55 (4s, 12H, CH3),  3.76 (d, 1H, J=13.0Hz, H6),  3.81 (d, 1H, 
J=13.0Hz, H6’),  4.06 – 4.20 (dd, 2H, J = 11.6Hz, 3.8Hz, H1/H1’),  4.28 (d, 1H, J=7.6Hz, H5), 
 4.57 – 4.63 (m, 2H, H3,4),  6.32 (br, 1H, NH2),  7.12 (br, 1H, NH2),  9.12 (s, 1H, -NH).  
13C NMR (CDCl3, 67.5MHz): 24.30, 25.90, 26.03, 26.91, 61.15, 70.13, 70.50, 72.24, 100.39, 
109.02, 109.30, 143.62, 180.23.  
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Preparation of 2,3:4,5-Di-O-isopropylidene-β-D-arabino-hexos-2-ulo-2,6-pyranose 
thiosemicarbazone 33 
 
Thiosemicarbazone 51 (2.0g/7.54mmol) was dissolved in pyridine (200ml).  FeCl3.6H2O (28ml 
of a 2M solution in ethanol) was added and the reaction was heated to 50°C for 1 hour.  
TLC/LCMS showed that no remaining starting material was present.  The reaction was cooled 
and concentrated in vacuo.  The resulting brown solid was taken up in ethyl acetate (150ml), 
filtered and washed with water (100ml).  The aqueous was further extracted with ethyl acetate 
(3x50ml).  The organic layers were combined and washed with water (150ml) and brine 
(150ml).  The solvent was removed in vacuo to give a brown paste and this crude material was 
purified by column chromatography on silica.  Fractions containing product were combined 
and the solvent evaporated.  The product was obtained as an off-white solid (1.36g/55%).  The 
melting point range of the solid was recorded as 179-181°C (literature value: 185-187°C).51  
LCMS showed product in 98% purity with m/z 330.2 (MH+) in the corresponding mass 
spectrum.      1H NMR (CDCl3, 270MHz):  1.31, 1.37, 1.57 (3s, 12H, CH3),  3.84 (d, 1H, 
J=13.0Hz, H6),  4.00 (dd, 1H, J=2.1Hz, 13.0Hz, H6’),  4.27 (dd, 1H, J=1.3Hz, 7.6Hz, H5),  
4.66 (dd, 1H, J=2.7Hz, 8.1Hz, H4),  4.92 (br, 2H, NH2),  5.00 (d, 1H, J=2.7Hz, H3).  13C 
NMR (CDCl3, 67.5MHz): 24.1, 24.79, 25.90, 26.24, 61.15, 70.13, 70.40, 73.64, 100.39, 
109.02, 110.30, 161.62, 169.50.    
 
 
Preparation of 2,3-O-isopropylidene-β-D-arabino-hexos-2-ulo-2,6-pyranose 
thiosemicarbazone 34 
  
Thiosemicarbazone 33 (500mg/1.53mmol) was dissolved in THF (10ml).  5N HCl (1ml) was 
added.  The reaction was stirred overnight at room temperature.  LCMS and TLC showed 
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remaining starting material was present so the reaction was heated to 50°C for 5 hours.  The 
reaction was neutralised to pH 7 by the addition of sodium carbonate (325mg) and partitioned 
between ethyl acetate (10ml) and brine (10ml).  The organics were separated and concentrated 
in vacuo.  The crude yellow solid was purified by column chromatography on silica eluted with 
10-25% acetone/heptane.  Relevant fractions were collected and the solvent evaporated.  
Product was obtained as a white solid (88mg/20%).  LCMS showed product in 94% purity with 
m/z 290 (MH+) in the corresponding mass spectrum.  The melting point range of the solid was 
recorded as 153-155°C.  1H NMR (DMSO, 270MHz):  1.34, 1.45 (2s, 3H, CH3),  3.56 – 3.67 
(m, 2H, H6,6’),  3.80 – 3.88 (m, 1H, H5),  3.99 – 4.07 (m, 1H, H4),  4.66 (d, 1H, J=3.24Hz, 
H3),  4.77 (d, 1H, J=6.75Hz,  OH),  5.07 (d, 1H, J=4.59Hz,  OH),  7.29 (ds, 2H, NH2).  
 
 
Preparation of 2,3:4,5-Di-O-isopropylidene-β-D-arabino-hex-2-ulosonitrile 49 
 
Oxime 48 (100mg/0.37mmol) was dissolved in THF (2ml) under N2.  Thionyl chloride (54µl 
as a solution in 0.2ml THF/0.74mmol) was added dropwise.  The reaction was heated to reflux 
overnight.  TLC showed full consumption of starting material.  3M sodium hydroxide (aq) 
(0.1ml) was added to the reaction raising the pH to ca. 11.  The reaction was then concentrated 
in vacuo and the resulting orange syrup was purified by column chromatography on silica (2g) 
eluted with 10% acetone/ heptane (35ml).  Product containing fractions were combined and the 
solvent evaporated.  Product was obtained as a yellow sticky syrup (85mg/ 90%).  LCMS 
showed product with m/z 256 (MH+) and 278 (MNa+) in the corresponding mass spectrum.  
1H NMR (CDCl3, 270MHz):  1.35, 1.48, 1.53, 1.55 (4s, 12H, CH3),  3.75 (dd, 1H, J=1.6Hz, 
13.0Hz, H6),  3.82 (dd, 1H, J=1.6Hz, 13.0Hz, H6’),  4.24 (d, 1H, J=8.1Hz, H4),  4.59 – 4.64 
(m, 2H, H3, 5).  
13C NMR (CDCl3, 67.5MHz): 23.86, 24.41, 25.69, 25.89, 61.39, 69.39, 69.51, 
93.87, 106.87, 109.93, 111.50, 116.58.    
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Preparation of 2,3:4,5-Di-O-isopropylidene-1-(tetrazol-5’-yl)-β-D-arabinopyranose 30 
 
Nitrile 49 (100mg/ 0.39mmol) was dissolved in DMF (2ml) under N2.  Sodium azide (51mg/ 
0.78mmol) and ammonium chloride (42mg/ 0.78mmol) were added and the reaction was stirred 
at 100°C for 16 hours.  TLC confirmed consumption of the starting material.  The reaction was 
concentrated in vacuo to give an orange residue which was dissolved in DCM (10ml), filtered 
through a syringe frit and concentrated in vacuo.  An orange syrup was obtained which was 
purified by column chromatography on silica eluted with 10-20% acetone/ heptane.  Fractions 
containing product were combined and the solvent evaporated.  Product was obtained as a white 
solid (76mg/65%).  LCMS showed product with m/z 299 (MH+) and 321 (MNa+) in the 
corresponding mass spectrum.  The melting point range of the solid was recorded as 137-139°C 
(literature value: 144-146°C).51 1H NMR (CDCl3, 270MHz):  1.29, 1.32, 1.62, 1.63 (4s, 12H, 
CH3),  3.94 (d obs, 1H, J=13.0Hz, H6),  4.06 (dd, 1H, J=1.6Hz, 13.0Hz, H6’),  4.33 (d, 1H, 
J=7.8Hz, H5),  4.68 (dd, 1H, J=2.4Hz, 7.8Hz, H4),  4.88 (d, 1H, J=2.4Hz, H3).  13C NMR 
(CDCl3, 67.5MHz): 23.70, 24.73, 25.80, 26.07, 61.39, 69.63, 69.97, 74.48, 97.62, 109.29, 
111.34, 156.49.    
 
 
Preparation of 1,2:3,4-Di-O-isopropylidene-1-(2′-methyl-1′,3′,4′-oxadiazol)-5′-yl-β-D-
arabinopyranose 31 
 
Tetrazole 30 (400mg/1.34mmol) was dissolved in acetic anhydride (10ml) and the reaction was 
heated to reflux under N2 for 5 hours.  TLC confirmed reaction completion.  The reaction was 
cooled to room temperature and ethanol (5ml) was added to quench the reaction.  The reaction 
was concentrated in vacuo to give a yellow syrup which was purified by column 
chromatography on silica eluted with 10% acetone/heptane.  Product containing fractions were 
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combined and the solvent evaporated.  Product was obtained as a white solid (223mg/53%).  
LCMS showed product in 95% purity with m/z 313 (MH+) in the corresponding mass spectrum.  
The melting point range of the solid was recorded as 104-106°C (literature value: 100-
102°C).51    1H NMR (CDCl3, 270MHz):  1.33, 1.36, 1.45, 1.59 (s(x4), 12H, CH3),  2.55 (s, 
3H, CH3)  3.91 (d, 1H, J=13.0Hz, H6’),  4.01 (dd, 1H, J=1.6Hz, 13.0Hz, H6”),  4.30 (d, 1H, 
J=7.8Hz, H5),  4.68 (dd, 1H, J=2.2Hz, 7.8Hz, H4),  5.02 (d, 1H, J=2.3Hz, H3).  13C NMR 
(CDCl3, 67.5MHz):  11.12, 24.27, 24.59, 25.81, 26.11, 61.63, 69.96, 70.16, 73.13, 97.83, 
109.55, 110.57, 164.53, 164.62.  
 
 
Preparation of 1,2:3,4-Di-O-isopropylidene-1-(2′-phenyl-1′,3′,4′-oxadiazol)-5′-yl-β-D-
arabinopyranose 32 
 
Tetrazole 30 (400mg/1.34mmol) was dissolved in pyridine (4ml) under N2.  Benzoyl chloride 
(0.66ml/1.61mmol) was added and the reaction heated to 50°C.  TLC confirmed reaction 
completion after 3 hours.  Water (4ml) was added to the reaction which was then concentrated 
in vacuo and the residue taken up in DCM (20ml) and washed with NaHCO3 (aq.)(20ml).  The 
organic layer was separated, dried over MgSO4, filtered and concentrated in vacuo.  The 
resulting orange syrup was purified by column chromatography on silica eluted with 5% 
acetone/heptane.  Product containing fractions were combined and the solvent evaporated.  The 
product was obtained as a white solid (539mg/95%).  LCMS showed product in 97% purity 
with m/z 375 (MH+) in the corresponding mass spectrum.  1H NMR (CDCl3, 270MHz):  1.33, 
1.38, 1.38, 1.51 (4s, 12H, CH3),  3.95 (d, 1H, J=13.0Hz, H6),  4.04 (d, 1H, 13.0Hz, H6’),  
4.33 (d, 1H, J=7.8Hz, H5),  4.71 (dd, 1H, J=2.2Hz, 7.8Hz, H4),  5.10 (d, 1H, J=2.2Hz, H3), 
 7.50 (m, 3H, aromatic),  8.09 (m, 2H, aromatic).  13C NMR (CDCl3, 67.5MHz):  24.37, 
24.64, 25.95, 26.14, 61.69, 70.06, 70.22, 73.25, 98.08, 109.63, 110.67, 123.70, 127.28, 128.31, 
128.97, 129.08, 132.02, 164.40, 165.49.  
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2.7.5. Synthesis of N-acetyl zonisamide 
Preparation of N-acetyl zonisamide 24 
 
Zonisamide 17 (200mg/0.94mmol) was added to acetic anhydride (5ml) under N2 and DMAP 
(11mg/0.094mmol) was added.  The reaction was heated to 90°C for 24 hours and completion 
was confirmed by TLC and LCMS. The reaction was cooled to room temperature, ethanol 
(5ml) was added and the reaction concentrated in vacuo.  The resulting residue was azeotroped 
with toluene (3 x 5ml) to remove any residual acetic acid.  An off-white solid (254mg) was 
obtained which was purified using a silica pad eluted with 10-20% ethyl acetate/heptane.  
Product was obtained as a white solid (197mg/82%) after drying in vacuo at 45°C for 16 hours.  
LCMS showed product in 94% purity with m/z 255 (MH+) and 277 (MNa+) in the 
corresponding mass spectrum.  1H NMR (DMSO, 270MHz):  1.99 (s, 3H, CH3),  5.30 (s, 
1H, NH),  7.48 (t, 1H, J=7.29Hz, Ar),  7.71 (t, 1H, J=7.29Hz, Ar),  7.81 (d, 1H, J=7.83Hz, 
Ar),  7.97 (d, 1H, J=7.83Hz, Ar).  
 
 
   
2.7.6. Synthesis of additional five-membered heterocyclic analogues of topiramate 
Preparation of mesylate 63 
 
2,3:4,5-Di-O-isopropylidene-α-D-fructopyranose 39 (5.00g/19.2mmol) was dissolved in DCM 
(60ml) and cooled to 0°C under N2.  Et3N (5.35ml/38.4mmol) was added maintaining the 
reaction temperature at <5°C.  Methane sulfonyl chloride (1.8ml/23.04mmol) was added 
dropwise maintaining reaction temperature <5°C throughout addition.  The reaction was 
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warmed gradually to room temperature.  After one hour, TLC confirmed reaction completion.  
The reaction was poured over saturated NaHCO3 (aq.).  The organic layer was separated and 
the aqueous further extracted with DCM (2x50ml).  The organic layers were combined, washed 
with water (200ml), brine (200ml) and dried over MgSO4.  After filtering, the solvent was 
removed in vacuo to give a white solid which was dried in vacuo at 40°C for 16 hours 
(6.22g/96%).  MS data revealed a peak with m/z of 339 (MH+).  1H NMR (CDCl3, 400MHz): 
 1.34, 1.41, 1.47, 1.54 (4s, 12H, CH3),  3.05 (s, 3H, S-CH3),   3.78 (d, 1H, J=13.6Hz, H6),  
 3.91 (d, 1H, J=13.6Hz, H6’),  4.20 – 4.26 (m, 2H, H1/H1’),  4.31 – 4.35 (m, 2H, H3,5),  
4.62 (dd, 1H, J=2.8Hz, 8.0Hz, H4). 
  
 
Preparation of tosylate 62 
 
 
2,3:4,5-Di-O-isopropylidene-α-D-fructopyranose 39 (1.00g/3.84mmol) was dissolved in 
pyridine (15ml) under N2.    p-Toluene sulfonyl chloride (880mg/4.61mmol) was added and the 
reaction was stirred at room temperature for 16 hours.  The reaction was concentrated in vacuo 
and the residue taken up in ethyl acetate (20ml).  The solution was washed with water (20ml), 
saturated NaHCO3(aq.)(20ml), brine (20ml) and dried over MgSO4.  After filtering, the solvent 
was removed in vacuo to give a clear, colourless syrup.  The crude material was purified by 
column chromatography on silica eluted with 10-20% ethyl acetate/heptane.  Product 
containing fractions were combined and the solvent evaporated.  The product was obtained as 
a white solid which was dried in vacuo at 40°C for 16 hours (915mg/57%).  LCMS showed 
product in 96% purity with m/z 415 (MH+) and 437 (MNa+) in the corresponding mass 
spectrum.  1H NMR (CDCl3, 270MHz):   1.30, 1.35, 1.54 (s(x3), 12H, CH3),  2.43 (s, 3H, 
CH3),  3.69 (d, 1H, J=13.0Hz, H6),  3.85 (d, 1H, J=13.0Hz, H6’),  4.02 (dd obs, 2H, 
J=12.2Hz, 1.9Hz, H1,1’),  4.18 (d, 1H, J=7.8Hz, H5),  4.29 (d, 1H, J=2.4Hz, H4),  4.64 (dd, 
1H, J=2.4Hz, 7.8Hz, H3),  7.33 (d, 2H, J=8.1Hz, aromatic),  7.78 (d, 2H, J=8.1Hz, aromatic).   
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Preparation of triflate 60 
 
2,3:4,5-Di-O-isopropylidene-α-D-fructopyranose 39 (3.84g/ 14.77mmol) was dissolved in 
DCM (50ml) and cooled to 0°C under N2.  Et3N (4.09ml/29.54mmol) was added and the 
reaction temperature was maintained at 0°C.  Trifluoromethane sulfonic anhydride 
(5.0g/17.72mmol) was added dropwise maintaining reaction temperature <5°C throughout the 
addition.  The reaction was stirred at <5°C for 1 hour after which time TLC indicated remaining 
starting material.  Et3N (2.0ml/14.8mmol) was added followed by trifluoromethane sulfonic 
anhydride (1.6g/5.9mmol) which was added dropwise maintaining reaction temperature <5°C 
throughout addition.  TLC indicated that no starting material was remaining.  The reaction was 
warmed to room temperature and poured over water (150ml).  The organic layer was separated 
and the aqueous was further extracted with DCM (2x50ml).  The organic layers were combined 
and washed with water (100ml), brine (100ml) and dried over MgSO4.  After filtering, the 
solvent was removed in vacuo.  A brown syrup was obtained which was purified by column 
chromatography on silica eluted with 10-20% ethyl acetate/heptane.  Relevant fractions were 
combined and the solvent evaporated.  A yellow oil (3.69g/64%) was obtained.  The mass 
spectrum contained peak with m/z 393 (MH+) and 415 (MNa+).  1H NMR (CDCl3, 400MHz): 
 1.36, 1.41, 1.48, 1.57 (s(x4), 12H, CH3),  3.80 (d, 1H, J=12.0Hz, H6),  3.92 (d, 1H, 
J=12.0Hz, H6’),  4.26 (d, 1H, J=7.2Hz, H3),  4.29 (d, 1H, J=3.2Hz, H5),  4.41 (d, 1H, 
J=10.4Hz, H1),  4.53 (d, 1H, J=10.4Hz, H1’),   4.64 (dd, 1H, J=3.2Hz, 7.2Hz, H4).  13C NMR 
(CDCl3, 100MHz):  24.02, 25.12, 25.82, 26.58, 61.71, 69.80, 70.23, 70.55, 74.14, 99.93, 
118.20, 120.27, 123.30. 
 
 
Preparation of nitrile 61 
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Triflate 60 (3.5g/8.92mmol) was dissolved in DMSO (65ml) and NaCN (874mg/17.84mmol) 
was charged.  The reaction was heated to 80°C for 12 hours after which time TLC confirmed 
that the reaction was complete.  The reaction was partitioned between water (100ml) and ethyl 
acetate (100ml).  The organic layer was separated and the aqueous further extracted with ethyl 
acetate (2x50ml).  The organic layers were combined and washed with water (150ml), brine 
(150ml) and dried over MgSO4.  After filtering, the solvent was removed in vacuo to give a 
dark orange syrup which was purified by column chromatography on silica eluted with 10% 
ethyl acetate/heptane.  Relevant fractions were combined and the solvent evaporated to give a 
colourless syrup (1.3g/54%).  MS showed peaks with m/z 270 (MH+) and 292 (MNa+).  1H 
NMR (CDCl3, 400MHz):  1.36, 1.49, 1.56 (3s, 12H, CH3),  2.82 (d, 1H, J=12.6Hz, C 
H),  3.02 (d, 1H, J=12.6Hz, H1’),  3.78 (d, 1H, J=13.6Hz, H6),  3.90 (d, 1H, J=13.6Hz, H6’), 
 4.24 (d, 1H, J=8.0Hz, H3),  4.33 (d, 1H, J=3.2Hz, H5),  4.65 (dd, 1H, J=3.2Hz, 8.0Hz, H4).  
13C NMR (CDCl3, 100MHz):  24.14, 25.22, 25.99, 26.60, 28.94, 62.12, 70.08, 70.54, 72.19, 
100.17, 109.43, 109.62, 116.01. 
 
 
Preparation of tetrazole 35 
 
Nitrile 61 (330mg/1.23mmol) was dissolved in DMF (10ml) under nitrogen and NaN3 
(1.1mg/17.22mmol) and NH4Cl (921mg/17.22mmol) were added.  The reaction was heated to 
105°C and after 120 hours, TLC indicated reaction completion.  The reaction was cooled to 
room temperature and was partitioned between DCM (50ml) and water (50ml).  The organic 
layer was separated and the aqueous further extracted with DCM (3x25ml).  The combined 
organics were washed with water (5x100ml), brine (100ml) and dried over MgSO4.  After 
filtering, the solution was concentrated in vacuo to give a yellow syrup.  The crude material 
was purified by column chromatography on silica eluted with 10-50% ethyl acetate/heptane.  
Product containing fractions were combined and the solvent evaporated to give a white solid 
(207mg/54%).  MS showed peaks with m/z 313 (MH+) and 335 (MNa+).  Melting point was 
recorded as 156-158°C.  1H NMR (CDCl3, 400MHz):  1.36, 1.49, 1.57 (s(x3), 12H, CH3),  
2.82 (d, 1H, J=17.2Hz, H1),  3.03 (d, 1H, J=17.2Hz, H1’),  3.77 (d, 1H, J=12.8Hz, H6),  
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3.84 (d, 1H, J=12.8Hz, H6’),  4.24 (d, 1H, J=7.2Hz, H3),  4.33 (d, 1H, J=2.4Hz, H5),  4.65 
(dd, 1H, J=2.4Hz, 7.2Hz, H4).  
13C NMR (CDCl3, 100MHz):  24.01, 24.79, 25.96, 26.28, 
35.67, 53.51, 61.79, 70.21, 70.44, 73.70, 109.37, 109.40, 156.84. 
 
 
Preparation of methyl oxadiazole 36 
 
 
Tetrazole 35 (50mg/0.16mmol) was dissolved in acetic anhydride (1.25ml).  The reaction was 
stirred at 130°C for 12 hours.  TLC confirmed reaction completion.  The reaction was cooled 
to room temperature and quenched with ethanol (3ml).  The reaction was concentrated in 
vacuo.  The residue was azeotroped with toluene (3x3ml) to remove residual acetic acid.  A 
brown syrup was obtained which was purified by column chromatography on silica eluted with 
50% ethyl acetate/heptane.  Product containing fractions were combined and the solvent 
removed in vacuo.  Product was obtained as a pale yellow solid (25mg/48%).  MS showed a 
peak with m/z 327 (MH+).  Melting point was recorded as 134-136°C.  1H NMR (CDCl3, 
400MHz):  1.09, 1.35, 1.47, 1.51 (s(x4), 12H, CH3),  2.53 (s, 3H, CH3),  3.35 (d, 1H, 
J=14.8Hz, H1),  3.44 (d, 1H, J=14.8Hz, H1’),  3.76 (d, 1H, J=12.8Hz, H6),  3.89 (d, 1H, 
J=12.8Hz, H6’),  4.23 (d, 1H, J=7.6Hz, H3),  4.48 (d, 1H, J=2.4Hz, H5),  4.64 (dd, 1H, 
J=2.4Hz, 7.2Hz, H4).  
13C NMR (CDCl3, 100MHz):  11.38, 24.39, 24.87, 26.25, 26.67, 34.12, 
62.12, 70.59, 70.84, 72.29, 101.73, 109.15, 109.49, 162.80, 164.61. 
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Preparation of phenyl oxadiazole 37 
 
 
Tetrazole 35 (250mg/0.8mmol) was dissolved in pyridine (5.0ml) and benzoyl chloride 
(110µl/1.1mmol) was added.  The reaction was stirred at 50°C for 16 hours after which time 
TLC confirmed reaction completion.  The reaction was cooled to ambient temperature and 
concentrated in vacuo to give a pale brown syrup.  This residue was taken up in ethyl acetate 
(20ml) and the solution washed with saturated sodium hydrogen carbonate (aq) (25ml), dried 
over MgSO4, filtered and concentrated in vacuo.  The crude material was purified by column 
chromatography on silica eluted with 10-20% ethyl acetate/heptane.  Product containing 
fractions were combined and the solvent removed in vacuo.  Product was obtained as a white 
solid (194mg/63%).  LCMS showed a peak with m/z 389 (MH+).  1H NMR (CDCl3, 400MHz): 
 1.03, 1.33, 1.44, 1.49 (4xs, 12H, 4xCH3),  3.51 (2xd, 2H, J=6.8, 14.8Hz, H1,1’),  3.77 (d, 
1H, J=12.8Hz, H6),  3.91 (d, 1H, J=12.8Hz, H6’),  4.23 (d, 1H, J=8.0Hz, H3),  4.57 (d, 1H, 
J=2.4Hz, H5),  4.65 (dd, 1H, J=2.4, 8.0Hz, H4),  7.47 – 7.52 (m, 3H, Ar),  8.05 (d, 2H, 
J=8.0Hz, Ar).  13C NMR (CDCl3, 100MHz):  24.20, 24.71, 26.07, 26.46, 35.83, 62.02, 70.46, 
70.68, 71.95, 100.00, 101.65, 109.03, 109.33, 124.06, 127.03, 128.63, 129.10, 131.71, 162.43, 
165.41. 
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CHAPTER 3.  Attempted Synthesis of Iminosugar Analogues of 
Topiramate 
A key objective of the project was to consider and investigate structural modifications to 
topiramate that might influence its pharmacological effects.  The in silico modelling work 
identified the topiramate analogue 25 as a target compound.  25 was shown to have positive 
affinity with the active sites of the CA isozymes of particular interest to the project.  The 
analogues 25, 26, 27 and 28 represent an interesting class of compounds called iminosugars 
that are well documented within the scientific literature. 
 
Figure 36: Iminosugar analogues of topiramate 
 
3.1. Iminosugars as natural products and therapeutic agents 
Iminosugars are analogues of monosaccharides in which the endocyclic oxygen is replaced by 
a nitrogen atom.  The iminosugar class of compounds has been subject to significant research 
and development during the last 25 years.  Iminosugars were recognised as having potential 
biological and therapeutic applications following the discovery during the 1980s that several 
naturally occurring iminosugars were potent inhibitors of the glycosidase family of enzymes. 
63  This stimulated, not only research into the biomedical application of iminosugars, but also 
the synthesis of novel and modified iminosugars.2  
 
Iminosugars are naturally occurring sugar mimics and are widespread in plants and 
microorganisms. To date over 100 iminosugars have been isolated from natural sources.64  
Iminosugars can be classified into five key structural classes and representative structures are 
shown in Figure 37.65 
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• Polyhydroxylated piperidines – for example, 5-amino-5-deoxy-glucopyranose, trivially 
named nojirimycin, 64 was discovered in 1966 as the first natural glucose related 
iminosugar.  Nojirimycin was first identified as an antibiotic produced by Streptomyces 
roseochromogenes and was shown to be a potent inhibitor of α- and β-glucosidases.66 
67  1-Deoxynojirimycin (DNJ) 65 was isolated from the roots of the mulberry trees and 
the species has been shown to produce many other iminosugars.  Several other plant 
species and microorganisms have been shown to naturally produce a range of epimers 
and functional relations of nojirimycin and DNJ. 65 
• Pyrrolidines – for example, 2,5-Dideoxy-2,5-imino-d-mannitol (DMDP) 66 was found 
in leaves of the legume Derris elliptica in 1976 and was later shown to be present, along 
with several other derivatives, in many disparate species of plants and 
microorganisms.68 
• Indolizidines – for example, swainsonine 67 and castanospermine 68 were isolated 
from the legumes Swainsona canescens and Castanospermum australe in Australia 
after finding that the plants from which they derive were toxic to livestock.65   Although 
this class of iminosugars have a less obvious structural relationship to monosaccharides, 
the configuration of the hydroxyl substituents on the ring can be compared to those of 
sugars.  Castanospermine 68 may be regarded as a bicyclic derivative of DNJ 65 with 
an ethylene bridge between the hydroxymethyl group and the ring nitrogen.  The 
stereogenic centres of its 6-membered ring were shown by X-ray crystallography to 
correspond to gluco-configuration.65 
• Pyrrolizidines – for example, alexine 69 was the first compound of this group to be 
isolated from natural sources from the legume Alexa leiopetala. 65 
• Nortropanes – for example, calystegine 70 which were first discovered as secondary 
metabolites of plants and are abundant in the underground organs and roots of 
Calystegia sepium.65  This group of iminosugars all contain a nortropane ring system, 
two to four hydroxyl groups varying in position and stereochemistry and a novel 
aminoketal functionality which results in a tertiary hydroxyl group at the bicyclic ring 
bridgehead. 
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Figure 37: Representative structures of naturally occurring iminosugars 
 
Iminosugars have been shown to inhibit or moderate the activity of a wide range of enzymes 
that act on carbohydrates.2  Glycosidases are involved in the degradation of complex 
carbohydrates and glycoconjugates, for example glycoproteins, by catalysing the hydrolysis of 
glycosidic linkages.  The enzymes are typically named after the substrates upon which they 
act, for example, lactase, amylase and sucrase.  Glycotransferases are enzymes that establish 
natural glycosidic linkages involved in the synthesis of various glycoconjugates.  It is thought 
that iminosugars are potent inhibitors of these carbohydrate processing enzymes as they 
resemble the cationic transition states formed during glycoside catalysis.69  Iminosugars can be 
considered to be in their protonated state at physiological pH and the resulting ammonium ions 
mimic the oxocarbenium character of the hydrolysis transition states of carbohydrate substrates 
(Figure 38) and block the enzyme active sites.64   
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Figure 38: Diagrammatic representation of the resemblance of iminosugars to hydrolysis 
transition states of carbohydrate substrates in glycosidases 64 
   
The glycosidase and glycotransferase enzymatic groups are involved in a wide range of 
important biological processes and their inhibition can affect the synthesis, metabolism and 
degradation of carbohydrates.70  The ability to modulate the activity of these carbohydrate 
processing enzymes has many potential medical applications as the biological processes they 
control are so widespread.  Defects in the activity of glycosidases and glycotransferases are 
implicated in many diseases and medical conditions related to metabolic disorders, for 
example, diabetes, cancer and viral infections.64  Hence, the discovery of new drugs and 
therapeutic strategies to influence enzymatic activity is of great interest.  Certain iminosugars 
offer interesting candidates in this regard as they have a number of positive characteristics; 
they are chemically and metabolically stable, they have high aqueous solubility, oral 
bioavailablilty is good and their ability to cross the blood-brain barrier enables penetration of 
the central nervous system. Also, manipulation of the stereochemistry of the iminosugar 
scaffold enables a greater degree of opportunity for selective and specific inhibitors. 
 
At present there are 25 known natural iminosugar glycosidase inhibitors.69  DNJ 64 and 
castanospermine 68 have been shown to inhibit intestinal disaccharidases and delay post 
prandial hyperglycemia making them potential antidiabetic and obesity drugs.  A synthetic 
derivative of DNJ, N-hydroxyethyl DNJ (Glyset/Miglitol) 71 was commercialised in 1996 as 
a treatment for type II diabetes.71  DMDP 66 is best known for its ability to inhibit glucosidase 
I and swainsonine 67 competitively inhibits α-mannosidase II.69   1,4-dideoxy-1,4-imino-D-
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arabinitol, also known as DAB-1 72, is a potent inhibitor of glycogen phosphorylase which is 
the enzyme responsible for the degradation of glycogen into glucose monomers.69  This makes 
it, and its synthetic derivatives, potential drugs for the treatment of type II diabetes as it can 
modulate glucose levels.  Another iminosugar clinically used as a drug is miglustat 73 used for 
the treatment of Type I Gaucher disease, a genetic disorder resulting in an excessive 
accumulation of glucosylceramide, a membrane lipid in lysosomes, resulting in liver and bone 
marrow problems.69  The disease is caused by the dysfunctional activity of glucocerebrosidase, 
the enzyme responsible for the destruction of glucosylceramide.  Miglustat offers an effective 
substrate reduction therapy by inhibiting the enzyme responsible for glucosylceramide 
production, glucosylceramide synthase.  This reduces the amount of glucosylceramide rather 
than acting upon the dysfunctional glucocerebrosidase.72    
 
 
Figure 39: Structure of iminosugars that are glycosidase inhibitors or in clinical use 
 
However, the activity of iminosugars is not restricted to interactions with carbohydrate 
processing enzymes or in their role as glycomimetics. The utility of iminosugars to a range of 
other targets such as matrix metalloproteinase with potential for oncology treatment and the 
local treatment of skin disorders such as psoriasis is also under investigation.73  
 
The exploitation of iminosugars as therapeutics has been modest to date having resulted in only 
eight clinical candidates and the two marketed drugs noted earlier.64  It is costly and time 
consuming to isolate iminosugars in the pure form from natural sources in sufficient quantities 
to enable full toxicological and clinical evaluation.74  Thus, the development of synthetic 
analogues of natural iminosugars has received much research since the first synthetic 
iminosugar, nojirimycin 64, was reported by Paulsen in 1967.75  Homonojirimycin (HNJ) 74 
is an iminosugar which was made synthetically by Bayer’s chemists almost 10 years before 
natural α-homonojirimycin was isolated for the first time from Omphalea diandra.71 
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Figure 40: Structure of homonojirymicin (HNJ) 
 
3.2. Synthesis of iminosugars 
Given the enormous therapeutic potential of iminosugars, the development of efficient and 
general synthetic methodologies for their synthesis and the generation of structural diversity 
has become the objective of many synthetic chemistry research groups.  The structure of 
iminosugars presents a number of synthetic challenges.  Firstly, iminosugars are generally 
stereochemically complex molecules containing at least four contiguous stereogenic centres.  
These must be obtained with high stereochemical control as the stereochemistry of one 
particular hydroxyl group within the molecule can dramatically change the biological activity 
of a compound.  Secondly, the piperidine ring, pyrrolidine ring or bicyclic scaffold must be 
generated efficiently.  The molecules are highly polar which can complicate isolation and 
purification methodologies.  In addition, the presence of a high number of functional groups, 
particularly hydroxyl groups, requires cautious protection and deprotection strategies to ensure 
chemoselectivity during syntheses.   
 
With five key structural classes of iminosugars and numerous synthetic ring forms and 
derivations, there is a vast literature on the synthesis of a wide range of iminosugars employing 
a variety of chemistries to achieve the final targets.  The approach of using carbohydrates as 
starting materials for iminosugar syntheses is well represented in the literature.  However, other 
inexpensive chiral-pool starting materials including amino acids and tartaric acids have also 
been successfully used in the synthesis of iminosugars.  Asymmetric methodologies and 
chemoenzymatic approaches also feature in the literature.71  Rather than attempt to provide an 
exhaustive list of iminosugar syntheses, several key synthetic strategies which have been used 
to prepare iminosugars in the piperidine class will be discussed and some interesting examples 
provided.  Synthetic methodologies are grouped in respect of whether carbohydrate or non-
carbohydrate starting materials are used and then classified according to the key step to form 
the requisite C-N bond or bonds.        
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3.2.1. Carbohydrates as starting materials 
Due to their commercial availability and structural relationship with iminosugars, 
carbohydrates have been used as starting materials in the preparation of a range of 
iminosugars.71  A structurally related carbohydrate as a starting material provides a means of 
introducing the correct stereochemistry at the relevant stereogenic centres into the final 
iminosugar.  Figure 41 shows the stereochemical relationship between D-glucose and 
nojirimycin.   
 
 
Figure 41: Stereochemical relationship between D-glucose and the iminosugar, nojirimycin 
 
A wide range of carbohydrates is available providing an excellent variety of chirons that will 
facilitate the introduction of stereochemical characteristics into the target iminosugar.  
Strategic, stereoselective chemical transformations to either retain or alter the chirality of a 
particular stereogenic centre can be used to increase the diversity of iminosugar targets by 
providing access to epimeric or anomeric relations.70  Depending upon the target, the main 
challenge in employing carbohydrates as starting materials is the differentiation of the hydroxyl 
groups often necessitating the inclusion of several protection and deprotection steps into 
syntheses.    
 
To prepare an iminosugar from a carbohydrate requires the introduction of two carbon-nitrogen 
bonds and is a crucial step in the total synthesis of iminosugars in both the piperidine and 
pyrrolidine forms.  Figure 42 illustrates the key bond disconnections in the formation of the 
piperdine ring of an iminosugar.   
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Figure 42: Key C5-N and/or C1-N disconnections in the formation of a piperidine ring 
  
Figure 43 provides a generic outline of the key steps involved in preparing an iminosugar from 
a general carbohydrate chiron.  The first step is the introduction of an amino group or precursor 
into the carbohydrate generally by the conversion of one of the hydroxyl groups.  A favoured 
method for doing this is via nucleophilic displacement with common nitrogen nucleophiles 
including hydrazine, ammonia, benzylamine, phthalimide and azide.  Of these, the azide group 
offers benefits in that it is a powerful nucleophile, once installed it is unreactive under a broad 
range of reaction conditions and is readily reduced to the corresponding amine functionality 
when required.   Tosylates and mesylates are often used as leaving groups but a range of other 
leaving groups have been reported.71  The activation of the amino function and an appropriate 
functional group in a suitable corresponding position within the molecule are generally 
required for the cyclisation that generates the C-N bond or bonds.  Various methods have been 
used to promote cyclisation including intramolecular SN2 reactions, electrophilic induced 
cyclisation, reductive amination and ring closing metathesis.71  Further modification to the 
carbon backbone is often required to afford the iminosugar the appropriate functionalisation.   
 
 
 
 
 
 
Figure 43: Generic route to iminosugars in the piperidine and pyrrolidine forms from a general 
carbohydrate starting material.76 
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3.2.1.1. C-N bond formation by intramolecular SN2 reactions 
Intramolecular cyclisation to form the piperidine ring can be accessed via the displacement of 
a leaving group by an amino group or masked amino group.  The ring opening of an epoxide 
by an amino group is another strategy regularly used to induce cyclisation.  An advantage of 
an SN2 intramolecular reaction to form the C5-N bond of an iminosugar is that it leads to 
inversion of configuration at the C5 position due to the displacement of a leaving group.  This 
allows potential access to iminosugars in the L-series.71   
Cipolla et al 77 developed a new synthetic procedure whereby a variety of C-glycosides could 
be synthesised from different carbohydrates.  The general scheme involves the reaction of a 
tetra-O-benzyl protected monosaccharide with a primary amine to introduce the amino group 
followed by the stereoselective addition of a Grignard reagent to the glycosamine.  The 
subsequent cyclisation of the resulting amino alcohol is mediated by an intramolecular SN2 
displacement of a triflate group.  Altering the primary amine and the Grignard reagent affords 
the flexibility to synthesise a great variety of piperidine iminosugars.  Scheme 23 provides an 
example of the steps involved in preparing an iminosugar in the L-series, (2S,3R,4R,5S,6R)-2-
hydroxymethyl-6-propyl-3,4,5-trihydroxypiperidine 79 from 2,3,4,6-tetra-O-benzyl-D-
glucopyranose 75. 
 
Scheme 23: Example of ring formation by SN2 displacement.  Synthesis of (2S,3R,4R,5S,6R)-
2-hydroxymethyl-6-propyl-3,4,5-trihydroxypiperidine.   
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An efficient synthesis of the C5 epimer of 1-deoxynojirimycin 65, l,5-dideoxy-1,5-imino-L-
iditol (1-deoxy-L-idonojirimycin) 84, via an SN2 displacement reaction was reported by Fowler 
et al (Scheme 24).  78  In this instance, 2,3,4,6-tetra-O-benzyl-D-glucitol 81 was prepared by 
the reduction of commercially available 2,3,4,6-tetra-O-benzyl-D-glucopyranose 80.  The two 
resulting hydroxyl groups were mesylated to give the methanesulfonyl derivative 82 that was 
reacted with benzylamine to afford 83.  Subsequent hydrogenolysis gave the desired compound 
84.  An alternative, more time efficient method of preparing 84 has been described. 79  In this 
case, the C1 mesylate group is substituted with an amino group by treating 82 with sodium 
azide followed by an in situ Staudinger reaction with triphenylphosphine.  A spontaneous, 
intramolecular SN2 cyclisation resulted providing the desired O-benzyl protected piperidine 
iminosugar 83. 
      
 
Scheme 24: Example of ring formation by SN2 displacement.  Synthesis of l,5-dideoxy-1,5-
imino-L-iditol.   
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3.2.1.2. Examples of C-N bond formation by reductive amination 
A reductive amination reaction to form the C5-N and/or C1-N bond offers several advantages 
to an iminosugar synthetic strategy.  The reaction fully utilises the intrinsic reactivity of the 
amino group already introduced into the molecule.  One or two stereogenic centres are 
concomitantly generated as a result of the reaction.  Reductive amination is compatible with 
many other functional groups that may be present in the molecule. 
Scheme 25 illustrates the synthetic strategy adopted by Godin et al 80 for the preparation of 
various α and β-1-C substituted-1 deoxynojirimycins.  L-sorbose 85 is a readily available 
carbohydrate and was selected as the starting material for the synthesis to take advantage of its 
three stereogenic centres at C2, C3 and C4 which are present in the desired structure.  An 
orthogonal protecting group strategy was designed to ensure the discrimination of hydroxyl 
groups during various key synthetic steps.  The key intermediate in the synthesis is 92, an 
imine.  In the particular instance shown in Scheme 25, the imine is employed as a means to 
introduce diversity into the molecule by the diastereoselective addition of organometallic 
nucleophiles.  Following the extension of the chain, intramolecular reductive amination of the 
latent keto function of the aminosorbose derivative 93 was achieved with sodium 
cyanoborohydride.  Removal of the benzyl groups via catalytic hydrogenation afforded the 
desired product 95. 
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Scheme 25: Synthesis of nojirimycin C-ethyl glycoside.  Example of ring formation by 
reductive amination strategy. 
Another example of where intramolecular reductive amination has been used to successfully 
prepare a piperidine type iminosugar is shown in Scheme 26.81  The synthesis of 1-
deoxymannojirimycin 101 includes five steps from the carbohydrate D-fructose.  Here, the 
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reductive amination step occurs concurrently with the reduction of the azide to an amino group 
by catalytic hydrogenation.  The unmasked amine then reacts with the hemiketal of the furanose 
ring to form the iminosugar.     
 
Scheme 26: Example of ring formation by reductive amination strategy.  Synthesis of 1-
deoxymannojirimycin.   
 
3.2.1.3. Electrophile induced C-N bond formation 
A further strategy is to use an electrophile to induce the intramolecular cyclisation step.  
Cyclisation of unsaturated amino alkenes has usually been promoted with mercury (II) salts or 
N-iodosuccinimide (NIS). 82 83 84  An advantage of this method is that the piperidine ring is 
formed and an organomercurial or iodo derivative also results that constitute versatile 
precursors for further functionalisation.  Scheme 27 83 provides an example of a synthetic 
strategy in which NIS is used to mediate the cyclisation of amino alkene 105.  The iodo product 
106 is a key precursor of imino-C-glycosides compounds and the overall scheme offers a highly 
efficient route from tetra-O-benzyl-D-galactopyranose.   
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Scheme 27: Example of ring formation by electrophile induced cyclisation.  Synthesis of a 
1,2,6-trideoxy-2-6-imino-1-iodoheptitol derivative.   
 
3.2.2. Non-carbohydrates as starting materials 
A disadvantage of using carbohydrates as starting materials in the synthesis of iminosugars is 
that they can necessitate the need for long synthetic sequences with low overall yields; this can 
limit the commercial potential of an iminosugar.  Attempts to overcome this perceived barrier 
have generated interesting recent advances in the use of non-carbohydrates as precursors to 
iminosugars with approaches employing amino acids and their derivatives, nitrogen containing 
heterocycles and nitrones reported.64  In most cases, the use of alternative starting materials 
simplifies the key chemical steps involved in preparing an iminosugar which improves 
convenience and increases commercial viability.    
3.2.2.1. Amino acids as starting materials 
Commercially available Garner aldehyde 102 which is derived from D-serine has found 
successful application in providing a chiral building block in the syntheses of iminosugars. 70 
Fagomine 107 was successfully synthesised from Garner aldehyde as illustrated in Scheme 
28.85  The synthesis begins with a Wittig reaction of Garner aldehyde with 
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methyltriphenylphosphonium iodide in the presence of sodium bis(trimethylsilyl)amide to give 
an olefin.  This compound then undergoes hydrolysis with p-toluene sulphonic acid, followed 
by O-silylation to afford 103.  Then follows a three step sequence, N-Boc deprotection, 
alkylation and subsequent N-protection, to give the butenylated product 104.  The ring closing 
metathesis step, (vii) in Scheme 28, is a key step in the overall reaction scheme.  Grubbs 
catalyst, bis(tricyclohexylphosphine)benzylidineruthenium(IV) dichloride, was used to effect 
the ring closure.  Stereoselective dihydroxylation of the double bond of 105 introduced the two 
hydroxyl groups.  Deprotection of the silyl ether and N-Boc group gave the desired product.  
 
 
Scheme 28: Example of the use of an amino acid starting material. Synthesis of 3-epi-fagomine 
from Garner aldehyde.  
 
Scheme 28 provides an example of an important and well utilised iminosugar construction 
methodology when non-carbohydrate starting materials are used in which a dual strategy of 
ring closing metathesis and cis-hydroxylation is employed.  Several iminosugars have been 
prepared using this method with a typical procedure involving the ring closing metathesis of a 
suitably functionalised nitrogen containing diene to yield a dehydropiperidine that is 
subsequently dihydroxylated, often using OsO4.
69  The scope of ring closing metathesis as a 
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tool in the synthetic strategies of iminosugars has widened due to the ongoing development of 
stable, reactive and functional group tolerant olefin metathesis catalysts.86  Of the several 
catalysts described in the literature, three of the most popular are the ruthenium derived 
catalysts developed by Grubbs, 108, 109 and 110.   
 
Figure 44: Example of catalysts employed in ring closing metathesis 
  
3.2.2.2. Tartaric acids as starting materials 
Some syntheses of iminosugars have been reported from tartaric acid, its diasteroisomers and 
derivatives.  Tartaric acid can be considered as a four carbon skeleton moiety that has a threo-
type configuration and is a useful chiral building block.70  Scheme 29 details the synthesis of 
the iminosugar 116 from an aldol reaction between the protected threose derivative 111 and 
the nucleophilic metal chelated N-protected analine tert-butyl ester 112 as the key step.87  After 
removal of the benzyl group of 113, a cyclisation under Mitsonobu conditions yielded 
compound 114.  The labile isopropylidene ketal was cleaved and the resulting diol along with 
the other unprotected hydroxyl group were protected with benzyl groups.  The iminosugar 116 
was accessed by reduction of the tert-butyl ester with lithium aluminium hydride, deprotection 
of the tosyl amide by titration with sodium napthalide and cleavage of the benzyl ethers by 
catalytic hydrogenation.     
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Scheme 29: Synthesis of an iminosugar from a tartaric acid derivative 
3.2.2.3. Asymmetric methodologies 
The asymmetric epoxidation of allylic alcohols, the asymmetric dihydroxylation of olefins and 
the asymmetric aminohydroxylation of alkenes are the three most prominent catalytic 
oxidations and their efficiency has been fully demonstrated in iminosugar synthesis. 70  An 
elegant example of the successful application of the methodology is shown in Scheme 30, the 
synthesis of 1-deoxygulonojorimycin 125 from furfural and is analogous to the methodology 
in which furfural was successfully converted to D- and L-carbohydrates. 70 88  Vinyl furan 118 
was prepared by the addition of furfural 117 to an ethereal solution of TMSMgCl followed by 
acidic treatment of the resulting alcohol.  Enantiomerically enriched N-CBz-protected amino 
alcohols 119 and 120 were obtained by applying the Sharpless asymmetric aminohydroxylation 
chemistry to vinyl furan using an ether solution of vinyl furan with the sodium salt of N-
chlorobenzylcarbamate and an OsO4/(DHQ)2PHAL admixture.   
The regioisomers 119 and 120 were separated by chromatography and the primary alcohol 
group of 119 was protected as its silyl ether.  Next, an aza-Achmatowicz rearrangement with 
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m-CPBA led to the formation of the hemiaminal 122 which was treated with ethyl orthoformate 
to give the corresponding ethylaminal.  The allylic alcohol 123 was obtained by reduction and 
diastereoselective catalytic OsO4 dihydroxylation of 123 gave 124.  Deoxygulonojirimycin 125 
was produced by hydrogenolysis which was purified by isolation as the p-toluene sulphonate 
salt. 
 
Scheme 30: An example of an asymmetric methodology.  Synthesis of 1-deoxynojirimycin 
from furfural.   
122 
 
It is worthy of note that of all the examples quoted thus far, 125 is one of a few reported 
compounds containing the hemiaminal function within the pyranose ring.  This functionality is 
a requisite of the target compounds of this project (see Figure 36, page 102) and therefore 
synthetic examples of compounds which include a hemiaminal are of particular interest.  
Iminosugars that contain the hemi aminal chemotype have been shown to have an intrinsic 
instability75 and need almost to be trapped, as with the CBz protected nitrogen atom and the 
ethereal oxygen in this example, prior to the iminosugar’s isolation as a p-toluene sulphonate 
salt.  This would form a key consideration when determining the synthetic viability of the target 
compounds.  
      
3.2.2.4. Chemoenzymatic approaches 
Several groups have employed chemical or enzymatic resolution as a key aspect in the 
synthesis of iminosugars.  Banwell et al 89 successfully employed microbial oxidation of 
chlorobenzene to provide a versatile and readily elaborated starting material for the syntheses 
of several iminosugars.  Scheme 31 shows the synthesis of 1-deoxymannojirimycin (DMJ) 
from 126 which is derived from chlorobenzene.   
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Scheme 31: An example of the inclusion of a chemoenzymatic step.  Synthesis of 1-
deoxymannojirimycin from a chlorobenzene derivative.   
The readily prepared acetonide derivative of 126 was subject to epoxidation with m-CPBA and 
the resulting epoxide 127 converted to the chlorohydrin 128 upon reaction with lithium 
chloride.  An SN2 type displacement reaction with lithium azide followed to give 129 which 
was O-benzylated to give 130.  Ozonolytic cleavage of this compound followed by a sodium 
borohydride reductive work up and subsequent protection of the ensuing primary alcohol using 
TBSCl afforded the azido-ether 131.  Two-fold hydrogenolysis of 131 resulted in the formation 
of lactam 132 which was converted to the corresponding piperidine with a borane sulphide 
124 
 
complex.  The resulting borane-amine complex was cleaved with methanol and palladium on 
carbon.  The desired compound DMJ 134 was obtained as the TFA salt. 
Another example of where chemoenzymatic methods play a key role in the preparation of an 
iminosugar is shown in Scheme 32.90  In this instance a homoisofagomine type iminosugars 
137 and 138 were prepared without relying on the chiral pool with the key stereoselective 
carbon-carbon bond forming step being catalysed by aldolase.  The acetal of the starting 
material 135 is cleaved under mild acidic conditions.  Dihydroxyacetonephosphate (DHAP) 
was added followed by rabbit muscle aldolase (RAMA) to catalyse the formation of the carbon-
carbon bond.  The resulting phosphate was hydrolysed using acid phosphatase.  The N-formyl 
group was removed by treatment with hydrochloric acid and subsequent catalytic 
hydrogenation of the crude imine gave a mixture of 137 and its epimer 138 which were 
separated by column chromatography.    
 
Scheme 32: Example of the use chemoenzymatic methodology.  Synthesis of a 
homoisofagomine type iminosugar   
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3.2.2.5. Miscellaneous starting materials 
An aza-Diels Alder type reaction was used by Schurer91 as a key step to providing 
polysubstituted piperidines from non-carbohydrate starting precursors.  A versatile and very 
mild methodology was demonstrated in which various 1,3-disubstitued butadienes, for example 
139, were reacted with an electron deficient dienophile, in this instance, N-trichloro-
ethylidene-p-toluenesulfonamide, to form compounds similar to 140 which can be regarded as 
potential precursors of iminosugar derivatives (Scheme 33). 
 
 
Scheme 33: Example of aza-Diels-Alder reaction used to construct piperidine ring.  Synthesis 
of a polysubstituted piperidine as an iminosugar precursor.  
The potential of iminosugars as therapeutic agents has led to the development of many new 
methodologies for the synthesis of both known and novel iminosugars.  Since 2005, 
methodologies for piperidine type iminosugar synethesis have extended well precedented 
procedures such as reductive amination and metathesis and have led to the development of 
strategies that include de novo methods and the use of bioorgano-catalysis.69  The range of 
starting materials and precursors for iminosugar syntheses have also expanded to fully exploit 
not only the wide range of available carbohydrates but to incorporate the use of other chirons 
and compounds beyond the chiral pool.  Future studies in the field of iminosugars are likely to 
focus upon developing syntheses that are more efficient, enable the introduction of increased 
structural diversity and deliver higher stereocontrol. 
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3.3. Iminosugar analogues of topiramate 
The ultimate synthetic targets of the project were novel iminosugar analogues of topiramate 
(25–29) (see page 101).  The compounds were identified as “hits” by the in silico modelling 
work as results demonstrated that they were promising candidates as interactions with active 
sites demonstrated the potential for selectivity and binding within the target enzymes. 
Iminosugar 25 and its derivatives are novel compounds; thus their attempted synthesis was 
supported.  A review of the literature identified that iminosugars that are structurally similar to 
the monosaccharide D-fructose in its pyranose form both from natural sources and produced 
synthetically are extremely rare.  Therefore, it was anticipated that the synthesis of iminosugars 
containing the D-fructose scaffold would not be facile.  Consideration of the various 
methodologies and chemistries that have been employed to synthesise iminosugars from a 
range of starting materials suggested that the preparation of iminosugar analogues of 
topiramate would pose several synthetic challenges.  A key issue was how to form the 
piperidine ring whilst retaining and stabilising the anomeric hydroxyl group at the C2 position 
during cyclisation.  Two widely used methods to effect the cyclisation step to form an 
iminosugar, either via an SN2 displacement reaction or by reductive amination, result in the 
loss of the oxygen atom from the carbon atom that forms the new C-N bond.  This oxygen atom 
within the topiramate iminosugar analogues ultimately forms part of the 2,3-acetal group with 
the adjacent hydroxyl group at the C3 position being an important structural feature of the 
compound with respect to binding.   
 
The presence of an oxygen atom at the C2 position in the desired iminosugar results in a 
hemiaminal structure that would be predicted to result in an inherent instability within the 
molecule.  For example, nojirimycin 141 has been reported as being highly unstable and can 
only be isolated and stored as its bisulfite adduct.75  The majority of stable iminosugars that 
have been successfully synthesised, isolated and have shelf lives of sufficient length to make 
them viable compounds are either iminosugar C-glycosides, in which the oxygen atom of the 
hemiaminal function is replaced by a methylene group or “deoxy” variants of iminosugars 
(Figure 45). 71, 92  A comparison of the generic structures of each of these iminosugar variants 
is shown in Figure 45; nojirimycin 141, contains the unstable hemiaminal functionality and 
homonojirimycin 143 has a C-C bond at the C2 position to form a C-glycoside.  Contrastingly, 
1-deoxynojirmycin 142, has no adjoining atoms to the C2 carbon.  Both 143 and 142 are stable 
compounds.70 
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Figure 45: General structure of “deoxy” iminosugars 142 and C-glycoside iminosugars 143  
 
Another potential synthetic challenge was the timing of the introduction of the sulfamate group 
into the compound.  The early introduction of the sulfamate functional group would necessitate 
its stability to multi-step syntheses in which a variety of chemical conditions would be 
employed.  Conflictingly, the introduction of the sulfamate group towards the latter stages of 
any preparative route would require the sugar moiety to be able to withstand the relatively 
harsh sulfamoylation conditions.  Development of the syntheses of metabolites of topiramate 
previously undertaken had provided some evidence of the robustness of the sulfamate group to 
selected reaction conditions, for example, hydrogenolysis.  However, it has been noted that the 
O-sulfamate group is particularly labile to basic conditions and its reactivity/polarity can 
compromise its successful passage through several steps of chemical synthesis and result in 
challenging separations.93  The development of sulfamates in which N-protection was achieved 
with either 4-methoxy- or 2,4-dimethoxybenzyl groups (Figure 46) have been shown to be 
stable to many common reaction conditions.93  Such sulfamate protection strategies might offer 
synthetic opportunities should orthogonality with other protecting groups be favourable.              
 
Figure 46: Generic structure of a 2,4-dimethoxybenzyl N-protected sulfamate 
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Accounting for the evident challenges of synthesising an iminosugar based upon topiramate 
and the general lack of corresponding literature, the focus of the developmental chemistry was 
to derive a direct route and address the primary objective which was to establish proof in 
principle for the synthetic viability and stability of this class of compound.  It was hoped that 
this would facilitate the development of alternative efficient and versatile synthetic routes to 
prepare a range of iminosugars analogous of topiramate.   
As D-fructose is structurally similar to topiramate (Figure 47) and contains the same 
stereogenic centres as those desired in the iminosugar analogues, it was considered an 
appropriate starting material, being both commercially available and cheap.  However, very 
few syntheses of iminosugars utilising D-fructose as a starting material have been reported.94 
Whilst it was successfully used in the relatively facile synthesis of 1-deoxymannonojirimycin 
(DNJ) 65 (see page 104), this compound is less complex as it lacks the key hemiaminal 
functionality.95 To date there appears to be no direct precedent for the preparation of a 
piperidene type iminosugar containing the fructose configuration from either the carbohydrate 
starting material or alternatives.96  A review of more general literature on carbohydrate 
chemistry also identified that the use of D-fructose as a chiral building block is not as developed 
as other monosaccharides such as D-glucose. 97  In addition, D-fructose was regularly noted as 
being problematical to work with.  Thus, as the key starting material, it was important initially 
to gain a familiarisation in working, characterising and isolating relatively simple D-fructose 
analogues that would also develop the proposed synthetic route. 
 
Figure 47: Stereochemical relationship between D-fructose, topiramate and iminosugar 
analogues 
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3.3.1. Early synthetic stages  
With these aims in mind, the initial synthetic plan shown in Scheme 34 was devised to attempt 
to prepare an O-benzylated iminosugar 151 as a simpler model compound to assess the stability 
of the key hemiaminal subunit present in the ultimate synthetic targets.  It was intended to 
afford a relatively direct route to an iminosugar from D-fructose 144 and will provide 
confirmation of the general ease of preparation and stability of such compounds.  The synthetic 
route incorporates several reactions that are very common in iminosugar syntheses and for 
which there is much literature precedent, albeit with different carbohydrate substrates.  The 
proposed methodology also enables late stage modification of the final cyclisation steps and 
the ability to introduce structural variation at the nitrogen atom should the “naked” hemiaminal 
prove to be very labile and predominating in its open chain form.  A further advantage of the 
proposed synthetic scheme is that it does not include a single step that would be predicted to 
lead to epimerisation.   
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Scheme 34: Proposed synthetic route to O-benzyl protected iminosugar 152 
 
The first stage of Scheme 34 is a glycosidation reaction of D-fructose to obtain the methyl-D-
pyranoside 145.  The aim of the reaction was to differentiate the anomeric hydroxyl group in 
order to selectively functionalise at remaining positions within the compound in subsequent 
stages.  Glycosidation is an extremely common reaction in carbohydrate chemistry and is often 
achieved using the Fischer glysosidation methodology.  During the Fischer glycosidation, the 
formation of a glycoside is mediated by the reaction of an unprotected aldose or ketose with an 
alcohol in the presence of an acid catalyst.  The Fischer glycosidation is an equilibrium process 
and as such can lead to a mixture of ring size isomers, anomers and, in some cases, small 
amounts of acyclic forms of the carbohydrate.  The relative proportion of products obtained 
can theoretically be controlled by manipulating the duration of the reaction.  Shorter reaction 
times tend to lead to furanose ring forms and longer reaction times to the more 
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thermodynamically stable pyranose forms.  The methyl glycosidation reaction of D-fructose 
can typically result in the formation of several products, the most likely of which are methyl-
α-D-fructopyranoside 153, methyl-β-D-fructopyranoside 154, methyl-α-D-fructofuranoside 
155 and methyl-β-D-fructofuranoside 156.     
 
 
 
Figure 48: Structures of potential products of methyl glycosidation reaction of D-fructose 
 
A standard Fischer glycosidation procedure was attempted with D-fructose following a 
literature procedure successfully employed in the formation of L-sorbose methyl glycosides in 
which hydrochloric acid is generated in situ from acetyl chloride in methanol.98  The progress 
of the reaction was found to be extremely slow under the ambient conditions used to prepare 
the methyl glycosides of L-sorbose and vigorous heating was required to induce the reaction.  
The work up of the reaction also proved challenging with the removal of inorganic salts from 
the quenched reaction mixture proving surprisingly difficult.  A further review of the literature 
indicated that a Fischer glycosidation of D-fructose was commonly found to produce 
unsatisfactory results when attempting to prepare methyl fructosides.  Two alternative 
glycosidation procedures were considered.  Ramstadius et al 99 reported a method of preparing 
ethyl glycosides of D-fructose with a Fischer type glycosidation using bromoethanol (Scheme 
35).  An advantage of the reaction was that the crystalline bromide derivative of the α- and β-
ethyl pyranosides precipitated from the reaction mixture making isolation straightforward.  
However, the bromide intermediates must be reduced prior to any subsequent chemistry which 
adds a further stage of chemistry to the overall synthetic scheme which is less favourable. 
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Scheme 35: Preparation of ethyl fructoglycoside with bromoethanol99 
 
Ultimately, the glycosidation reaction to obtain 145 was carried out in refluxing methanol in 
the presence of ammonium chloride and was adapted from a literature procedure.100    Reaction 
progression was found to be relatively swift and was monitored by TLC.  The formation of two 
distinct compounds was visible by TLC and reaction completion was indicated by TLC 
following 16 hours at reflux temperature.  Although at least four products of the reaction were 
anticipated only two spots were visible by TLC.  However, TLC investigations did not identify 
a solvent system that would successfully elucidate the two spots further suggesting that two or 
more of the products from the reaction co-eluted.  The separation of the products from the 
reaction proved to be challenging.  An extractive separation of the products of the reaction 
using boiling acetone was initially attempted as this had proven successful for the isolation of 
the α- and β methyl glycosides of L-sorbose.98  However, despite exhaustive attempts, it was 
not a viable methodology to separate the products of the methyl glycosidation reaction of D-
fructose.  Separation was attempted by column chromatography on silica. Further TLC 
investigations identified a suitable three component solvent system that adequately separated 
the two spots visible by TLC.  Using 25 equivalents of silica was found to be satisfactory.  It 
was necessary to adsorb the crude reaction mixture onto silica and dry load it onto the column 
due to the relative insolubility of the crude products in the chosen eluent.  Chromatography 
proved challenging and resulted in only partial separation of the crude reaction mixture.   The 
more hydrophobic of the two compounds that appeared as the top spot by TLC was readily 
separable although it was necessary to recolumn the material obtained from several mixed 
fractions to maximise yields.  Analysis of the product by 1H NMR confirmed that it was a 
single compound, not a mixture, and that it had been isolated cleanly.  The product was 
obtained as a yellow oil in a 38% yield.  The correct mass of 195 (MH+) for an isomer of methyl 
fructoside was confirmed by mass spectrometry.  Comparison of 1H and 13C NMR spectra of 
this compound with the limited published data available suggested that it was one of the 
133 
 
undesired five membered methyl fructofuranosides.98, 100, 101  Further support that this 
compound was a fructofuranoside was provided by analysis of the splitting patterns of the four 
hydroxyl groups in the 1H NMR spectrum in DMSO-d6 which is shown in Figure 49.  The 
hydroxyl groups were initially identified by D2O shake.   Two hydroxyl groups were clear 
doublets at ca. 5ppm and the other two hydroxyls were represented as observed triplets.  
Examination of the structure of fructofuranosides 155 and 156 shows that both molecules 
contain two primary alcohol groups and two secondary alcohol groups which would conform 
to the observed splitting patterns in the 1H NMR spectrum.  In contrast, the two 
fructopyranosides 153 and 154 each contain only one primary hydroxyl group and would thus 
result in a different 1H NMR splitting pattern.  The lower spot on the TLC was also isolated 
and was shown to contain a mixture of products by NMR.  It was anticipated that three 
compounds were present, the anomer of the methyl fructofuranoside successfully isolated and 
two methyl fructopyranosides. 
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Figure 49: 1H NMR spectrum of the product isolated from the methyl glycosidation reaction of D-fructose 
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The next step in the reaction sequence to prepare 146 was fast tracked with the mixture of 
products obtained from the successful first stage reaction to trial whether further separation of 
the anomers would be possible at this stage.  The data collected from the O-benzyl protection 
reaction was positive but a greater amount of material was required.  Therefore, the 
glycosidation reaction was scaled up significantly to allow development and characterisation 
and to yield enough material to fully investigate the downstream chemistry.  The reaction was 
successfully scaled up to process one kilogram of D-fructose.  Column chromatography was 
made feasible on this larger scale by investigating the effect of reducing the amount of silica 
used for chromatography.  It was found that reducing the equivalents of silica used to 10 times 
that of the mass of the crude products resulted in the successful separation of the faster running 
methyl furanoside in a yield comparable to that obtained on the small scale.      
A number of small scale reaction trials were carried out to determine whether the ratio of 
products could be influenced by increasing the reaction duration.  It was hoped that leaving the 
reaction for longer than 16 hours would favour the formation of the more thermodynamically 
stable and desired fructopyranosides.  Reactions were allowed to proceed for 24, 36, 48 and 72 
hours and were monitored by TLC.  There was no discernible differences in the reaction 
profiles by TLC.  Each reaction was worked up and the crude mixture of compounds subjected 
to column chromatography.  In each case, a methyl fructofuranoside was cleanly isolated in a 
similar yield to that obtained in the initial 16 hour reaction.  It was not possible to resolve the 
other three isomers readily so it was difficult to assess whether there was any improvement to 
the ratio of fructopyranosides present in the mixture.   
  
On the basis that the three other isomers could not be separated, the subsequent stage of 
chemistry, an O-benzylation reaction, was initially trialled on the crude mixture of products to 
determine the outcomes and assess if further efforts in purifying the crude materials was 
required at this stage or more successful on the O-benzyl protected materials. 
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Scheme 36: O-Benzylation of methyl pyranosides 
 
O-benzyl protection of the remaining four hydroxyl groups in each of the compounds present 
within the mixture of anomeric pyranosides and remaining furanoside was readily achieved by 
adding sodium hydride to a solution of benzyl bromide and the three substrates in DMF.  The 
transformation is widely used in carbohydrate chemistry and the methodology adopted is 
reported numerously.  A modification to the order of addition of reagents was made when 
carrying out the reaction on a larger scale to prevent significant exotherming and foaming of 
the reaction.  It was found that controlling the rate of addition of benzyl bromide to a cooled 
solution of the substrates and sodium hydride in DMF gave a more controllable reaction profile 
on a larger scale.  Benzyl ethers were chosen as a suitable protecting group following 
consideration of the planned stages of chemistry shown in Scheme 34.  Benzyl ethers are 
relatively stable to a range of reaction conditions and show good orthogonality to several other 
typical hydroxyl protecting groups.  Their inclusion here was useful; they were compatible 
with the proposed chemistry and there was precedent of their use in related synthetic schemes. 
71 69 
As anticipated, three products were obtained from the reaction.  The major product, which was 
obtained in a 60% yield, was easily separated by column chromatography.  Data from mass 
spectrometry confirmed that it was an isomer of the desired product with the compound giving 
the anticipated mass.  The isomeric identity of the material was determined in various ways.  
An initial review of the 1H NMR spectrum of the material contained certain distinct signals 
which were indicative of a methyl fructofuranoside.  Within the 1H NMR spectrum two 
distinctive sets of diastereotopic protons were visible which supported the view that the second 
furanose anomer had been isolated.  To support the identification further a readily identifiable 
marker within the 1H NMR spectrum was required.  The splitting patterns of the hydroxyl 
groups present within the methyl fructofuranoside isolated in the stage 1 reaction proved very 
useful to the identification process.  However, in this compound, all of the hydroxyl groups 
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were protected with benzyl ethers.  It was considered pertinent to remove the benzyl ethers to 
expose the hydroxyl groups and undertake a further NMR assessment.  A catalytic atmospheric 
hydrogenation was thus carried out to afford the unprotected methyl fructoglycoside.  Analysis 
of the resulting product by 1H NMR in DMSO-d6 revealed four hydroxyl groups, two of which 
were doublets and two of which were represented by an observed doublet of doublets.  This 
would be indicative of the compound containing two primary and two secondary alcohol 
groups which fitted for the anticipated structure of the fructofuranoside.  This provided further 
support of the compound’s identity.  One additional investigation was undertaken in which a 
small amount of the discarded methyl fructofuranoside from the stage 1 reaction was O-
benzylated employing the same reaction conditions.  The NMR of the resulting product 
contained the same distinctive proton shifts considered indicative of a furan based compound.  
It was now felt appropriate to confirm the identity of the isolated compound as the second 
undesired methyl fructofuranoside.                 
The other two compounds were therefore assumed to be the desired O-benzyl protected  and 
 fructopyranosides.  The two desired fructopyranoside products were obtained in a combined 
yield of 24%.  As the separation of the two anomers was very challenging and ultimately not 
necessary to the subsequent chemistry, no additional efforts were made in this regard and the 
mixture of products was retained and processed through to the next stage within the synthetic 
scheme.   
 
 
 
Scheme 37: Acid mediated hydrolysis 
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The acid mediated hydrolysis reaction to obtain 147 was relatively straightforward.  The two 
methyl pyranosides were dissolved in acetic acid and 1M aqueous sulfuric acid was added.  
The reaction was heated to 50°C and swift reaction completion was indicated by HPLC and 
TLC in 1.5 hours.  LCMS and 1H NMR analysis confirmed the presence of two compounds in 
an approximate 13:1 ratio with a combined yield of 83%.  LCMS confirmed the desired 
products had been obtained with both peaks in the chromatogram showing the correct mass in 
the corresponding mass spectrum. Following neutralisation and reaction work up the crude 
material was purified by a silica pad to remove residual impurities.  Attempts to separate the 
two anomers proved unsuccessful here due to the very challenging nature of the separation.  
However, as with previous steps, it was deemed unnecessary to fully separate the two anomers 
at this stage and the mixture of products was carried forward to the next stage with the aim of 
fast tracking to the key acyclic compounds 148.   
 
 
Scheme 38: Ring opening reduction 
 
A standard methodology to achieve the reduction of carbohydrates into the corresponding 
alditols is to reduce the aldehyde or ketone present within the open chain form of the sugar 
with a hydride reagent.  Although the open chain form of the ketone is usually present in very 
low concentration, reactions involving the ketone take place very rapidly.  Sodium borohydride 
is often used to effect the reduction as would be the case for any other ketone or aldehyde.  The 
ring opening reduction of 147 was achieved with sodium borohydride in THF and water and 
the reaction was observed to proceed rapidly at ambient temperature.  An epimeric mixture of 
products was expected and the reaction resulted in the formation of the two corresponding 
alditols, 1,3,4,5-tetra-O-benzyl-D-glucitol 157 and 1,3,4,5-tetra-O-benzyl-D-mannitol 158.  
The two epimers were produced in a roughly 5:1 ratio by 1H NMR.   
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Figure 50: Structures of alditol products from ring opening reduction reaction 
 
The 1H NMR of the mixture of products in deuterated chloroform clearly shows the presence 
of two hydroxyl groups with different coupling patterns confirming that there was a primary 
and secondary hydroxyl group was present in both of the reduced sugars.  This was the expected 
outcome as examination of the structures of 159 and 160 confirms.  The two products were 
again not easily separable by chromatography but it was again not deemed necessary to 
separate the products here.   
 
 
 
Scheme 39: Activation of primary alcohol group with p-toluenesulfonyl chloride 
 
The next stage in the preparative route was to activate the primary alcohol to a good leaving 
group in anticipation of the subsequent nucleophilic displacement step.  This was successfully 
achieved using p-toluenesulfonyl chloride to give tosylate 149 in accordance with Scheme 39.  
By controlling the reaction conditions with respect to temperature and duration, selective 
tosylation of the primary alcohol was possible.  The reaction was conducted at room 
temperature over a 24 hour period in the presence of a 10% mole loading of catalytic DMAP.   
The successful preparation of the mono tosylated product was confirmed by 1H NMR and 
LCMS.  As anticipated, two epimeric products were obtained.  Both products were visible by 
1H NMR and LCMS in roughly a 5:1 ratio.  In the 1H NMR spectrum, only one hydroxyl group 
was present in each compound along with corresponding aromatic signals that indicated the 
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presence of only one tosyl group.  The achievement of the correct chemoselectivity of the tosyl 
group was confirmed by the splitting pattern of the single hydroxyl group signal which was a 
doublet suggesting coupling to only one other proton, as would be the case for the remaining 
secondary alcohol.  There was also a marked chemical shift of the diastereotopic protons 
adjacent to the tosylate group with no evidence of OH coupling.  A yield of 85% was achieved 
for the epimeric mixture.    A small amount of a bis-tosylated alditol was obtained as a by-
product of the reaction.  Isolation and purification of this product, although undesired, enabled 
NMR and LCMS data to be obtained.  The 1H NMR spectrum of the material contained no 
signals that related to hydroxyl groups and the correct number of aromatic protons for the bis-
tosylated product were observed.  LCMS showed the correct mass for the bis-tosylated product.  
The positive identification of the bis-tosylated product was useful in that it provided further 
support to the identity of the input and output materials of the reaction.  The separation of the 
two epimers of 149 was not required and the epimeric mixture was progressed to the next 
synthetic step.  
 
The formation of the corresponding mesylate was also attempted using similar reaction 
conditions as those employed for the tosylation reaction.  It proved more difficult to 
successfully achieve the desired mono mesylation at the primary alcohol position only when 
using methane sulfonyl chloride.  Thus, tosylate 149 was selected as the preferred compound 
for onward processing. 
  
To further confirm that the correct pyranose isomers of fructose had been isolated, additional 
chemistry was performed on the two furanose isomers isolated during the earlier stages of the 
synthetic scheme in accordance with Scheme 40.  At each stage TLC and 1H NMR data for the 
products was compared to that of the products obtained for the same reactions with the 
pyranose isomers.  In all cases, differences in the data confirmed that the products of the 
reactions were not equivalent.  The key results were generated from the ring opening reduction 
and the subsequent tosylation reactions.  On ring opening, the furanose and pyranose isomers 
form differently constituted alditols.  For the pyranoses, the two epimeric alditols contain one 
secondary alcohol attached to the carbon at the C2 position and one primary alcohol at the C6 
position as in alditols 159 and 160.  For the furanoses, the resulting alditols contain two 
secondary alcohols in the C2 and C5 positions as in alditol 165.  The differences in the two 
alcohol groups in alditols 159 and 160 enabled this chemoselectivity to be exploited in the 
subsequent tosylation step.  It was shown that under certain conditions, the primary hydroxyl 
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group would selectively react with p-toluene sulfonyl chloride whilst the secondary hydroxyl 
group did not undergo any reaction.  Employing similar conditions for the tosylation reaction 
of alditol 165 resulted in bis-tosylation which could not be avoided.  This does suggest that 
both of the hydroxyl groups where chemically similar and selectivity was therefore not possible 
and alditol 166 was obtained.      
 
 
 
 
Scheme 40: Earlier stages of synthetic scheme with furanose isomers 
 
  
 
 
Scheme 41: Nucleophilic displacement of tosyl group with an azide group 
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The successful formation of tosylate 149 generated the opportunity for the introduction of a 
precursor to an amino group into the carbohydrate by converting the activated hydroxyl group 
via a nucleophilic displacement reaction. This was considered a critical stage in the overall 
synthetic scheme.  Several nitrogen containing nucleophiles were considered and the azide 
group was selected based upon the propensity of its use reported in reviewed literature.   
Initially the reaction to displace the tosyl group with an azide group to prepare 150 produced 
disappointing results.  The use of one equivalent of sodium azide at room temperature in DMF 
as solvent resulted in very slow reaction progression.  To ascertain whether altering key 
reaction parameters would improve reaction outcomes several small scale trial reactions were 
run in parallel.  The effect of the number of equivalents of sodium azide and temperature were 
initially considered.  The results, as shown in Table 7, indicated that both temperature and the 
stoichiometric amount of sodium azide present in the reaction affected both the time taken for 
the reaction to go to completion and the product yield.  As expected, the rate of reaction 
increased with increased temperature.  However, the reactions carried out at 100°C showed 
lower yields than the reactions conducted at lower temperatures.  This suggested that higher 
temperatures resulted in the degradation of products and/or starting materials which limited the 
yield.  The amount of sodium azide used was found to have little effect at 100°C but a greater 
stoichiometric amount at 50°C gave a shorter reaction time. The most favourable conditions 
with respect to reaction duration and product yield were considered to be the addition of two 
stoichiometric equivalents of sodium azide at 50°C.  The reaction was scaled up using these 
conditions generating positive results. 
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Number of 
equivalents of 
NaN3 
Solvent Reaction 
Temperature 
Time taken for 
full 
consumption of 
starting 
material 
Product Yield 
1 DMF 20°C Starting 
material 
remaining 
after 96 
hours 
- 
1.5 DMF 50°C 32 hours 53% 
2 DMF 50°C 21 hours 55% 
1.5 DMF 100°C 16 hours 43% 
2 DMF 100°C 16 hours 41% 
 
Table 7: Results of trial nucleophilic displacement reactions  
It was anticipated that the products of the reaction would be two epimeric alcohols.  However, 
in-reaction monitoring by HPLC indicated the presence of three products of the reaction.  
Following reaction work up, it was possible to cleanly isolate one of the products by column 
chromatography which provided sufficient material to undertake analysis.  1H NMR and LCMS 
confirmed that the compound was not one of the desired alditols which suggested that it was 
an unwanted by-product of the reaction.  It was postulated that the contaminant arises from the 
intramolecular displacement of the tosylate or azido by the alcohol forming a cyclic 
tetrahydropyran-like product.  A proposed structure is shown in Figure 51.  This structure 
would correspond with the mass spectrometry data obtained for the identified   The 1H NMR 
spectrum of the by-product has no visible hydroxyl group which does provide a further 
indication that it may be a cyclic species.   
 
 
Figure 51: Proposed structure of the by-product of the nucleophilic displacement reaction 
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The two other products of the reaction were not adequately separable by column 
chromatography and were isolated as a mixture in a 12:1 ratio.  A 58% yield overall was 
achieved.    Analysis of these two compounds by 1H NMR and LCMS provided data to support 
that they were the two desired epimeric azido alcohols.  Only one hydroxyl group per 
compound was visible in the 1H NMR spectrum and no aromatic signals were present 
indicating the removal of the tosyl group.  LCMS confirmed the correct mass for each product.  
As the azide group has a characteristic and strong absorption by FTIR, the material was also 
analysed by FTIR.  The spectrum is shown in Figure 53 and the characteristic peak at a 
frequency of 2100cm-1 is indicative of a typical azide stretching absorption.  A mixture of the 
two products was progressed to the next stage of chemistry. 
 
 
 
Figure 52: FTIR spectrum of azido alcohol 150             
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Scheme 42: Oxidation reaction of azido alcohol 150 
 
Oxidation of azido alcohol 150 to the azido ketone 151 was readily achieved using Dess-Martin 
periodinane in dichloromethane.  Dess-Martin reagent was selected as an oxidant as there was 
literature precedent for its successful use in oxidising primary alcohols.76  The oxidation 
reaction with Dess-Martin periodinane proved successful. Reaction completion was incredibly 
swift with full consumption of the starting material observed after 30 minutes at room 
temperature.  Only one product was visible by TLC as was expected as any stereochemistry at 
the C2 position would be lost post oxidation of the hydroxyl group.  The single compound was 
readily purified by column chromatography.  The compound was positively identified using a 
range of methods in addition to 1H NMR.  LCMS contained a single peak in the chromatogram 
that gave the correct mass in the corresponding mass spectrum.  Analysis of the product by 13C 
NMR clearly indicated the presence of a carbon atom constituent of a carbonyl group at 
208ppm.  The FTIR spectrum of azido ketone 151, contained a distinctive carbonyl bond 
stretching absorption at a frequency of 1730cm-1 along with the retention of the peak at 
2010cm-1 that confirmed retention of the azido group.  Azido ketone 151 was obtained in a 
65% yield. 
 
As the oxidation reaction with Dess-Martin periodinane had had such successful outcomes, it 
was deemed unnecessary to further develop this reaction using alternative oxidants at this stage. 
 
As an interesting aside, a small scale oxidation reaction of by-product 167 from the 
nucleophilic displacement reaction with sodium azide was trialled.  The same reaction 
conditions were applied to those described above.  The compound did not undergo any reaction 
at all which reinforced the view that there was no hydroxyl group present in the compound 
further supporting that the compound was a cyclic species.   
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3.3.2. Key cyclisation step 
 
 
Scheme 43: Reduction of the azide group 
 
The reduction of the azide group to the corresponding primary amine group is a key step in the 
synthesis of iminosugars.  There is much literature precedent to suggest that the reduction of 
the azide group, when in the presence of an electrophilic carbonyl group in a suitable position, 
will result in concomitant reductive amino cyclisation.102 103  A variety of methods of reducing 
the azide group have been reported including hydrogenation and the Staudinger reaction.104, 105    
A Staudinger reaction with triphenylphosphine was attempted to see if the efficient cyclisation 
of the azido ketone 151 could be induced, leading to the desired cyclic iminosugar 152.  Despite 
adjusting reaction conditions and attempting the reaction using polystyrene-supported 
triphenylphosphine, the outcome was either that reaction progression was minimal, in which 
case unreacted starting material was recovered, or where the reaction did proceed, degradation 
appeared to occur and no discrete product could be isolated from the reaction.  It was assumed 
that although the azide was being successfully reduced, the resulting primary amine and 
subsequent intramolecular reaction with the ketone led to a product that was unstable and which 
undergoes decomposition readily. 
 
The results of this initial Staudinger reaction suggested that the key cyclisation step to give 
iminosugar 152 may not be as facile as had been hoped.  Several different approaches to attempt 
to successfully induce cyclisation formed the next critical path in the chemistry development 
work.    
 
• Stabilising the amine  
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The results of the previous Staudinger reaction suggested that improving the stability of both 
the primary amine and the desired cyclic product required consideration.  A reasonable option 
was thought to be the immediate protection of the primary amine with a BOC group.  It was 
hoped that the BOC group might increase amine stability, facilitate a more controlled 
intramolecular cyclisation, reduce product degradation and allow for the improved purification 
of the product.  Literature examples demonstrated that the presence of a BOC group does not 
prevent the reductive amino cyclisation 105,70 and there were literature procedures for one-pot 
Staudinger reduction and subsequent BOC protection reactions. 106, 107  One-pot reactions were 
attempted with azido ketone 151 in which the azide was reduced using Staudinger conditions 
in the presence of di-tert-butyl dicarbonate.  It was hoped that as the resulting amine formed, 
it would be “captured” as the BOC-amine conferring additional stability.  Disappointingly, 
despite trialing a series of alternative reaction conditions and introducing BOC-ON ([2-(tert-
butoxycarbonyloxymino)-2-phenylacetonitrile]), a successful outcome with isolation of the 
desired product was not achieved.  
The lack of success in completing the final stage of the planned synthetic route shown in 
Scheme 34 necessitated the development of an alternative synthetic strategy. Scheme 44 was 
proposed.  In this case, azide reduction and the subsequent BOC protection of the resulting 
amine occur prior to the oxidation step to generate the corresponding electrophilic site in the 
molecule at the C2 position.   
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Scheme 44: Alternative latter stages of synthetic route to O-benzyl protected iminosugar 
 
 
A similar sequence of reactions to that shown in Scheme 44 has been reported although it was 
employed on a D-arabinose derived BOC protected amino alcohol 171 (Scheme 45).108   
Promisingly, the final oxidation step was reported as having resulted in spontaneous oxidative 
cyclisation to the desired iminosugar 172.  
 
 
Scheme 45: Final oxidation step in the preparation of a D-arabinose iminosugar precursor 
 
The reduction of the azide group using lithium aluminium hydride was successful in reducing 
the azide group of 150 to furnish the primary amine giving amino alcohol 168.   A 70% yield 
was achieved and satisfactory analysis of the product was obtained to confirm the isolation of 
the correct product.  The subsequent BOC protection of the primary amine was also a facile 
and swift reaction.  1H NMR, 13C NMR and LCMS were used to positively identify the BOC-
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protected amino alcohol 169.  The subsequent oxidation of the alcohol group with Dess-Martin 
periodinane required an elevated reaction temperature and longer reaction duration than used 
in the analogous reaction shown in Scheme 42.  The reaction was carried out at 45°C rather 
than at room temperature and needed approximately 16 hours to achieve completion.  This may 
be as a consequence of the BOC group introducing additional steric hindrance into the molecule 
making the secondary alcohol group less accessible to the oxidant.  It was hoped that the 
oxidation reaction would result in the formation of the cyclic iminosugar 170 as indicated for 
the analogue in the literature. 108   Initial analysis of the product of the oxidation reaction by 
LCMS confirmed the correct mass for the desired product. However, 1H NMR data proved 
more ambiguous.  It was unclear from the data collected whether the desired cyclic compound 
170 had been successfully prepared or if the compound had remained in its acyclic form 169.   
 
 
 
 
Figure 53: Possible acyclic product of oxidation reaction of 169  
 
Additional analysis of the iminosugar suggested that it was the acyclic form 173. The FTIR 
spectrum of the product showed two absorption bands within the carbonyl region; the first peak 
at 1708cm-1 corresponded to that present in the FTIR spectrum of BOC protected amino alcohol 
169 indicative of the carbonyl bond within the BOC protecting group.  The second absorption 
peak was at a frequency of 1735cm-1 and suggested that a second carbonyl bond was present 
within the compound.  This would confirm the ketone functionality in 173.  Also, the FTIR 
spectrum showed a peak at 3436cm-1 which is within the normal frequency range for an N-H 
bond which would also be present within 173 but not in cyclic 170.  In order to provide further 
structural evidence, a range of NMR experiments were carried out. 1H NMR spectra were 
obtained in different deuterated solvents and assignment of protons was aided by 2D COSY 
experiments.  The presence of an “amino” proton represented as a triplet in the spectra was 
noted.  Its presence would concur with the acyclic compound 173.   In addition, three protons 
attached to the core sugar framework appeared further downfield in the spectrum than the 
chemical shifts of the corresponding protons in the starting material.  This could be explained 
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by the presence of a ketone at the C2 position in the iminosugar chain.  13C NMR spectra of 
the material confirmed the correct number of carbon atoms, the assignment of which was aided 
by a DEPT135 experiment.  Peaks at 156ppm and 209ppm suggest the presence of two 
carbonyl carbon atoms within the molecule.  The peak at 156ppm corresponds with the 
expected resonance of the relevant carbon atom in the BOC group.  All of the analytical data 
collected for the product of the oxidation reaction pointed to the compound being acyclic 173 
rather than cyclic 170. 
 
• Attempting to induce cyclisation 
As the acyclic product 173 was suspected, efforts were focused on how to induce 
intramolecular cyclisation of 173 to reform the ring structure and the following investigations 
were undertaken: 
• The oxidation reaction of amino alcohol 169 was repeated at both very high and very 
low concentrations to establish if reaction volume was critical to cyclisation.  There 
were no observable differences in reaction progression or products at either extreme of 
concentration.  
• Various NMR scale experiments were undertaken in a variety of deuterated solvents to 
establish if solvent effects altered the cyclisation equilibrium.  Each sample was 
subjected to variable temperatures and the resulting spectra compared to the data 
initially obtained.  No changes were observed in any of the solvents used.   
• Each sample had 5% v/v acetic acid added to assess if pH was a factor in inducing 
cyclisation.  1H NMR data was obtained for each sample immediately following 
addition of acetic acid and after 12, 24 and 48 hours of standing at room temperature.  
The samples were then subjected to gentle heating.  Again, no changes to NMR spectra 
were observed.   
• The compound was treated with a Lewis acid (zinc chloride/aluminium chloride) in 
order to attempt to activate the ketone and induce cyclisation.  This also proved 
unsuccessful.   
The removal of the BOC protecting group with aqueous hydrochloric acid to afford the primary 
amine occurred readily in the presence of the ketone.   However, isolation of a stable product 
either as the free amine or as a hydrochloride salt was not achieved.  This was not unexpected 
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as a stable product could not be isolated from the Staudinger reduction of amino ketone 151 
which was an attempt to achieve the same outcome but with a different method of activating 
of the amino group. 
Reasons why the iminosugar 173 may prefer an acyclic configuration rather than reforming the 
six-membered ring and generating a cyclic form were considered in order to establish what 
modifications could be introduced into the molecule to promote cyclisation.  This generated 
three key ideas, (i) functionalising the amine to alter its nucleophilicity, (ii) removing and/or 
changing the bulky O-benzyl protecting groups, and (iii) modification of the electrophilicity of 
the ketone that results from the oxidation of the secondary alcohol group by introducing 
alternative functionality at the C2 position.  
 
 
• Altering the nucleophilicity of the amine 
By modulating the nucleophilicity of the amine, it was hypothesised that the likelihood of 
forming a cyclic iminosugar could be increased.  It has been demonstrated that a primary amine 
attached to the carbon atom at the C6 position does not lead to a stable product whereas a BOC 
protected amine appears to reduce the nucleophilicity of the amine sufficiently to prevent 
cyclisation.  The objective was thus to add different electron-withdrawing and electron-
donating groups with varying steric demand to the nitrogen atom.  The effect of these groups 
on the outcome of the subsequent oxidation reaction would then be assessed.  It was hoped that 
the results of these model reactions would provide valuable information to support ongoing 
synthetic chemistry towards the ultimate target compounds 25 - 29.  Starting with amino 
alcohols 168 and 169, three main routes to achieving functionalisation of the amine were 
proposed as shown in Scheme 46. 
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Scheme 46: Proposed generic routes to N-functionalisation of amino alcohols 168 and 169 
N-alkylation by reductive alkylation and direct N-alkylation with an alkyl halide were 
considered reasonable methods of introducing an electron-donating group to the amine of 168.  
Several small scale reductive alkylation reactions were attempted using a variety of aldehydes, 
reducing agents (sodium triacetoxyborohydride/sodium cyanoborohydride/sodium 
borohydride), reaction conditions (pH/temperature/use of dessicants) and addition protocols 
(all-in reaction/prior imine formation) in order to derive a set of optimised reaction parameters.  
Supporting 1H NMR experiments were carried out to improve reaction monitoring and to try 
and understand the kinetics of each reaction in respect of imine and product formation.  Small 
scale reactions showed that compounds 174 and 175, Schemes 47 and 48, could be successfully 
synthesised by reductive alkylation with propionaldehyde and hexanal respectively.  However, 
only very small amounts of each compound were isolated.    
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Scheme 47: Preparation of amino alcohol 174 
 
 
Scheme 48: Preparation of amino alcohol 175 
 
Attempts to scale the reactions up using identical conditions proved frustratingly unsuccessful.  
Slow reaction progression and complicated reaction profiles were obtained in both cases and 
the results achieved on the small scale could not be repeated.  It was postulated that the 
secondary alcohol group attached to the carbon at the C2 position interfered with the imine 
intermediate leading to a capricious reaction.  A solution to this would be to orthogonally 
protect the secondary alcohol group prior to carrying out the reductive alkylation reaction.  As 
protection of the alcohol group was required for both N-alklylation and acetylation reactions 
several protecting groups were considered to ensure flexibility.    
It is possible to protect the hydroxyl group in amino alcohol 169 with a variety of protecting 
groups.  An O-benzoyl group and a triethyl silyl group were successfully installed in 
accordance with Schemes 49 and 50 respectively.   
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Scheme 49: O-benzoyl protection of amino alcohol 169 
 
 
Scheme 50: O-triethyl silyl protection of amino alcohol 169 
 
A limited number of small scale direct N-alkylation reactions were undertaken on both 
substrates 176 and 177 using various alkyl halides.    Some success with the reaction of 176 
with  methyl iodide (Scheme 51) was achieved with positive identification of 178 by 1H NMR 
and LCMS.  However, only a very small amount was isolated and the reactions require further 
optimisation in order to enable the isolation of sufficient material to carry out the sequence of 
reactions proposed in Scheme 46.  Unfortunately the opportunity to undertake further 
development of these reactions was not available due to time constraints.  This would form an 
interesting area for future development. 
 
 
Scheme 51: N-alkylation of protected acylic azasugar 176 
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The addition of the O-benzoyl group to amino alcohol 169 and subsequent deprotection of the 
N-BOC group enabled the acetylation of the nitrogen atom with acetic anhydride.  Although 
an electron withdrawing group, it is significantly less bulky than the N-BOC group and it was 
thought that its reduced size may help to induce intramolecular cyclisation.  To test this 
hypothesis, the reactions detailed in Scheme 52 were carried out to prepare the iminosugar 183.  
Similar analysis of the compound that resulted from the final oxidation step to that which was 
conducted for iminosugar 173 was undertaken to determine whether the cyclic 183 or acyclic 
182 iminosugar had been prepared.  The 1H NMR, 13C NMR and FTIR spectra of the compound 
again suggested the acyclic iminosugar 182. 
    
 
Scheme 52: Preparation of iminosugar 183 
 
• Altering the protecting groups 
Alongside attempts to functionalise the nitrogen atom, two reactions to remove the bulky O-
benzyl protecting groups from iminosugars 169 and 173 by catalytic hydrogenation were 
carried out (Schemes 53 and 54).  In both cases the reaction was facile with the protecting 
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groups readily removed.  Characterisation of both compounds was achieved by 1H NMR, 13C 
NMR, FTIR and mass spectroscopy.  1H NMR confirmed that two products were obtained from 
the hydrogenation of iminosugar 169 as was expected due to the epimer at the C2 position in 
compound 184.  It was noted that the reaction detailed in Scheme 53 was carried out more as 
a proof in principle exercise than to progress a line of chemistry.  The utility of compound 184 
was limited as obtaining a useful product by differentiating and selectively protecting various 
hydroxyl groups followed by oxidation at the relevant position within the molecule would be 
very challenging.         
 
 
Scheme 53: Debenzylation of iminosugar 169 
 
Iminosugar 185, as anticipated, was obtained as a single product.  The FTIR spectrum of 185 
showed two clear peaks indicative of two carbonyl stretches which confirmed that over 
reduction of the ketone had not occurred during the hydrogenation.  Compound 185 was of 
greater interest than 184 as the retention of the ketone afforded opportunities to undertake 
further chemistry with the compound to induce the formation of a cyclic iminosugar.   
 
 
Scheme 54: Debenzylation of iminosugar 173 
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It was successfully demonstrated that the four alcohol groups could be successfully re-
protected with pivaloyl groups (Scheme 55).  Although the pivaloyl group is sterically large, it 
is electronically different to an O-benzyl group and it was of interest for comparison purposes.   
 
 
Scheme 55: Protection of 185 with pivaloyl chloride  
 
Had time permitted subsequent reactions would have been conducted with compound 186 to 
assess whether there was any potential of obtaining a cyclic iminosugar with different 
functionalisation around the sugar ring.  It would be interesting to trial various reaction 
conditions to see if compound 187 could be obtained.  Another potential step would be to 
ascertain whether the removal of the N-BOC group in 186 would result in a stable and isolable 
product.   
 
Scheme 56: Potential formation of cyclic iminosugar 
 
Changing the protecting groups does offer scope for further development particularly if 
combined with the successful functionalisation of the amine.  Unfortunately, there was 
insufficient research time to fully develop these more interesting areas of chemistry that may 
ultimately lead to a cyclic iminosugar. 
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• Modulating the electrophilicity of the ketone 
It was thought that controlled reaction conditions may enable selective functionalisation of the 
primary alcohol at position C2 in iminosugar 185.  If this could be successfully achieved, it 
may be possible to modulate the reactivity of the ketone in such a way that stable intramolecular 
cyclisation is promoted.  Reconsidering the ultimate target compounds which are analogues of 
topiramate, iminosugar 185 may facilitate the installation of the important sulfamate group at 
the C2 position, 188, if adequate chemoselectivity could be achieved.  This would not only 
potentially alter the overall reactivity and stability of the iminosugar pre and post cyclisation 
but also means a key structural feature of the desired compound would be in place.  
  
 
Scheme 57: Selective functionalisation of deprotected iminosugar 185 
 
A number of small scale trials of the reaction outlined in Scheme 57 were conducted using 
conditions that mirrored those successfully employed previously to install a sulfamate group 
onto a primary alcohol.  Positive results were indicated with potential scope for controlling 
chemoselectivity to the desired primary hydroxyl position.  Had further time been available, 
this was a route that would be interesting to explore and optimise as it could lead to a range of 
alternative options for onward chemistry development. 
   
3.4.  General conclusions 
The overall objective of this section of the project was to prepare an iminosugar analogue of 
topiramate.  The in silico modelling work had suggested that such a compound would be an 
active candidate for CA inhibition.  As there was no published precedent for an iminosugar that 
was structurally and stereochemically equivalent to D-fructose, the initial aim was to 
demonstrate the viability of this class of compound.  Thus a “model compound”, an O-benzyl 
protected variant, was the first synthetic target that would also enable a total synthesis with 
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appropriate modification.    The successful preparation of this model iminosugar via the 
selected route would enable targeted derivatisation and route development on a sound basis.   
As topiramate contains a D-fructose core, a synthetic plan was developed that successfully 
utilised D-fructose as a starting material.  It has been demonstrated that some of the standard 
transformations employed in the preparation of iminosugars can be applied to D-fructose 
whose utility in iminosugar synthesis has not been explored fully and as such the exercise was 
also useful in terms of developing methodology.  However, using D-fructose as a starting 
material has not been without challenges, particularly during the isolation and characterisation 
of its various anomers, a challenge that was necessary during the early stages of the selected 
synthetic scheme.  Literature procedures which had been successfully applied to other 
monosaccharides required adaptation in order to produce the desired result with D-fructose and 
its derivatives.  For example, the standard Fischer glycosidation reaction that has been applied 
successfully to a range of monosaccharides including glucose and arabinose, proved inefficient 
with D-fructose and an alternative methodology to prepare methyl fructoglycosides was 
employed.  Several of these early stage reactions have been developed and have been shown 
to be repeatable and, to an extent sufficiently scaleable, to provide multi-gram scale quantities 
of intermediates.  It is recognised that selected reactions within these early stages would benefit 
from further optimisation and process development but this was not deemed a priority.  Each 
key intermediate was ultimately produced and fully characterised using a variety of techniques 
applicable to detailed structural elucidation as necessary.  Of particular importance during the 
early stages of chemistry was the differentiation between the furan and pyran forms of 
derivatives of D-fructose.  In addition to standard characterisation techniques, several test 
reactions were conducted on isolated furans so as to provide further positive identification of 
the undesired compounds for comparison.  This was very useful, especially in the absence of 
significant amounts of literature data.  The successful isolation of the desired pyranose isomers 
in the early stages of the synthetic scheme enabled a fast-track approach to be taken in respect 
of the downstream chemistry in order to rapidly gain an understanding of the more novel 
reactions and intermediates.  The early stages were successfully scaled up to provide material 
to enable the more interesting downstream chemistry to be fully explored. 
Several adaptations to the synthetic scheme initially proposed were necessary.  It was readily 
established that the presence of the free amine within the compound was unlikely to furnish a 
stable and isolable iminosugar.  Thus, protection of the amine with a BOC group was postulated 
as a means of introducing additional stability.  The synthetic scheme was modified accordingly 
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and the new reactions investigated and developed.  The successful formation of the BOC 
protected amino ketone, 171, provided an important juncture to the overall project.  The fact 
that the compound remained acyclic and that attempts to induce cyclisation were not successful 
generated several hypotheses that were developed into alternative strategies to attempt to 
prepare a cyclic iminosugar.  The stability and nucleophilicity of the protected amine, the 
electophilicity of the corresponding ketone and the general stereoelectronics of the molecule 
were all considered as avenues for consideration and provided scope for further development.  
This led to the trialling of alternative chemistries that attempted to exploit the different 
opportunities offered by each potential variation to the compound.   Functionalisation of the 
amino group with both electron donating and electron withdrawing groups generated a 
supplementary series of experiments that, if pursued, may lead to a cyclic compound.  
Likewise, the selective addition of the sulfamate group into the molecule in the desired position 
may influence the reactivity of the ketone sufficiently to facilitate cyclisation.  Installing the 
sulfamate group into the molecule earlier in the synthesis offers opportunities for further 
investigation, particularly to consider what effect the presence of this key functional group 
would have on the chemistry attempted here.  Alternative hydroxyl protecting strategies may 
offer a means of altering the overall stereoelectronics of the molecule and although this was 
only touched upon briefly, there is a wide scope for onward investigation. 
Unfortunately, within the confines of this thesis, preparing a cyclic model iminosugar based 
upon D-fructose proved difficult to achieve although this was not immediately surprising given 
the general lack of precedent contained in the literature.  However, the research conducted has 
provided pertinent information and data about particular reactions of D-fructose and several of 
its derivatives that has led to the suggestion of several potential alternative synthetic pathways 
towards a cyclic iminosugar. 
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3.5. Experimental details 
 
3.5.1. Synthesis of intermediates of iminosugar analogues of topiramate 
Preparation of methyl--D-fructopyranoside 153/ methyl--D-fructopyranoside 154/ methyl-
-D-fructofuranoside 155/  methyl--D-fructofuranoside 156: 
  
 
D-fructose (750g/4.2mol), ammonium chloride (111g/2.1mol) and methanol (8.25L) were 
charged to a 10L flange flask fitted with a condenser.  The reaction was stirred and heated to 
reflux (ca. 64°C) overnight after which time TLC indicated reaction completion. The reaction 
was cooled to room temperature and anhydrous sodium hydrogen carbonate (27.5g) was added 
to raise the pH of the reaction to 7.  The reaction was vacuum filtered to remove the solids and 
concentrated in vacuo to give an opaque yellow syrup (861g).  This was dissolved in methanol 
(2.5L), adsorbed onto silica and purified by column chromatography on silica eluted with 
7:1.5:1.5 DCM/ ethyl acetate/ methanol.  Relevant fractions were combined and the solvent 
evaporated.  A mixture of products was obtained (221g).  Mixed fractions were combined, 
adsorbed onto silica and repurified by column chromatography on silica using the same 
conditions as employed in the first column.  An additional 89.5g of a mixture of products was 
obtained resulting in a total yield of 39%.  In addition, 266g (33%) of an undesired 
fructofuranose anomer was isolated as a pale yellow syrup.  Data for the isolated isomer, 
assumed to be 155: 1H NMR (DMSO-d6, 270MHz):  3.16 (s, 3H, O-CH3),  3.30 – 3.71 (m, 
6H, H1,1’,3,4,6,6’),  3.84 (t, 1H, J=5.13Hz, H5),  4.29 (t, 1H, J=5.67Hz, OH),  4.73 (t, 1H, 
J=5.13Hz, OH),  5.06 (d, 1H, J=5.9Hz, OH),  5.14 (d, 1H, J=5.7Hz, OH).  13C NMR (DMSO-
d6, 67.5MHz):  48.33, 59.77, 61.60, 77.19, 81.07, 82.91, 107.70.  MS: m/z of 212 (MH2O+) 
and 217 (MNa+).    
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Preparation of 1,3,4,5-tetra-O-benzyl-methyl-α/β-D-fructopyranoside 146 
 
 
A mixture of 153, 154 and 156 (310g/ 1.6mol) was dissolved in anhydrous DMF (9L) under 
N2 in a 20L flange flask fitted with an overhead stirrer.  The solution was cooled to <0C with 
an IPA/CO2 bath.  Benzyl bromide (1.14L/9.6mol) was added dropwise maintaining reaction 
temperature <0C.  Sodium hydride (60% in oil) (393g/9.8mol) was added gradually to prevent 
exotherms and significant off gassing and to ensure complete dissolution of the sodium 
hydride.  The reaction was stirred at <0C for a further hour following complete addition of the 
sodium hydride. The reaction was warmed to room temperature and was stirred under N2 
overnight.  A dense precipitate formed.  TLC indicated reaction completion.  The reaction was 
cooled to <0C and methanol (3L) was added to the reaction cautiously to control any exotherm 
and gas evolution.  The reaction was vacuum transferred into a second 20L flask containing 
water (3L) and was stirred for 30 minutes.  Ethyl acetate (5L) was added and the reaction stirred 
for a further 30 minutes.  The organic layer was separated and the aqueous further extracted 
with ethyl acetate (2 x 1L). The combined organics were washed with water (5 x 1L), brine 
(1L) and dried over MgSO4.  After filtering, the reaction was concentrated in vacuo to give a 
yellow liquid.  The crude material was purified by column chromatography on silica eluted 
with 5-25% ethyl acetate/heptane.  Product containing fractions were combined and the solvent 
evaporated.  One product was isolated as a yellow syrup (532g/60%).  This was the second 
undesired fructofuranose, 163.  The other two products were isolated as a mixture as a pale 
yellow syrup (212.8g/24%).  Only one product was visible by 1H NMR.  1H NMR (CDCl3, 
270MHz:  3.28 (s, 3H, O-CH3),  3.50 (d, 1H, J=12.4Hz, H6),  3.67 (d, 1H, J=9.7Hz, H1),  
3.77 – 3.80 (m, 2H (overlapping), H1’,3),  3.88 (dd, 1H, J=1.6, 12.4Hz, H6’),  3.96 (dd, 1H, 
J=3.5, 10.2Hz, H4),  4.37 (d, 1H, J= 10.2Hz, H5),  4.41 – 4.94 (m, 8H, O-CH2-Ph),  7.24 – 
7.40 (m, 20H, aromatic). 
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Preparation of 1,3,4,5-tetra-O-benzyl-methyl-α/-D-fructofuranoside 163 
 
Experimental details as for 146.   
1H NMR (CDCl3, 270MHz:  3.30 (s, 3H, O-CH3),  3.52 – 3.54 (m, 2H, H1,1’),  3.64 (s, 2H, 
H6,6’),  3.81 (dd, 1H, J=2.3, 5.6Hz, H4),  4.04 (d, 1H, J=2.3Hz, H3),  4.11 (q, 1H, J=5.6, 
H5),  4.36 – 4.65 (m, 8H, O-CH2-Ph),  4.36 (d, 1H, J=10.0Hz, H1),   4.43 (d, 1H, J=11.9Hz, 
O-CH2-Ph),  4.56 - 4.81 (m, 6H, O-CH2-Ph),   7.22 – 7.31 (m, 20H, aromatic). 
 
Preparation of 1,3,4,5-tetra-O-benzyl-α/β-D-fructose 147 
 
  
 146 (150g/0.27mol) was dissolved in acetic acid (1.8L) in a 5L flange flask.  1M H2SO4 (72ml) 
was added and the reaction was heated to 50C and stirred for 4 hours.  TLC/LCMS showed 
consumption of the starting material.  The reaction was cooled to room temperature and was 
vacuum transferred to a 10L flange flask containing water (3L).  Ethyl acetate (3L) was added 
and the reaction stirred for 15 minutes.  Solid sodium hydrogen carbonate (136g) was added 
until rapid effervescence ceased.  The organic layer was separated and the aqueous was further 
extracted with ethyl acetate (3x1.5L).  The combined organics were washed with saturated 
sodium hydrogen carbonate solution (aq) (3x1L), water (3L) brine (3L), dried over MgSO4, 
vacuum filtered and concentrated in vacuo to give a pale yellow syrup (142g).  The crude 
material was purified by column chromatography on silica eluted with 10% - 40% ethyl acetate/ 
heptane.  Relevant fractions were combined and the solvent evaporated to give the products as 
a yellow syrup (131g/ 90%).  LCMS shows two peaks in a ratio of 10:1 both with a m/z of 563 
(MNa+) with a purity of >98%.  1H NMR (CDCl3, 270MHz) (data for major anomer):  3.36 
(br, 1H, OH ),  3.43 – 3.55 (2xd, 2H, J=10.0Hz, H6,6’ ),  3.78 – 3.83 (m, 3H, H3,4,5),  3.95 
(s, 2H, H1,1’),  4.50 – 4.96 (m, 8H, O-CH2-Ph),  7.25 – 7.38 (m, 20H, aromatic).   61.02, 
71.3, 72.1, 72.2, 73.9, 75.6, 73.3, 75.9, 79.0, 98.2, 128.81 – 130.55(aromatics x20), 137.8, 
138.2, 138.5, 138.5.  
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Preparation of 1,3,4,5-tetra-O-benzyl-α/β-D-fructofuranose 164: 
 
 
163 (0.5g/ 0.9mol) was dissolved in acetic acid (2ml).  1M H2SO4 (0.15ml) was added and the 
reaction was heated to 50C overnight.  TLC/ LCMS showed consumption of the starting 
material so the reaction was cooled to room temperature and poured over water (10ml) and 
ethyl acetate (20ml) was added.  Anhydrous sodium hydrogen carbonate (5g) was added until 
rapid effervescence ceased.  The organic layer was separated and the aqueous was further 
extracted with ethyl acetate (3x 5ml).  The combined organics were washed with saturated 
sodium hydrogen carbonate solution (aq) (20ml), water (20ml), brine (20ml) and dried over 
MgSO4.  After vacuum filtering, the reaction was concentrated in vacuo to give a colourless 
syrup (0.421g).  The crude material was purified by column chromatography on silica eluted 
with 10% - 40% ethyl acetate/heptane.  Relevant fractions were combined and the solvent 
evaporated to give the product as a pale yellow syrup (0.28g/57%).  LCMS showed a m/z of 
563 (MNa+) with a purity of >98%.  1H NMR (CDCl3, 270MHz):  3.32 (br-s, 1H, OH ),  
3.53 – 3.58 (m, 2H, H6,6’ ),  3.64 (d, 2H, J=12.0Hz H1,1’),  3.81 (dd, 1H, J=2.5, 5.4Hz, H4), 
 4.04 (d, 1H, J=2.5Hz, H3),  4.11 (q, 1H, J=5.4, H5),  4.36 – 4.65 (m, 8H, O-CH2-Ph),  
7.22 – 7.31 (m, 20H, aromatic). 
 
Preparation of 1,3,4,5-tetra-O-benzyl-D-glucitol/1,3,4,5-tetra-O-benzyl-D-mannitol 148: 
 
147 (122.0g/ 0.23mol) was dissolved in THF (1.95L) and water (0.98L) was added.  Solid 
sodium borohydride (87.0g/ 2.3mol) was added and the reaction was stirred at room 
temperature for 2 hours.  TLC/ LCMS showed no remaining starting material so the reaction 
was cooled to <10°C with an ice bath and saturated aqueous ammonium chloride solution (aq) 
(1.5L) was added gradually to control exotherm and gas evolution.  The reaction was 
considered fully quenched once no further gas evolution was observed.  Ethyl acetate (3L) was 
added and the layers separated.  The aqueous was further extracted with ethyl acetate (3x1L).  
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The organics were combined, washed with water (2L), brine (2L), dried over MgSO4, vacuum 
filtered and concentrated in vacuo.  A colourless syrup (119.0g/ 95%) was obtained.  LCMS 
showed a single peak at 99% purity with m/z of 543 (MH+) and 565 (MNa+).  Two epimers 
visible in the 1H NMR in a 5:1 ratio.  1H NMR (CDCl3, 270MHz) (data for major isomer):  
2.35 (t, 1H, OH ),  2.72 (d, 1H, OH ),  3.38 – 3.51 (m, 2H, H1,1’),  3.74 – 4.01 (m, 6H, 
H2,3,4,5,6,6’),  4.40 – 4.74 (m, 8H, O-CH2-Ph),  7.20 – 7.33 (m, 20H, aromatic).  13C NMR 
(CDCl3, 67.5MHz):  62.50, 71.85, 73.35, 74.25, 75.31, 75.69, 79.50, 84.28, 84.56, 127.95 – 
128.68 (aromatics x20), 135.01, 136.58, 137.58, 137.95.   
 
 
 
Preparation of 1,3,4,5-tetra-O-benzyl-6-toluenesulphonyl-D-glucitol/1,3,4,5-tetra-O-benzyl-
6-toluenesulphonyl-D-mannitol 149: 
 
148 (118.0g/ 0.217mol) was dissolved in pre-dried DCM (2.36L) under N2.  Triethylamine 
(60.5ml/0.435mol) and DMAP (2.65g/ 0.022mol) were added.  Tosyl chloride (82.0g/ 
0.435mol) was added as a solid in portions and the reaction was stirred at room temperature 
under N2 for 24 hours.  TLC/ LCMS showed reaction completion so the reaction was quenched 
by the addition of saturated sodium bicarbonate solution (aq) (2L).  The organic layer was 
separated and the aqueous was further extracted with DCM (3x 1L).  The organic layers were 
combined and washed with water (2L), brine (2L) and dried over MgSO4.  After vacuum 
filtering, the solvent was removed in vacuo to give a yellow oil (189.4g).  The crude material 
was purified by column chromatography on silica eluted with 7:1.5:1.5 heptane/ DCM/ ethyl 
acetate.  Relevant fractions were combined and the solvent evaporated.  The products were 
obtained as a yellow syrup (128.1g/ 85%).  LCMS showed the presence of two products in a 
ratio of 5:1 with >95% purity.  Both peaks showed a m/z of 719 (MNa+) and 697.5 (MH+) in 
the corresponding mass spectrum. 1H NMR (CDCl3, 270MHz)(for major isomer):  2.40 (s, 
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3H, CH3),  2.50 (d, 1H, J=6.2Hz, OH ),  3.34 – 3.48 (m, 2H, H1,1’),  3.66 (dd, 1H, J=5.94, 
2.97Hz, H4),  3.85 – 3.97 (m, 3H, H3,5,6),  4.19 – 4.25 (m, 1H, H6’),  4.33 – 4.68 (m, 9H, O-
CH2-Ph/ H2),  7.19 – 7.32 (m, 20H, aromatic),  7.34 - 7.36 (m, 4H, aromatic (OTs)).  13C 
NMR (CDCl3, 67.5MHz):  22.60, 69.3, 71.22, 73.25, 73.35, 74.25, 75.31, 75.69, 78.65, 79.50, 
84.28, 127.65 – 129.75 (aromatics x20), 134.50, 135.62, 136.77, 138.44, 140.30, 145.20.   
 
The bis-tosylated product was also isolated in small amounts from the reaction.  LCMS 
confirmed the compound had a m/z of 873.6 (MNa+).  1H NMR (CDCl3, 270MHz):  2.34 (s, 
3H, CH3), 2.37 (s, 3H, CH3),  3.34 (dd, 1H, J=5.4, 11.34Hz, H1),  3.58 (dd, 1H, J=5.4, 
11.34Hz, H1’),  3.74 – 3.76 (m, 2H, H4,5),  3.88 – 3.92 (m, 1H, H3),  4.08 – 4.54 (m, 10H, 
O-CH2-Ph/ H6,6’),  4.83 – 4.88 (m, 1H, H2),  7.08 – 7.26 (m, 20H, aromatic (OBn)),  7.66 – 
7.71 (4xd, 8H, J=2.8Hz, aromatic (OTs)).   
  
 
 
Preparation of 150: 
 
 
149 (128.1g/ 0.18mol) was dissolved in anhydrous DMF (3.2L) under N2.  Sodium azide 
(21.1g/ 0.324mol) was added and the reaction was heated to 50C and stirred for 24 hours.  
TLC/ LCMS indicated full consumption of the starting material so the reaction was cooled to 
room temperature and water (4L) was added cautiously.  Ethyl acetate (3L) was added and the 
reaction stirred for 30 minutes.  The organic layer was separated and the aqueous further 
extracted with ethyl acetate (3x 1L).  The organics were combined and were washed with water 
(6x 1L), brine (1L) and dried over MgSO4.  The reaction was vacuum filtered and concentrated 
in vacuo to give a yellow oil (103.4g).  The crude material was purified by column 
chromatography on silica eluted with 8:1:1 heptane/ ethyl acetate/ DCM.  Relevant fractions 
were collected and the solvent evaporated.  The products were obtained as a colourless syrup 
(48.5g/58%).  LCMS showed two peaks in a ratio of 12:1 both with m/z 590.6 (MNa+) in >97% 
purity.  1H NMR (CDCl3, 270MHz)(data for major epimer):  2.61 (d, 1H, J=6.2Hz, OH),  
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3.35 – 3.48 (m, 2H, H1,1’),  3.53 – 3.55 (m, 2H, H3,5),  3.67 (dd, 2H, J=2.7, 5.9Hz, H4),  3.81 
– 3.85 (m, 1H, H6),  3.90 – 3.96 (m, 2H, H6’,2),  4.39 – 4.73  (m, 8H, O-CH2-Ph),  7.21 – 
7.34 (m, 20H, aromatic).  13C NMR (CDCl3, 67.5MHz):  50.96, 71.22, 71.25, 73.35, 74.25, 
75.65, 75.98, 78.55, 81.52, 82.28, 127.10 – 129.25 (aromatics x20), 135.50, 135.62, 135.99, 
138.49.  FTIR (CH2Cl2): 2102.8 (N3). 
 
Preparation of 151: 
 
 
150 (1.39g/ 2.45mmol) was dissolved in pre-dried DCM (10ml) under N2 and cooled to 0C.  
Dess-Martin periodinane (1.25g/ 2.94mmol) as a suspension in DCM (5ml) was added 
dropwise maintaining the reaction temperature at 0C.  The reaction was stirred for a further 
10 minutes at 0C and then warmed to room temperature.  After 30 minutes of stirring, TLC 
and LCMS indicated consumption of the starting material.  Ethyl acetate (40ml) was added to 
the reaction and it was cooled to <5C.  Saturated sodium thiosulfate solution (aq) (10ml) was 
added to quench any remaining oxidant followed by saturated sodium bicarbonate solution (aq) 
(10ml).  The organic layer was separated and the aqueous further extracted with DCM (2x 
10ml).  The organics were combined and washed with saturated sodium bicarbonate solution 
(aq) (30ml), brine (30ml) and dried over MgSO4.  After filtering, the solvent was removed in 
vacuo to give a clear colourless syrup (1.19g).  The syrup was purified by column 
chromatography on silica eluted with 8:1:1 heptane/ ethyl acetate/ DCM.  Relevant fractions 
were collected and the solvent evaporated.  The product was obtained as a colourless syrup 
(0.91g/ 65%).  LCMS showed a peak with m/z 588.6 (MNa+) in 96% purity.  1H NMR (CDCl3, 
270MHz):  3.35 (dd, 1H, J=4.1, 13.0Hz, H6),  3.69 (d, 1H, J=13.0Hz, H6’),  3.74 – 3.83 (m, 
1H, H4),  4.09 – 4.13 (m, 1H, H5),  4.21 – 4.69 (m, 10H, O-CH2-Ph, H1,1’),  7.17 – 7.35 (m, 
20H, aromatic).  13C NMR (CDCl3, 67.5MHz): 50.1, 72.1, 73.4, 74.0, 74.3, 74.9, 78.2, 79.2, 
84.3, 128.0 – 128.7 (aromatics x20), 136.95, 137.52, 137.98, 138.26, 208.0.  FTIR (CH2Cl2): 
2101.4 (N3), 1730.5 (C=O). 
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Preparation of 168: 
 
 
Lithium aluminium hydride (1M solution in THF) (147ml) was charged to a flask under N2 and 
was cooled to -5°C.  150 (41.90g/ 0.07mol) was dissolved in THF (1L) and the solution added 
dropwise to the solution of lithium aluminium hydride.  The reaction was stirred at <0°C for 
30 minutes and was then allowed to warm gradually to room temperature.  After 2 hours, LCMS 
confirmed reaction completion and the formation of the desired product.  The reaction was 
cooled to 0°C and water (5.6ml) was added dropwise ensuring that the rate of addition 
controlled any exotherms and off gassing.  15% sodium hydroxide (aq) (5.6ml) was added 
cautiously followed by water (16.7ml).  After warming to room temperature, the reaction was 
stirred for 30 minutes.  A gelatinous solid formed in the flask.  The reaction was filtered through 
a pad of Celite which was rinsed with THF (350ml).  The THF was removed in vacuo and the 
clear residue was dissolved in ethyl acetate (250ml).  The reaction was washed with water 
(150ml), brine (150ml) and dried over magnesium sulfate.  After filtering, the reaction was 
concentrated in vacuo to give a colourless syrup (28.0g/70%) that solidified to a white solid on 
standing.  LCMS purity of 96% with corresponding mass spectrum showing m/z of 564 (MNa+) 
and 542 (MH+).  96% purity by NMR assay.  1H NMR (CDCl3, 270MHz):  2.75 (br-s, 1H, 
OH),  3.04 – 3.06 (m, 2H, H6,6’),  3.39 – 3.53 (m, 2H, H1,1’),  3.70 (dd, 1H, J=5.4Hz, H4),  
3.81 – 3.85 (m, 1H, H5),  3.93 – 4.00 (m, 2H, H2,3),  4.38 – 4.72 (m, 8H, O-CH2-Ph),  7.19 
-7.24 (m, 3H, aromatic),  7.26 -7.34 (m, 17H, aromatic),  7.57 (br-s, 2H, NH2).  13C NMR 
(CDCl3, 67.5MHz):  69.32, 72.02, 73.36, 74.30, 74.62, 74.72, 75.50, 75.91 78.35, 79.50, 
127.81 – 128.55(aromatics x20), 136.50, 138.62, 139.45, 139.69. 
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Preparation of 169: 
 
169 (31.39g/ 0.06mol) was dissolved in THF (775ml) and charged to a 1L flask under N2 and 
cooled to <5°C with an ice bath.  Triethylamine (16.73ml/0.12mol) was added portionwise 
over 30 minutes and the reaction stirred for an additional 30 minutes.  Boc anhydride 
(16.5ml/0.072mol) as a solution in THF (20ml) was added to the reaction dropwise maintaining 
the reaction temperature at <5°C.  The reaction was stirred for 30 minutes and then allowed to 
warm to room temperature gradually.  TLC/LCMS confirmed reaction completion with 
complete consumption of starting material.  The reaction was concentrated in vacuo to remove 
THF and the resulting residue was dissolved in ethyl acetate (300ml) and the solution washed 
with water (300ml), brine (300ml) and dried over MgSO4.  After filtering, the solvent was 
removed in vacuo to give a yellow oil (41.41g).  The oil was purified by column 
chromatography on silica eluted with 10-20% ethyl acetate/heptane.  Product fractions were 
combined and the solvent evaporated to afford the product as a yellow syrup (25.41g/63%).  
LCMS purity of 97% was recorded with corresponding mass spectrum showing m/z of 665 
(MNa+) and 543 (M-Boc+).  1H NMR shows two isomeric products in a roughly 5:1 ratio as 
identified by two OH signals.  99% purity by NMR assay.  1H NMR (CDCl3, 270MHz)(data 
for major product):  1.42 (s, 9H, Boc),  2.78 (d, 1H, J=6.2Hz, OH),  3.38 – 3.53 (m, 4H, 
H6,6’,1,1’),  3.71 (dd, 1H, J=5.4H, H4),  3.77 – 3.80 (m, 1H, H2),  3.92 – 4.01 (m, 2H, H5,3), 
 4.36 – 4.74 (m, 8H, O-CH2-Ph),  4.92 (t, 1H, J=5.0Hz, NH),  7.19 -7.23 (m, 2H, aromatic), 
 7.26 -7.36 (m, 18H, aromatic ).  13C NMR (CDCl3, 67.5MHz):  28.42, 42.20, 69.32, 71.20, 
72.98, 74.50, 74.82, 74.98, 75.54, 75.98, 78.65, 79.65, 127.41 – 129.52 (aromatics x20), 
136.50, 138.62, 139.45, 139.69, 155.62. 
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Preparation of 171: 
 
 
169 (1.28g/ 1.99mmol) was dissolved in pre-dried DCM (25ml) under N2.  Dess-Martin 
periodinane (1.00g/2.39mmol) was added.  The reaction was heated to 40°C in an oil bath and 
stirred for 12 hours.  TLC and LCMS indicated consumption of the starting material so the 
reaction was cooled to room temperature.  DCM (25ml) was added to the reaction and it was 
cooled to <5C.  Saturated sodium thiosulfate solution (aq) (10ml) was added to quench any 
remaining oxidant followed by saturated sodium bicarbonate solution (aq) (10ml).  The organic 
layer was separated and the aqueous further extracted with DCM (2x10ml).  The combined 
organics were washed with saturated sodium bicarbonate solution (aq) (30ml), brine (30ml) 
and dried over MgSO4.  After filtering, the solvent was removed in vacuo to give a yellow 
syrup (1.31g).  The syrup was purified by column chromatography on silica eluted with 8:1:1 
heptane/ ethyl acetate/ DCM.  Relevant fractions were collected and the solvent evaporated.  
The product was obtained as an opaque colourless syrup (0.97g/76%).  LCMS showed a peak 
with m/z 662.7 (MNa+) and 540.5 (M-Boc+) in 97% purity.  1H NMR (CDCl3, 270MHz):  
1.44 (s, 9H, Boc),  3.44 – 3.56 (m, 2H, H1,1’),  3.67 – 3.72 (m, 2H, H5,3),  3.99 (dd, 1H, 
J=3.78, 7.83Hz, H4),  4.18 – 4.60 (m, 11H, O-CH2-Ph, H6,6’,2),  4.70 (br, 1H, NH),  7.18 – 
7.36 (m, 20H, aromatic).  13C NMR (CDCl3, 67.5MHz: 28.36, 42.60, 71.19, 73.27, 74.14, 
74.32, 74.71, 78.56, 79.28, 79.44, 84.10, 127.71 – 128.53 (aromatics x22), 136.78, 137.19, 
155.85, 208.48.   
 
 
 
 
 
 
 
 
 
171 
 
Preparation of 168: 
 
169 (1.0g/ 1.56 mmol) was dissolved in DCM (20ml) and TFA (2ml) was added.  The reaction 
was stirred at room temperature.  After two hours, TLC and LCMS indicated complete 
consumption of starting material.  The reaction was poured over saturated sodium bicarbonate 
solution (aq) (40ml).  The organic layer was separated.  The aqueous was further extracted with 
DCM (3x10ml).  The organic layers were combined, washed with saturated sodium bicarbonate 
solution (aq) (40ml), water (40ml), brine (40ml) and dried over MgSO4.  After filtering, the 
solvent was removed in vacuo to give a pale yellow syrup (0.82mg/97%) that solidified on 
standing.  LCMS purity of 93% with corresponding mass spectrum showing m/z of 564 (MNa+) 
and 542 (MH+).  97% purity by NMR assay.  1H NMR (CDCl3, 270MHz):  2.75 (br-s, 1H, 
OH),  3.04 – 3.06 (m, 2H, H1,1’),  3.39 – 3.53 (m, 2H, H6,6’),  3.70 (dd, 1H, J=5.4Hz, H4),  
3.81 – 3.85 (m, 1H, H5),  3.93 – 4.00 (m, 2H, H2,3),  4.38 – 4.72 (m, 8H, O-CH2-Ph),  7.19 
-7.24 (m, 3H, aromatic),  7.26 -7.34 (m, 17H, aromatic),  7.57 (br-s, 2H, NH2).  13C NMR 
(CDCl3, 67.5MHz):  69.32, 72.02, 73.36, 74.30, 74.62, 74.72, 75.50, 75.91 78.35, 79.50, 
127.81 – 128.55(aromatics x20), 136.50, 138.62, 139.45, 139.69. 
 
 
Preparation of 184: 
 
169 (1.10g/1.72mmol) was dissolved in methanol (20ml).  The solution was charged to a 
suspension of palladium on carbon (10%) (0.366g/3.44mmol) in methanol (20ml) under N2.  
Hydrogen was sparged into the reaction at atmospheric pressure.  The reaction was heated to 
40˚C in an oil bath.  After 7 hours the reaction was sampled.  Analysis by LCMS and 1H NMR 
indicated that although there had been reaction progression, the reaction was incomplete.  The 
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reaction was stirred under a hydrogen atmosphere at room temperature overnight.  The 
hydrogen sparge was reinstated and the reaction reheated to 40˚C.  After 7 hours the reaction 
was sampled.  Analysis by LCMS and 1H NMR indicated that there was no remaining starting 
material within the crude reaction mixture but the reaction remained incomplete.  The reaction 
was stirred under a hydrogen atmosphere at room temperature overnight.  The hydrogen sparge 
was reinstated and the reaction reheated to 40˚C.  After 4 hours the reaction was sampled.  1H 
NMR indicated reaction completion with no remaining O-benzyl groups signals visible.  The 
reaction was cooled to room temperature and placed under a nitrogen atmosphere.  The reaction 
was filtered through a pad of Celite which was rinsed with methanol (150ml).  The solvent was 
removed in vacuo to give a colourless syrup (599mg). The crude material was purified by 
column chromatography on silica eluted with 10% methanol/DCM.  Product fractions were 
combined and the solvent removed in vacuo to give a pale yellow syrup (0.441g/91%).   
Alcohol groups were identified by a D2O shake. MS recorded a m/z of 304 (MNa
+) and 182 
(M-Boc+) which would correspond with the desired product. 1H NMR (DMSO-d6, 270MHz) 
(major product):  1.38 (s, 9H, Boc),  2.83 – 2.91 (m, 1H, H1),  3.26 – 3.33 (m, 2H, H1’,6),  
3.41 – 3.55 (m, 4H, H3,4,5,6’),  3.62 – 3.67 (m, 1H, H2),  4.10 (d, 1H, J=7.0Hz, OH),  4.46 – 
4.51 (m, 2H, 2xOH),  4.57 (d, 1H, J=4.6Hz, OH),  4.64 (d, 1H, J=5.6Hz, OH),  6.43 (t, 1H, 
J=5.40Hz, NH).  13C NMR (DMSO-d6, 67.5MHz):  28.82, 44.54, 63.04, 69.26, 70.36, 73.70, 
74.25, 78.19, 156.51.  1H NMR (DMSO-d6, 270MHz): (identifiable signals from minor 
product; integrals as a fraction of 1H equivalent of major product.  All are exchangeables by 
D2O shake.)  4.29 – 4.35 (m, 0.2H, OH),  4.42 (t, 0.2H, J=6.21Hz, OH),  5.10 (d, 0.2H, 
J=5.94Hz, OH),  6.69 (t, 0.2H, J=5.67Hz, NH). 
 
Preparation of 185: 
 
173 (5.0g/7.8mmol) was dissolved in methanol (25ml).  The solution was charged to a 
suspension of palladium on carbon (10%) (1.66g/15.6mmol) in methanol (75ml) under 
nitrogen.  Hydrogen was sparged into the reaction at atmospheric pressure.  The reaction was 
heated to 40˚C.  After 7 hours the reaction was sampled.  Analysis by LCMS and 1H NMR 
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indicated that although there had been reaction progression, the reaction was incomplete.  The 
reaction was stirred under a hydrogen atmosphere at room temperature overnight.  The 
hydrogen sparge was reinstated and the reaction reheated to 40˚C.  After four hours the reaction 
was sampled.  1H NMR indicated reaction completion with no remaining O-benzyl groups 
visible.  The reaction was cooled to room temperature and placed under a nitrogen atmosphere.  
The reaction was filtered through a pad of Celite which was rinsed with methanol (500ml).  
The solvent was removed in vacuo to give a colourless syrup (4.70g).  The crude material was 
purified by column chromatography on silica eluted with 5-10% methanol in DCM.  Product 
fractions were combined and the solvent removed in vacuo to give a colourless syrup 
(1.818g/83%).  The syrup solidified to a white solid on standing overnight.   1H NMR in 
DMSO-d6 showed the correct number of alcohol groups were present in the product as 
identified by D2O shake.  MS showed a m/z of 302 (MNa
+) which corresponded with the 
desired product. 1H NMR (DMSO-d6, 270MHz):  1.37 (s, 9H, Boc),  3.09 – 3.12 (m, 2H, 
H1,1’),  3.23 (m, 2H, H4,5),  3.52 – 3.56 (m, 1H, H3),  3.73 – 3.85 (m, 2H, H6,6’),  4.71 (t, 
1H, J=6.21Hz, OH),  4.79 (d, 1H, J=6.48Hz, OH),  5.14 – 5.17 (m, 1H, OH),  5.60 (d, 1H, 
J=21.06Hz, OH),  6.43 (t, 1H, J=5.40Hz, NH).  13C NMR (DMSO-d6, 67.5MHz):  28.26, 
48.62, 62.86, 75.46, 76.38, 77.69, 79.02, 102.07, 155.58.   
   
Preparation of 176:  
 
169 (1.0g/ 1.56mmol) was dissolved in pre-dried DCM (12.5ml) under nitrogen.  Pyridine 
(2.5ml) was added and the reaction was cooled to ca 0°C with an ice bath and stirred for 30 
minutes.  Benzoyl chloride (0.26ml) was added dropwise and the reaction was stirred at 0°C 
for 30 minutes then was gradually warmed to room temperature and stirred under nitrogen 
overnight. HPLC showed that approximately 9% of starting material was remaining.  An 
additional charge of benzoyl chloride (0.13ml/ 0.6mmol) was made.  After one hour of stirring, 
TLC and HPLC indicated consumption of the starting material.  DCM (5ml) was added and 
the reaction was washed with water (10ml), 1M sodium hydroxide (10ml), 1M hydrochloric 
acid (10ml), brine (10ml) and dried over MgSO4.  After vacuum filtering, the solvent was 
removed in vacuo to give a yellow oil (1.42g).  The crude material was purified by column 
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chromatography on silica (20g) eluted with 10% ethyl acetate/ heptane (500ml).  Relevant 
fractions were collected and the solvent evaporated.  The product was obtained as a clear 
colourless syrup (0.89g/ 76%).  LCMS showed two peaks with m/z 768 (MNa+) and 646 (M-
Boc+) in 10:1 ratio.  1H NMR (CDCl3, 270MHz):  1.40 (s, 9H, Boc),  3.42 – 3.54 (m, 2H, 
H1,1’),  3.62 – 3.71 (m, 3H, H6,6’,3),  3.72 – 3.84 (m, 1H, H5),  3.99 (dd, 1H, J = 7.2, 2.7Hz, 
H4),  4.33 – 4.75 (m, 8H, O-CH2-Ph),  4.89 (br, 1H, NH),  5.55 (dd, 1H, J = 3.7, 7.8Hz, H2), 
 7.23 – 7.27 (m, 20H, aromatic),  7.43 (t, 2H, J = 7.8Hz aromatic),  7.56 (t, 1H, J=7.8Hz 
aromatic),  8.02 (d, 2H, J=7.8Hz aromatic).   
 
 
  Preparation of 179: 
 
176 (0.89g/ 1.19 mmol) was dissolved in DCM (20ml) and TFA (0.2ml) was added.  The 
reaction was stirred at room temperature and after two hours, TLC and HPLC indicated 
complete consumption of starting material.  The reaction was poured over saturated sodium 
bicarbonate solution (aq) (40ml) and the organic layer was separated.  The aqueous was further 
extracted with DCM (3 x 10ml).  The organic layers were combined, washed with saturated 
sodium bicarbonate solution (aq) (40ml), water (40ml), brine (40ml) and dried over MgSO4.  
After filtering, the solvent was removed in vacuo to give a pale yellow syrup (0.61mg/ 79%).  
LCMS purity of 95% with corresponding mass spectrum showing m/z of 668 (MNa+) and 647 
(MH+).  1H NMR (CDCl3, 270MHz):  2.95 – 3.02 (m, 2H, H1,1),  3.60 – 3.79 (m, 3H, H3,6,6), 
 3.92 (t, 1H, J=4.1Hz, H5),  4.05 (d, 1H, J=4.1Hz , H4),  4.40 – 4.53 (m, 4H, O-CH2-Ph),  
4.64 – 4.53 (m, 4H, O-CH2-Ph),  5.57 (dd, 1H, J=5.1, 4.56Hz , H2),  7.20 -7.30 (m, 20H, 
aromatic),  7.42 – 7.48 (m, 2H, aromatic),  7.56 – 7.61 (m, 1H, aromatic),  8.06 – 8.09 (m, 
2H, aromatic).  
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Preparation of 174:  
 
151 (50mg/0.09mmol) was dissolved in pre-dried THF (1ml) under nitrogen.  Propionaldehyde 
(64µl of a 10% v/v solution in THF/0.11mmol) was added followed by acetic acid (55µl of a 
10% v/v solution in THF/ 0.09mmol).  The reaction was stirred under nitrogen at room 
temperature for 30 minutes.  Sodium borohydride (8.1mg/0.13mmol) was added and after two 
hours TLC indicated minimal reaction progression.  The reaction was warmed to 40°C for two 
hours and TLC indicated no remaining starting material.  The reaction was poured over 
saturated sodium bicarbonate solution (aq) (10ml).  The aqueous was extracted with DCM (3 
x 5ml) and the organic layers combined, washed with water (10ml), brine (10ml) and dried 
over MgSO4.  After filtering, the solvent was removed in vacuo to give a pale yellow oil 
(55mg).  The crude material was purified by column chromatography on silica eluted with 5% 
methanol/ DCM.  Relevant fractions were collected and the solvent evaporated.  The product 
was obtained as a clear colourless syrup (11mg/20%).  LCMS showed a peak with m/z 585 
(MH+).  1H NMR (CDCl3, 270MHz):  0.82 (t, 3H, J=7.6Hz, CH3),  1.40 – 1.51 (m, 2H, CH2), 
 2.54 (t, 2H, J=7.6Hz, CH2),  3.00 (2xd overlapped, 2H, H1,1’),  3.41 – 3.52 (m, 3H, H6,3,5), 
 3.70 (dd, 3H, J=2.2, 6.5Hz, H4),  3.98 – 4.07 (m, 3H, H6’,2,OH),  4.39 – 4.74 (m, 8H, O-
CH2-Ph),  7.22 – 7.30 (m, 20H, aromatic).   
 
 
 
Preparation of 180: 
 
179 (100mg/0.16mmol) was dissolved in pre-dried DCM (1.5ml) and pyridine (1ml) under 
nitrogen.  The reaction was cooled to ca 0°C with an ice bath.  Acetic anhydride (15.8µl as a 
solution in 0.2ml DCM/0.16mmol) was added dropwise and the reaction stirred at 0°C for one 
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hour before the reaction was gradually warmed to room temperature.  After two hours, TLC/ 
LCMS confirmed reaction completion.  DCM (10ml) and water (10ml) were added and the 
organic layer separated.  The aqueous was further extracted with DCM (3x5ml).  The organics 
were combined, washed with saturated ammonium chloride solution (aq) (20ml), brine (20ml) 
and dried over MgSO4.  After filtering, the solvent was removed in vacuo to give a yellow 
syrup (104mg).  The crude material was purified by column chromatography on silica eluted 
with 5%-25% ethyl acetate/heptane.  Relevant fractions were combined and the solvent 
evaporated.  The product was obtained as a yellow syrup (59mg/54%).  LCMS showed two 
adjacent peaks each with m/z 688 (MH+) and 710 (MNa+) in 92% purity.  1H NMR (CDCl3, 
270MHz)(data for major epimer):  1.72 (s, 3H, CH3),  3.35 – 3.41 (m, 1H, H1),  3.61 – 3.73 
(m, 4H, H1’,6, 6’, 5),  3.89 (dd, 1H, J=2.7, 6.21Hz, H4),  3.96 – 3.98 (m, 1H, H3),  4.39 – 4.77 
(m, 8H, O-CH2-Ph),  5.55 (dd, 1H, J=2.7, 6.21Hz, H2),  5.81 – 5.85 (m, 1H, NH),  7.19 – 
7.29 (m, 20H, aromatic),  7.41 – 7.47 (m, 2H, aromatic),  7.55 – 7.58 (m, 1H, aromatic),  
8.02 – 8.06 (m, 2H, aromatic).   
   
Preparation of 181: 
 
 
180 (150mg/0.5mmol) was dissolved in methanol (3ml).  Potassium hydroxide 
(37mg/0.66mmol) was added and the reaction stirred at room temperature overnight.  The 
reaction was sampled and no starting material was present by TLC or LCMS.  6N HCl in 
ethanol (0.24ml) was added dropwise to raise the pH of the reaction to ca 7.  DCM (10ml) was 
added and the reaction was washed with water (10ml), brine (10ml) and dried over MgSO4.  
After filtering, the solvent was removed in vacuo to give a pale yellow syrup (142mg).  The 
crude material was purified by column chromatography on silica eluted with 4-10% ethyl 
acetate in heptane (100ml).  Relevant fractions were combined and the solvent removed in 
vacuo.  The product was obtained as a pale yellow syrup (109mg/85%).  LCMS showed one 
peak only with m/z 584 (MH+) and 606 (MNa+) in 92% purity.  1H NMR (CDCl3, 
270MHz)(data for major isomer):  1.75 (s, 1H, CH3),  2.77 (d, 1H, J=6.2Hz, OH),  3.31 – 
3.52 (m, 3H, H1,1’,6),  3.67 – 3.76 (m, 3H, H6’,4,5),  3.95 – 3.98 (m, 2H, H2,3),  4.45 – 4.74 
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(m, 8H, O-CH2-Ph),  5.85 – 5.87 (m, 1H, NH),  7.20 – 7.35 (m, 20H, aromatic).  13C NMR 
(CDCl3, 67.5MHz): 23.45, 38.59, 72.65, 74.30, 74.52, 74.69, 74.95, 78.52 79.80, 83.78, 
127.95 – 128.68 (aromatics x20), 135.01, 136.58, 137.58, 137.95, 170.07.    
  
 
   
Preparation of 182: 
 
 
181 (100mg/0.17mmol) was dissolved in DCM (2ml) and Dess-Martin periodinane 
(89mg/0.21mmol) was added.  The reaction was stirred under nitrogen at 45°C for 16 hours.  
TLC/ LCMS indicated no remaining starting material.  The reaction was diluted with DCM 
(5ml) and cooled to room temperature.  Saturated sodium thiosulfate solution (aq) (2ml) was 
added to quench any remaining oxidant followed by saturated sodium bicarbonate solution (aq) 
(5ml).  The organic layer was separated and the aqueous further extracted with DCM (2x 5ml).  
The combined organics were washed with saturated sodium bicarbonate solution (aq) (10ml), 
brine (10ml) and dried over MgSO4.  After filtering, the solvent was removed in vacuo to give 
a colourless syrup (108mg).  The crude material was purified by column chromatography on 
silica eluted with 1:1 heptane/ethyl acetate.  Relevant fractions were collected and the solvent 
evaporated.  The product was obtained as a colourless syrup (83mg/84%).  LCMS showed a 
peak with m/z 582.5 (MH+) and 604.1 (MNa+).  1H NMR (CDCl3, 270MHz):  1.78 (s, 3H, 
CH3),  3.48 – 3.63 (m, 2H, H1,1’),  3.64 – 3.67 (m, 1H, H5),  3.95 (dd, 1H, J=3.5, 6.8Hz, 
H4),  4.18 – 4.56 (m, 11H, O-CH2-Ph, H6,6’,3),  5.50 (t, 1H, J=10.5Hz, NH),  7.18 – 7.35 (m, 
20H, aromatic).  13C NMR (CDCl3, 67.5MHz): 23.21, 37.92, 71.35, 73.30, 74.19, 74.31, 
74.58, 79.80, 83.78, 127.95 – 128.68 (aromatics x20), 135.01, 136.58, 137.58, 137.95, 170.07, 
208.26.   
 
 
 
 
178 
 
 
Preparation of 175: 
 
 
151 (100mg/0.19mmol) was dissolved in pre-dried THF (2ml) under nitrogen.  Hexanal 
(18.5mg/019mmol) was added and the reaction was stirred under nitrogen at room temperature 
for two hours.  Sodium cyanoborohydride (14mg/0.19mmol) was added and the reaction was 
stirred at room temperature for 16 hours and TLC indicated no remaining starting material.  
The reaction was poured over saturated sodium bicarbonate solution (aq) (10ml).  The aqueous 
was extracted with DCM (3x5ml) and the organic layers combined, washed with water (10ml), 
brine (10ml) and dried over MgSO4.  After filtering, the solvent was removed in vacuo to give 
a yellow syrup (97mg).  The crude material was purified by column chromatography on silica 
eluted with 1-5% methanol/DCM.  Relevant fractions were collected and the solvent 
evaporated.  The product was obtained as a clear colourless syrup (39mg/34%).  LCMS showed 
a peak with m/z 626 (MH+).  1H NMR (CDCl3, 270MHz):  0.85(s, 3H, Me),  1.21 – 1.42 (m, 
8H, 4xCH2),  2.55 (t, 2H, J=7.8Hz, N-CH2),  2.97 (2xd overlapping, 2H, H1,1’),  3.40 – 3.47 
(m, 2H, H6,6’),  3.71 (dd, 1H, J=1.9, 6.2Hz, H4),  3.98 – 4.02 (m, 3H, H2,3,5),  4.40 – 4.72 
(m, 18H, O-CH2-Ph),  7.21 – 7.30 (m, 20H, aromatic).   
 
 
Preparation of 177: 
 
 
169 (500mg/0.78mmol) was dissolved in THF (10ml) under nitrogen and cooled to 0°C.  
Imidazole (106mg/1.56mmol) was added and the reaction stirred for 30 minutes to ensure full 
dissolution.  TESCl (1.17ml/0.78mmol) was added.  The reaction was stirred at 0°C for one 
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hour before allowing it to warm to room temperature gradually.  The reaction was stirred under 
nitrogen at room temperature for 16 hours.  TLC/LCMS indicated no remaining starting 
material.  Water (10ml) was added to the reaction followed by DCM (10ml).  The organic layer 
was separated and the aqueous further extracted with DCM (3x5ml).  The combined organics 
were washed with water (25ml), brine (25ml) and dried over MgSO4.  After filtering, the 
solvent was removed in vacuo to give a clear oil (570mg).  The crude material was purified by 
column chromatography on silica eluted with 1-5% ethyl acetate/heptane.  Relevant fractions 
were collected and the solvent evaporated.  Two distinct products were obtained as a clear 
colourless syrups (428mg/73%).  LCMS showed two peaks with m/z 757 (MH+) in a 12:1 ratio.  
1H NMR (CDCl3, 270MHz)(data for major isomer):  0.46 – 0.59 (m, 6H, 3xSiH2),  0.87 – 
0.99 (m, 9H, 3xCH3),  1.41 (s, 9H, Boc),  3.35 – 3.52 (m, 4H, H6,6’,1,1’),  3.70 (dd, 1H, J=2.2, 
6.8Hz, H4),  3.76 (br, 1H, H2),  3.91 – 4.00 (m, 2H, H3,5),  4.40 – 4.73 (m, 8H, O-CH2-Ph), 
 4.92 (br, 1H, NH),   7.18 – 7.29 (m, 20H, aromatic).   
 
 
 
Preparation of 186: 
 
 
185 (100mg/0.36mmol) was dissolved in pyridine (1ml) under nitrogen and cooled to <5°C.  
Pivaloyl chloride (173mg/1.44mmol) was added and the reaction was stirred at 0°C for one 
hour before allowing it to warm to room temperature gradually.  The reaction was stirred under 
nitrogen at room temperature for 16 hours after which time TLC indicated no remaining 
starting material.  The reaction was filtered and DCM (10ml) was added.  The reaction was 
washed with 1M HCl (10ml), saturated sodium bicarbonate (aq.) (10ml) and brine (10ml).  The 
reaction was dried over MgSO4, filtered and concentrated in vacuo to give a yellow syrup 
(84mg). The crude material was purified by column chromatography on silica eluted with 10-
50% ethyl acetate/heptane.  Relevant fractions were collected and the solvent evaporated.  MS 
180 
 
reported a m/z 616 (MH+) and 638 (MNa+).  1H NMR (CDCl3, 270MHz)(data for major 
isomer):  1.15 – 1.31 (m, 36H, 4xO-Piv),  1.43 (s, 9H, Boc),  3.37 – 3.59 (m, 2H, H1,1’),  
3.79 (d, 1H, H4),  3.96 – 4.37 (m, 4H, H5,3,6,6’),  4.78 (br, 1H, NH).  
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